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ABSTRACT  
 
Type 2 diabetes has become a worldwide epidemic. It is characterised by insulin 
resistance in major metabolic tissues, and failure of E-pancreatic cells to 
compensate for this abnormality. Insulin resistance is recognised as an early 
event in the pathogenesis of type 2 diabetes. Although the precise factors that 
lead to insulin resistance have not been elucidated fully, there is strong 
association between insulin resistance and lipid accumulation, in particular 
lipotoxic fatty acid metabolites in insulin-target tissues. Most recently, evidence 
has been presented to link abnormal fatty acid accumulation in muscle with 
reduced mitochondrial activity. However it was unclear if these aberrations are 
causally related to the development of insulin resistance and type 2 diabetes. 
The two major pathophysiological abnormalities that underlie type 2 diabetes 
have long been viewed to require two separate pathogenic processes. The 
resolution of type 2 diabetes after bariatric surgery has allowed the elucidation 
of the sequence of events that lead to the restoration of normal metabolism, 
paving the way for a new understanding of type 2 diabetes as a metabolic state 
precipitated by a single cause of chronic excess intra-organ lipid accumulation. 
Magnetic resonance technique provides a non-invasive way to evaluate 
metabolism in both normal and pathological states. Specifically, 31P magnetic 
resonance spectroscopy allows the observation of real-time ATP synthesis as a 
direct measurement of mitochondrial activity. 13C magnetic resonance 
spectroscopy can be applied to assess muscle glycogen concentration. Both 1H 
magnetic resonance spectroscopy and magnetic resonance imaging can be used 
to evaluate intra-organ lipid concentration. Collectively, these innovative 
techniques offer safe and powerful approaches to study the role of skeletal 
muscle oxidative capacity and intra-organ fatty acid accumulation and 
metabolism in the pathogenesis of type 2 diabetes. This thesis presents data 
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which lead to a simplified understanding of the aetiology and pathogenesis of 
type 2 diabetes. 
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1.1 Natural History of Type 2 Diabetes 
Type 2 diabetes is one of the most frequent metabolic disorders worldwide and 
the number of people with diabetes is rising rapidly due to increasing 
consumption of high-energy food and the increasing adoption of sedentary 
lifestyle. It is projected that by 2030 as many as 366 million of the population 
would have this metabolic disorder (Wild et al., 2004). In addition, the age of 
onset of type 2 diabetes is decreasing, giving rise to an increasing proportion of 
young people of working age being affected. This leaves individuals exposed to 
longer periods of hyperglycaemia and hence increased risks of developing 
diabetes-related complications. The global epidemic of type 2 diabetes is clearly 
a cause of serious health-related and socioeconomic burden on individuals and 
society alike.  
Type 2 diabetes is a complex, heterogenous, polygenic disease characterised 
by two fundamental defects: impaired insulin action in skeletal muscle, liver and 
DGLSRFW\HV DQG LPSDLUHG Ƣ-cell function. The sequence with which these 
metabolic abnormalities develop and their relative contributions in the causation 
of type 2 diabetes remain much debated. It has long been regarded by some that 
LQVXOLQUHVLVWDQFHLVWKHSULPDU\DEQRUPDOLW\DQGWKDWƢ-cell dysfunction is a late 
RFFXUUHQFHDULVLQJIURPWKHSURORQJHGLQFUHDVHGGHPDQGSODFHGRQWKHƢ-cell by 
insulin resistance (DeFronzo et al., 1992). Insulin resistance itself has been 
associated with increased lipid depositions in skeletal muscle and liver, and has 
recently been linked to a functional impairment of mitochondria.  
 
1.1.1 Observation of the earliest defect 
The Pima Indians who live in the Gila River Indian Community in Arizona 
have participated in a longitudinal study of diabetes and its complications since 
1965 (Bennett et al., 1971). The prevalence and incidence of type 2 diabetes in 
this community is the highest of any population in the world (Knowler et al., 
1981). In the Pima Indians, the prevalence of type 2 diabetes is over 50% above 
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the age of 55 and peaks at almost 70% around the age of 60 years (Knowler et 
al., 1990, Pavkov et al., 2007). Amongst the youths (15- to 24-year olds), type 2 
diabetes affects 6.4% of Pima Indians (a six-fold increase in prevalence over the 
last 40 years) (Dabelea et al., 1998, Pavkov et al., 2007). Diabetes was rare or 
largely unrecognised among the Pima Indians until the late 1930s when 
increasing settlers from the east led to disruption of their agriculture, curtailing 
subsistence farming and the ensuing change in lifestyle. Evidence suggests that 
the incidence of diabetes in this indigenous population did rise abruptly in the 
1930s, and this rise was followed by relatively stable incidence since that time, 
but with a shift to a younger age at onset of diabetes as a consequence of 
increasing childhood obesity and increasing frequency of exposure to diabetes 
in utero (Pettitt et al., 1983, Dabelea et al., 1998, Pavkov et al., 2007).  
Pima Indians with type 2 diabetes are characterised by obesity, insulin 
resistance, insulin secretory dysfunction and increased rates of endogenous 
glucose production, which are the characteristics that define type 2 diabetes 
across most populations (Bogardus et al., 1984). Compared with Caucasians, 
Pima Indians have, on average, lower insulin sensitivity and higher plasma 
insulin concentrations, both fasting and in response to intravenous and oral 
glucose loads (Bogardus et al., 1984). Prospective studies indicate that 
hyperinsulinaemia and abnormal insulin secretory function were both 
independent predictors of the development of type 2 diabetes in this 
population (Weyer et al., 1999a). In their study, Weyer and colleagues carried 
out repeated analyses on 17 Pima Indians who developed diabetes and 
compared these to a control group of 31 individuals who remained normal 
glucose tolerant over the same 5-year period of follow-up (Weyer et al., 1999a). 
Results demonstrated that both insulin secretion and insulin action significantly 
decrease early in the development of type 2 diabetes ² during the transition 
from normal glucose tolerance (NGT) to impaired glucose tolerance (IGT). 
With the progression from IGT to diabetes, the abnormalities in insulin 
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secretion and insulin action worsen in parallel with an increase in endogenous 
glucose output.  
IGT is well recognised as a risk factor for diabetes and studies have 
estimated that between 2% and 14% of individuals with IGT progress to type 2 
diabetes each year (Yudkin et al., 1990, Knowler et al., 2002). The progression 
rate is clearly influenced by age, ethnicity and the degree of glucose intolerance 
at baseline. Individuals with IGT have been found, on average, to be more 
obese and more insulin-resistant than those with NGT (Ferrannini and 
Camastra, 1998, Weyer et al., 1999b). Insulin sensitivity as measured with 
hyperinsulinaemic-euglycaemic clamp has been shown to be consistently lower 
in individuals with IGT compared with NGT across a variety of ethnic groups 
studied: 27% reduction in Pima Indians (Weyer et al., 1999b), 32% in Hispanics 
(Abdul-Ghani et al., 2006), and 21% in Japanese (Wasada et al., 2004). This 
magnitude of decline in insulin sensitivity in IGT subjects is comparable to that 
in normoglycaemic first-degree relatives of diabetic subjects (Gulli et al., 1992, 
Vauhkonen et al., 1998, Kashyap et al., 2004, Arslanian et al., 2005). In addition, 
defects in insulin secretory function have been reported to be present before 
overt diabetes developed. Abdul-Ghani and co-workers demonstrated that 
subjects with IGT have significant impairment in early insulin secretory 
response to ingested glucose (Abdul-Ghani et al., 2006). Studies by Weyer et al. 
(Weyer et al., 1999b) and Festa et al. (Festa et al., 2004) reported reductions 
between 8-18% in acute insulin response in IGT subjects compared with NGT 
individuals. Ahren and colleagues found a 32% decrease in acute insulin 
response in Caucasian postmenopausal women with IGT (Ahren and Pacini, 
1997).  
Normoglycaemic first-degree relatives of type 2 diabetes patients have an 
approximately 40% lifetime risk of developing diabetes. In addition to being 
more insulin-resistant than normoglycaemic individuals without family history 
of type 2 diabetes, they also exhibit impairment in insulin secretion. Eriksson 
and colleagues divided first degree relatives of type 2 diabetes patients into 
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those with normal glucose tolerance and those with impaired glucose tolerance 
according to a standard oral glucose tolerance test (OGTT) (Eriksson et al., 
1989). Insulin-stimulated glucose metabolism was assessed by the euglycaemic 
clamp technique and a comparable defect in glucose uptake was observed in 
both groups compared to healthy controls with no family history of type 2 
diabetes. However, the first-phase insulin response was normal in subjects with 
NGT whilst subjects with IGT had a decreased first-phase resSRQVH2·5DKLOO\
et al. also reported very early defect in insulin secretion, with alterations in 
oscillations of insulin secretion, in first-degree relatives of patients with type 2 
diabetes at time when their first-phase insulin response to intravenous glucose 
was still normal (O'Rahilly et al., 1988). Taken together, these studies suggest 
that both insulin resistance and impaired insulin secretion are necessary for the 
development of impaired glucose tolerance and type 2 diabetes. However, the 
temporal sequence with which these abnormalities change from NGT to IGT 
and to diabetes remains less clear. As yet, it is not possible to determine which 
of these characteristics is aetiologic and which is a secondary abnormality 
resulting from the disease process since some individuals with IGT will never 
go on to develop diabetes. 
  
1.1.2 Insulin resistance 
Insulin resistance, first described by Himsworth in 1930s, can be defined as the 
inability of target tissues to respond properly to circulating concentrations of 
insulin that is otherwise effective in normal subjects. Normally, insulin binds to 
insulin receptors on target organ cells, resulting in a series of cellular events that 
lead to intracellular glucose transport and metabolism. Skeletal muscle and liver 
are the two key insulin-responsive organs responsible for maintaining normal 
glucose homeostasis. Insulin resistance leads to impaired suppression of hepatic 
glucose production and to reduced peripheral uptake of glucose, both of which 
contribute to hyperglycaemia. In addition, insulin resistance in the adipose 
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tissue increases the flux of non-esterified fatty acid (NEFA) to the liver and 
skeletal muscle and consequently impairs the action of insulin on glucose 
metabolism in these tissues. 
There is ample evidence indicating that insulin resistance is an important 
and early feature of type 2 diabetes. Cross sectional studies have shown that 
virtually all patients with type 2 diabetes are insulin-resistant, and prospective 
studies have shown that insulin resistance precedes the onset of diabetes by 10 
to 20 years (Lillioja et al., 1988, DeFronzo et al., 1992). Insulin-resistance in 
young lean non-smoking offspring of parents with type 2 diabetes has been 
shown to be the best predictor for the later development of the disease 
(Warram et al., 1990, Martin et al., 1992). On the other hand, any perturbations 
that reduce insulin resistance such as exercise and weight loss prevented the 
development of type 2 diabetes (Tuomilehto et al., 2001, Knowler et al., 2002). 
The cellular mechanism of insulin resistance involves abnormal activation 
of a complex network of signalling pathways which regulate intermediary 
metabolism within insulin-sensitive cells. In normal target cells for the 
hormone, insulin action is initiated by insulin binding to its receptor in the 
plasma membrane. This is followed by activation of receptor-associated 
tyrosine kinase, which in turn initiates a cascade of reactions leading to the 
translocation of the glucose transporters to the cell membrane where they allow 
the uptake of glucose into the cell (Figure 1.1).  
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Figure 1.1 Schematic illustration of the insulin signalling pathway. Insulin binds 
to its receptor, resulting in autophosphorylation. This then catalyses the tyrosine 
phosphorylation of members of the insulin receptor substrates (IRS) family. 
Upon phosphorylation, these proteins interact with other signalling molecules 
which then activate several diverse pathways. One of these pathways is the 
activation of phosphatidylinositol-3 kinase (PI-3 kinase). This in turn activates 
protein kinase B (PKB) and Akt, which act on further pathways, resulting in 
glucose, lipid and protein metabolism, and specific gene expression. In muscle 
cells, Akt also promotes translocation of glucose transporter-4 (GLUT-4) to 
plasma membrane to allow glucose uptake into cell. Activation of PKB leads to 
the inactivation of glycogen synthase-3 kinase, thereby resulting in activation of 
glycogen synthase and therefore glycogen synthesis.  
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1.1.3 Ƣ-cell dysfunction 
Glucose homeostasis is maintained, in large part, by pancreatic Ƣ-cells which 
secrete insulin in proportion to increasing concentrations of glucose. Insulin 
lowers blood glucose by stimulating glucose uptake into skeletal muscle and 
adipose tissue and by decreasing glucose production by the liver. Ƣ-cell function 
has been shown to decline before hyperglycaemia develops. The United 
Kingdom ProspectivH'LDEHWHV6WXG\ZKLFKHYDOXDWHGƢ-cell function using the 
homeostasis model assessment (HOMA), indicated that at time when diabetes 
ZDVGLDJQRVHGƢ-cell function had already reduced by 50% (1995). Furthermore, 
the study confirmed that there was subsequent further decline in Ƣ-cell function 
and this was the same irrespective of treatment with dietary interventions alone, 
sulfonylurea, metformin or insulin (1995). Analysis of data from the Belfast Diet 
Study, a 10-year prospective evaluation of newly diagnosed patients with 
intensive dietary management, documented an inexorable increase in fasting 
plasma glucose as the years go by despite best possible clinic management 
(Hadden et al., 1986). Using the HOMA model, they observHG WKDW Ƣ-cell 
dysfunction began early on and reached a critical point between 3 and 5 years 
after diagnosis where the annual rate of Ƣ-cell decline accelerated abruptly (Levy 
et al., 1998). 
7KHGHIHFWVLQƢ-cell function in type 2 diabetes include absent first-phase 
and diminished second-phase insulin secretion in response to hyperglycaemia in 
hyperglycaemic clamp experiments (Ferner et al., 1986, van Haeften et al., 
1989). In addition, responses to non-glucose stimuli are delayed and/or blunted 
as well as decreased in maximal secretory capacity (Van Haeften et al., 1991, 
Dimitriadis et al., 1985). Insulin secretion normally decreases with age. The 
decline rate has been shown to be about 0.7-1.0% per year for basal and 
glucose-stimulated insulin secretion during adult human life in individuals with 
normal glucose tolerance (Chiu et al., 2000). The rate of decline is doubled in 
people with IGT (Szoke et al., 2008) and is approximately 6% per year in 
patients with type 2 diabetes (1995) Ƣ-cell mass has been shown to decrease 
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with increasing duration of diabetes (Weyer et al., 1999b, Leahy, 1990). 
Alterations in the timing and amount of insulin secreted have also been 
reported in relatives of patients with type 2 diabetes prior to the development 
of hyperglycaemia (Vauhkonen et al., 1998, O'Rahilly et al., 1988). There is 
ongoing debate as to whether insulin resistance is the primary defect that 
SUHFHGHVƢ-cell failure in the evolution of hyperglycaemia in type 2 diabetes, or 
vice versa. It has been generally thought that insulin resistance prHFHGHGƢ-cell 
G\VIXQFWLRQDQGFDXVHGƢ-FHOOIDLOXUHYLDWKHPHFKDQLVPRIƢ-cell exhaustion i.e. 
increased secretory demand due to peripheral insulin resistance resulting in 
FRQWLQXDO Ƣ-cell hyperstimulation and eventual failure. In the absence of a 
defect LQ Ƣ-cell function, individuals can compensate indefinitely for insulin 
resistance with appropriate hyperinsulinaemia.  
Knowledge of the molecular control of insulin secretion is important for 
understanding Ƣ-cell dysfunction of type 2 diabetes. Pancreatic Ƣ-cells sense 
glucose through its metabolism and the resulting increase in adenosine 
triphosphate (ATP) leads to the closure of the ATP-sensitive potassium KATP 
channel, causing plasma membrane depolarisation, influx of calcium ions, and 
finally insulin secretion (Figure 1.2) (Ashcroft and Gribble, 1999, Matschinsky 
et al., 1998). 
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Figure 1.2 Intracellular mechanisms through which glucose stimulates insulin 
secretion. Glucose is rapidly taken up by the pancreatic Ƣ-cell via GLUT-2. 
Following its entry, glucose is phosphorylated to glucose 6-phosphate (G6P) by 
the enzyme glucokinase for utilization. This generates ATP which closes the 
ATP-sensitive potassium KATP channels in the cell membrane, preventing the 
efflux of potassium ions that normally maintains resting membrane potential. 
This causes membrane depolarization and opening of voltage-gated calcium 
channels in the membrane, leading to influx of calcium ions. The increase in 
cytosolic calcium initiates exocytosis of insulin-containing granules. Glucose 
also stimulates synthesis of new insulin via transcription factor PDX 1.  
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1.2 Glucose Metabolism in Type 2 Diabetes 
Normal glucose homeostasis is maintained by 3 important mechanisms which 
occur in a coordinateGPDQQHUVHFUHWLRQRILQVXOLQE\SDQFUHDWLFƢ-cells, 2) 
suppression of hepatic glucose production, and 3) stimulation of glucose uptake 
by the liver and muscle. 
 
1.2.1 Skeletal muscle 
Skeletal muscle is the largest metabolically active tissue in the human body 
(approximately 20 kg in a man of average weight). When glucose is taken up by 
the muscle, it can undergo one of three fates: 1) be oxidized to carbon dioxide 
and water, 2) converted to lactate which is then released into blood or 3) be 
stored as glycogen or to a lesser extent as fat (via de novo lipogenesis). Using 
indirect calorimetry in combination with femoral vein catheterization and the 
euglycaemic-hyperinsulinaemic clamp, it has been shown that most of the 
glucose taken up by muscle in normal subjects undergoes non-oxidative glucose 
metabolism (DeFronzo et al., 1981). Combining indirect calorimetry and 13C 
magnetic resonance (MR) spectroscopy, Shulman and colleagues were able to 
show that during hyperglycaemic-hyperinsulinaemic conditions, skeletal muscle 
accounted for the vast majority of glucose uptake in normal subjects and that 
over 80% of this glucose was then stored as muscle glycogen (Shulman et al., 
1990). However, in type 2 diabetes subjects, the rate of muscle glycogen 
synthesis was 50% lower than the rate in normal subjects during 
hyperglycaemic-hyperinsulinaemic clamps (Shulman et al., 1990).  This study 
provided undisputed evidence that a defect in muscle glycogen synthesis is the 
major intracellular metabolic defect responsible for insulin resistance in type 2 
diabetes. Further work by the same group has shown that the defect in insulin-
stimulated glycogen synthesis in type 2 diabetes is attributable mostly to 
reduced insulin-stimulated glucose transport into skeletal muscle (Rothman et 
al., 1992, Cline et al., 1999). Similar observations were also made in lean insulin-
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resistant offspring of type 2 diabetes patients (Rothman et al., 1995) and in 
non-diabetic obese adults (Petersen et al., 1998), suggesting that the defect in 
insulin-stimulated muscle glycogen synthesis precedes the development of type 
2 diabetes. 
 
1.2.2 Liver 
The liver plays a pivotal role in maintaining normal glucose homeostasis 
especially during the fed-fasting transition. In the post-absorptive (i.e., fasting) 
state, at least 85% of endogenous glucose production is derived from the liver, 
and the remaining amount is produced by the kidney (Gerich et al., 2001). Both 
gluconeogenesis and glycogenolysis are responsible for maintaining normal 
rates of endogenous glucose production. The relative contributions of these 
two processes to glucose production have been shown by various studies to be 
dependent on duration of the fast (Rothman et al., 1991, Petersen et al., 1996, 
Landau et al., 1996). During the early stages of fasting (10-12 hour overnight), 
gluconeogenesis and glycogenolysis appear to contribute relatively equal 
proportion (55% : 45%) to whole-body glucose production, but with increasing 
duration of fast, the contribution from glycogenolysis decreases while that of 
gluconeogenesis increases (Roden et al., 2001). In the post-prandial state, whilst 
the peripheral tissues (predominantly skeletal muscle) account for the majority 
of insulin-stimulated glucose disposal, the liver plays a key role in buffering 
ingested carbohydrate by suppressing hepatic glucose output and stimulating 
glucose deposition as liver glycogen. Taylor and colleagues showed that hepatic 
glucose output is suppressed within 30 minutes after a liquid mixed meal and 
that approximately 19% of the carbohydrate content of the meal was deposited 
as glycogen in the liver (Taylor et al., 1996). 
It is well established that fasting hyperglycaemia in type 2 diabetes is 
strongly related to increased rates of endogenous glucose production (Fery, 
1994, Jeng et al., 1994). Tracer studies have shown that increased 
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gluconeogenesis is primarily responsible for the elevated fasting glucose levels 
in type 2 diabetes (Consoli et al., 1989, Magnusson et al., 1992, Gastaldelli et al., 
2000). In the post-prandial state, the suppression of endogenous glucose 
production is incomplete both because of hepatic insulin resistance, deficient 
insulin and excessive glucagon secretion in type 2 diabetes, thereby causing 
post-meal hyperglycaemia (Mitrakou et al., 1990, Campbell et al., 1988, Singhal 
et al., 2002). 
 
 
1.3 Lipid Abnormalities in Type 2 Diabetes 
1.3.1 Plasma lipids 
The importance of abnormal lipid metabolism in both the pathogenesis and 
aetiology of type 2 diabetes has long been recognised (McGarry, 2002). 
Increased plasma NEFA concentrations are typically associated with many 
insulin-resistant states, including obesity and type 2 diabetes (Boden, 1997). In a 
cross-sectional study of young, lean offspring of type 2 diabetic patients, 
Perseghin and colleagues found an inverse relationship between fasting NEFA 
concentration and insulin sensitivity suggesting that fasting NEFA 
concentration best predicts the risk of developing insulin resistance and type 2 
diabetes (Perseghin et al., 1997). Similarly, in the Pima Indian population, 
individuals with the high fasting NEFA levels had a 2.4 relative risk of 
developing type 2 diabetes independent of sex, percent body fat, waist/hip 
ratio, insulin-mediated glucose uptake and fasting triglyceride concentration   
(Paolisso et al., 1995). Conversely, lowering of NEFA levels by acipimox, a 
nicotinic acid that inhibits lipolysis, improves insulin resistance in type 2 
diabetic subjects (Vaag et al., 1991b, Santomauro et al., 1999, Bajaj et al., 2005). 
Sir Philip Randle first recognised the importance of the role of fatty acid in 
glucose dysregulation back in 1960s. He demonstrated that fatty acids 
effectively compete with glucose for substrate oxidation in isolated rat heart 
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muscle and diaphragms (Randle et al., 1963). As a result, he proposed that 
increased fat oxidation led to the inhibition of glucose oxidation, decreased 
glycolytic flux and eventually inhibition of glucose transport in muscle which all 
lead to hyperglycaemia. This homeostatic mechanism became known as the 
glucose-fatty acid cycle or more commonly, the Randle cycle. He postulated 
that the increase in fatty acid oxidation causes elevation of the level of intra-
mitochondrial acetyl coenzyme A (acetyl CoA), which subsequently inactivates 
pyruvate dehydrogenase. This in turn causes citrate concentration to increase, 
leading to the inhibition of phosphofructokinase and subsequent accumulation 
of intracellular glucose and glucose 6-phosphate. The accumulation of these 
latter two substrates results in the decrease in insulin-stimulated glucose uptake.  
There is a wealth of evidence to support the causative association between 
increased plasma lipid availability and impaired insulin-mediated glucose 
metabolism (Boden et al., 1994, Boden and Chen, 1995). Most of this 
information has been gained from studies employing artificial lipid infusion and 
pharmaceutical interventions to manipulate NEFA supply. Roden and 
colleagues observed a significant reduction in insulin-stimulated rates of muscle 
glycogen synthesis and whole-body glucose oxidation in healthy individuals 
given lipid infusion to raise NEFA levels (Roden et al., 1996). These 
observations were only detected 4.5 hours after elevations in NEFA levels, and 
were similar to those observed in patients with type 2 diabetes (Rothman et al., 
1992) and lean normoglycaemic insulin-resistant offspring of type 2 diabetic 
individuals (Rothman et al., 1995). Further work has shown that elevation of 
NEFA in healthy individuals resulted in significantly lower intracellular glucose 
concentrations during insulin stimulation, implying that the rate controlling step 
for NEFA-induced insulin resistance in humans is glucose transport (Dresner 
et al., 1999). In addition, lipid infusion studies have further demonstrated that 
increasing circulating NEFA enhances gluconeogenesis and impairs 
glycogenolysis in young insulin-sensitive individuals (Roden et al., 2000, Stingl 
et al., 2001). Augmented gluconeogenesis in turn is known to be primarily 
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responsible for the rise in fasting endogenous glucose production typically 
observed in type 2 diabetes (Hundal et al., 2000, Magnusson et al., 1992). The 
mechanisms by which NEFA induce gluconeogenesis remain poorly 
understood. It has been postulated that the activation of pyruvate carboxylase 
secondary to increases in acetyl CoA may be driving this (Bahl et al., 1997). 
 
1.3.2 Ectopic lipid accumulation 
The deposition of lipid in non-adipose tissue, also called ectopic lipid 
accumulation, is a central feature of type 2 diabetes. When excess lipid 
DFFXPXODWHVLQRUJDQVVXFKDVVNHOHWDOPXVFOHOLYHUKHDUWDQGSDQFUHDWLFƢ-cells, 
the lipids are stored within the cytosol, and not generally released into the 
circulation, but exert an influence on cellular glucose uptake and utilisation 
directly. Lipid can accumulate in ectopic sites in three ways: 1) through 
increased uptake of fatty acids, 2) through increased synthesis within the tissue 
involved, and/or 3) reduced fatty acid oxidation or disposal (Shulman, 2000). 
The relative contribution of each of these factors to ectopic lipid accumulation 
may well vary in different tissue and in different pathological states.  
There is greater than two-fold elevation of muscle lipid in people with type 
2 diabetes compared to normal non-diabetic subjects (Goodpaster et al., 2000). 
Using 1H magnetic resonance (MR) spectroscopy, lipid within muscle fibres, i.e. 
intramyocellular lipid (IMCL) and lipid located in adipocytes between muscle 
fibres, i.e. extramyocellular lipid (EMCL) can be distinguished (Boesch et al., 
1997, Szczepaniak et al., 1999). Furthermore, IMCL was found to exhibit an 
even stronger relationship between muscle triglyceride content and insulin 
resistance. Excess IMCL accumulation has been shown to be inversely 
correlated with insulin-stimulated whole body glucose disposal in healthy adults 
(Krssak et al., 1999), in first degrees relatives of people with type 2 diabetes 
(Perseghin et al., 1999) and in children (Weiss et al., 2003).  
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Although findings from above studies strongly suggest that lipid 
accumulation within muscle fibres can be associated with insulin resistance, 
there is also a paradox that increased IMCL can be found within muscle of 
highly trained athletes (Goodpaster et al., 2001). The high content of muscle 
triglyceride provides a reservoir for high rates of lipid oxidation, an important 
fuel depot for sustained anaerobic exercise suggesting that the muscles of these 
highly trained athletes have the metabolic capacity for efficient lipid utilisation 
(Brechtel et al., 2001). On the contrary, these precepts do not appear to apply 
to skeletal muscle in sedentary and insulin-resistant individuals in whom the 
expanded intramyocellular energy store is out of proportion to physiological 
needs. These findings raise the question as to whether the increased IMCL 
levels observed in insulin-resistant individuals are the cause of insulin resistance 
or rather the result of impaired oxidative capacity of their skeletal muscle.   
Hepatic triglyceride accumulation is frequently observed in obese 
individuals (Marceau et al., 1999) and is linked to insulin resistance and 
hypertriglyceridaemia (Marchesini et al., 2001, Seppala-Lindroos et al., 2002, 
Tiikkainen et al., 2002). The association between hepatocellular lipid content 
and features of insulin resistance has been examined in different populations. 
Hepatocellular lipid content was increased and associated with various 
measures of insulin resistance in type 2 diabetes (Anderwald et al., 2002, Ryysy 
et al., 2000, Mayerson et al., 2002, Kelley et al., 2003), in women with previous 
gestational diabetes (Tiikkainen et al., 2003), in obese (Seppala-Lindroos et al., 
2002) and in insulin-resistant lipodystrophic patients (Petersen et al., 2002, 
Sutinen et al., 2002). Liver fat content has also been linked with hepatic insulin 
resistance as measured by suppression of endogenous glucose production 
during hyperinsulinaemic clamps in patients with non-alcoholic fatty liver 
disease (Marchesini et al., 2001). Treatments targeting obesity and insulin 
resistance reverse the associated accumulation of hepatic triglyceride, and 
weight loss reduces hepatic fat store and improves insulin resistance (Tiikkainen 
et al., 2003). Rosiglitazone treatment in patients with type 2 diabetes results in a 
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40% reduction in plasma free fatty acid levels and hepatic triglyceride content, 
which is accompanied by a marked improvement in insulin-stimulated glucose 
metabolism during insulin clamp studies (Mayerson et al., 2002, Neuschwander-
Tetri et al., 2003).  
Experimental and autopsy data indicate that infiltration of pancreatic islets 
by adipocytes could possibly contribute tRƢ-cell dysfunction. In obese rodents 
observed during the development of diabetes, the onset of hyperglycaemia is 
SUHFHGHGE\D UDSLG LQFUHDVH LQHFWRSLF WULJO\FHULGHRYHUORDG LQƢ-cells (Lee et 
al., 1994) ZKLFK FRQWULEXWHV WR Ƣ-cell dysfunction through the process of 
lipoapoptosis (Shimabukuro et al., 1998). Tushuizen and colleagues were first to 
show that pancreas triglyceride content, measured by 1H MR spectroscopy, is 
doubled in patients with type 2 diabetes compared with age- and body mass 
index (BMI)-matched controls (Tushuizen et al., 2007). Pancreatic triglyceride 
FRQWHQW ZDV QHJDWLYHO\ FRUUHODWHG ZLWK Ƣ-cell glucose sensitivity even after 
correction for BMI, plasma glucose and triglycerides, but only in their obese 
normoglycaemic controls, suggesting that pancreatic triglyceride might 
FRQWULEXWHWRƢ-cell dysfunction in addition to effects induced by glucotoxicity. 
However, islet cell mass comprises only approximately 2% of the total pancreas 
mass and measurement of triglyceride levels exclusively within the islets in vivo is 
presently unachievable. Despite this, the validity of the method has been 
established and shown to be sensitive to detect differences between groups of 
volunteers from lean to obese with progressive levels of glucose intolerance to 
established type 2 diabetes (Lingvay et al., 2009).  
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1.4 Mitochondrial Dysfunction and Type 2 Diabetes 
Mitochondria are the primary location of fuel metabolism and ATP production. 
For this reason, there has been much recent interest in the role of the 
mitochondria in the development of type 2 diabetes.  
 
1.4.1 Mitochondrion 
Mitochondria are double-membrane organelles within all nucleated cells. Their 
primary function is to produce energy in the form of ATP from acetyl CoA 
derived from carbohydrates, fats and proteins. ATP is the universal currency of 
energy in the cell. It is an energy-rich molecule because it contains two 
phosphoanhydride bonds. Energy is released when these bonds are broken. 
ATP can be synthesized from adenosine diphosphate (ADP) by two processes: 
1) substrate-level phosphorylation and 2) oxidative phosphorylation. Substrate-
level phosphorylation is the process by which ATP is formed from the direct 
phosphorylation of ADP. This process does not require oxygen and is 
independent of the mitochondria, making it important for generating ATP 
when oxygen supply is limited. However, almost 90% of cellular ATP is 
generated by oxidative phosphorylation, a process by which ATP is formed as 
electrons are transferred from nicotinamide adenine dinucleotide (NADH) and 
flavin adenine dinucleotide (FADH2) to molecular oxygen, via a series of 
electron carriers that make up the electron transport chain (ETC) (Figure 1.3).  
Carbohydrates are converted to pyruvate through glycolysis, which takes 
place in the cytosol. Pyruvate is subsequently actively transported across the 
inner mitochondrial membrane, and into the mitochondrial matrix where it is 
oxidised and converted to acetyl CoA by pyruvate dehydrogenase. Fatty acids 
are transported into the mitochondria through the carnitine shuttle and further 
GHJUDGHGWRDFHW\O&R$WKURXJKƢ-oxidation. Both carbohydrate and fatty acid 
metabolism result in acetyl CoA, the primary substrate to enter the tricarboxylic 
acid cycle. This is a cyclical sequence of eight enzymatically driven chemical 
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reactions which oxidise acetyl CoA to carbon dioxide and in the process 
produces NADH and FADH2 for the ETC, which consists of four protein 
complexes. Complex I, III and IV act as proton pumps. Complex II is, in 
addition to complex I, an acceptor of reducing equivalents. The complexes are 
linked by two freely-diffusible membrane proteins: ubiquinone (coenzyme Q) 
and cytochrome c. The ETC results in a stepwise transfer of electrons from 
NADH and FADH2 to oxygen molecule to form water molecules. During this 
process, the energy that is released is harnessed into pumping of protons 
against their concentration gradient from the matrix of the mitochondria into 
the intermembrane space. The protons are allowed only to travel back into the 
mitochondrial matrix via an enzyme, F1F0ATP synthase, present in the inner 
mitochondrial membrane. The movement of the protons back activates the 
F1F0ATP synthase to catalyse the synthesis of ATP by combining ADP and Pi.  
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Figure 1.3 Diagrammatic illustration of oxidative phosphorylation, showing the 
different components of the electron transport chain and the F1F0ATP synthase 
in the inner membrane of mitochondrion. Upon transferring the electrons of 
NADH and FADH2 to complex I and II respectively, the electrons travel along 
the different complexes accompanied by the pumping of protons from the 
mitochondrial matrix into the intermembrane space. The protons in the 
intermembrane space subsequently travel back to the matrix passing through 
the F1F0ATP synthase, which goes along with the formation of ATP. 
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1.4.2 Measuring mitochondrial function  
As oxidative capacity depends on the presence of adequate mitochondrial 
content and/or individual mitochondrial functionality, mitochondrial 
aberrations could be due to lower mitochondrial content or true lower intrinsic 
functionality per mitochondrion itself (Phielix et al., 2011). Several markers for 
mitochondrial content are commonly used, such as mitochondrial 
deoxyribonucleic acid (DNA) copy numbers, citrate synthase activity or protein 
subunits of the ETC. These include biochemical measurement of oxidative 
enzyme activities such as succinate dehydrogenase and NADH-dehydrogenase 
subunit (both of these enzymes reflect ETC capacity) and measurement of 
mitochondrial oxygen consumption using high-resolution respirometry in either 
intact isolated mitochondria or in permeabilised muscle fibres. A method which 
permits mitochondrial function to be investigated in vivo is that of phosphorus 
MR spectroscopy. With this technique, phosphorus-containing metabolites in 
the muscle can be determined non-invasively and followed over time. Two 
different methods of 31P MR spectroscopy have been used to measure skeletal 
muscle mitochondrial function. The first technique involves the determination 
of the rate of unidirectional flux through ATP synthase in the non-exercising 
state by using the magnetization (saturation) transfer method, in which the 
signal derived from ATP is temporarily suppressed and subsequent changes in 
the steady state MR signal of free phosphate are quantified to calculate 
unidirectional ATP synthesis rate (Lebon et al., 2001). The other method 
measures phosphocreatine (PCr) kinetics during recovery from exercise (Kemp 
and Radda, 1994). During exercise, PCr concentrations decrease and ADP 
concentrations increase, with both recovering rapidly after exercise. As recovery 
is driven mainly by oxidative phosphorylation, the recovery rate of PCr reflects 
mitochondrial capacity. In contrast to the magnetization saturation transfer 
method, the PCr recovery method assesses mitochondrial function under 
conditions of increased metabolic demand. These in vivo measures of 
mitochondrial oxidative activity and capacity can be influenced by several 
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factors such as blood perfusion, circulating hormones and metabolites, and do 
not allow the discrimination between changes in mitochondrial content or 
lower function per mitochondrion.    
 
1.4.3 Mitochondria and insulin resistance in skeletal muscle 
Mitochondrial abnormalities have been reported in insulin resistance and type 2 
diabetes (Petersen et al., 2003, Petersen et al., 2004). More than a decade ago, 
Simonneau and colleagues first reported reduction in activity of oxidative 
enzymes in skeletal muscles from individuals with obesity and type 2 diabetes, 
raising the possibility of true mitochondrial aberrations in the pathogenesis of 
type 2 diabetes (Simoneau and Kelley, 1997). They showed that the ratio 
between maximal activities of glycolytic and oxidative enzymes in skeletal 
muscle of type 2 diabetes was different from that in skeletal muscle of obese or 
lean glucose-tolerant subjects and suggested that a mismatch between 
mitochondrial oxidative capacity and the capacity for glycolysis may be an 
important factor in the development of insulin resistance. Further work by 
Kelley and colleagues found that the overall capacity of the ETC (estimated 
using the activity of rotenone-sensitive NADH:O2 oxidoreductase) was reduced 
by 40% in skeletal muscle of type 2 diabetes compared to that in healthy 
volunteers (Kelley et al., 2002). In the same study, electron microscopic imaging 
revealed that mitochondria in skeletal muscle of type 2 diabetes were ~55% 
smaller than those in the muscle of lean healthy controls, with the 
mitochondrial surface area positively correlating with insulin sensitivity. 
Furthermore, there was elevated number of damaged mitochondria in skeletal 
muscle of type 2 diabetes subjects. 
The link between mitochondrial dysfunction and type 2 diabetes has been 
further extended by MR spectroscopy studies. Application of the saturation 
transfer method has shown that in vivo mitochondrial function in skeletal 
muscle of elderly people and insulin-resistant offspring of type 2 diabetes 
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patients was decreased under basal and insulin-stimulated conditions (Petersen 
et al., 2003, Petersen et al., 2004, Petersen et al., 2005b). Petersen and 
colleagues were first to report a reduction in mitochondrial oxidative 
phosphorylation in insulin-resistant offspring compared to insulin-sensitive 
controls, and this was associated with an increased IMCL content (Petersen et 
al., 2004). The authors suggested that inherited defects in mitochondrial 
phosphorylation in these young people, who had strong tendency to develop 
type 2 diabetes at later life, were responsible for causing lipid accumulation and 
insulin resistance. Using a similar method, Szendroedi and co-workers observed 
that type 2 diabetic subjects had lower fasting ATP turnover rate when 
compared to younger controls, but not when compared to sex-, age-, and 
weight-matched controls (Szendroedi et al., 2007). The observation of no 
abnormality in basal ATP synthesis in type 2 diabetes implies that abnormal 
mitochondrial function is unlikely a primary causative factor in type 2 diabetes. 
However, insulin stimulation was observed to increase ATP turnover rate in 
both groups of control subjects but failed to do so in the diabetic subjects. 
Using the PCr recovery method as an alternative method to investigate in vivo 
mitochondrial function, Schrauwen-Hinderling and colleagues found that 
mitochondrial function was compromised by ~45% in type 2 diabetic patients 
compared to matched healthy controls (Schrauwen-Hinderling et al., 2007). 
However, unlike Petersen et al., they found similar IMCL content between the 
groups suggesting that fatty acid metabolites, rather than lipid deposition are 
related to mitochondrial function.  
Current hypotheses link inherited or acquired mitochondrial dysfunction to 
a reduced ability to oxidise lipid, thereby promoting the accumulation of fatty 
acids and their metabolites within skeletal muscle as a mechanism of inducing 
insulin resistance (Lowell and Shulman, 2005). Increased levels of 
intramyocellular metabolites such as fatty acyl CoA, ceramide and diacylglycerol 
have been shown to impede insulin signalling, providing an indirect mechanism 
from impaired mitochondrial function to the development of type 2 diabetes 
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(Morino et al., 2005). Brehm and colleagues examined the interference of 
increased lipid availability on skeletal muscle ATP synthase flux (Brehm et al., 
2006). By elevating circulating lipids via lipid infusion, they found that glucose 
transport/phosphorylation was impaired in parallel with a reduction in the flux 
increase through ATP synthase upon insulin stimulation. This finding led the 
authors to conclude that physiologically elevated NEFA levels cause a 
reduction in insulin-stimulated muscle ATP production in parallel with the 
induction of insulin resistance. 
To further examine if mitochondrial impairment was due to reduction in 
mitochondrial content and/or intrinsic defect in functionality, ex vivo studies are 
necessary. Few studies have been carried out whereby measurement of 
mitochondrial function was normalised for mitochondrial content, using either 
citrate synthase or mitochondrial copy DNA number. Studies by Mogensen et 
al. (Mogensen et al., 2007) and Phielex et al. (Phielix et al., 2008) revealed 
functional impairment in mitochondria of type 2 diabetic patients after 
correction for mitochondrial content. In contrast, Boushel and colleagues 
found no impairment in mitochondrial function from biopsy study of skeletal 
muscle of type 2 diabetes subjects (Boushel et al., 2007). Any apparent 
impairment of oxidative phosphorylation and electron transport capacity 
disappeared when corrected for mitochondrial density. 
The finding of mitochondrial dysfunction in the pre-diabetic and diabetic 
states has led to an intensive search for target genes and proteins regulating 
mitochondrial biogenesis and function. DNA microarray studies have 
demonstrated decreased expression of peroxisomal proliferator activator 
UHFHSWRUƣ33$5ƣFRDFWLYDWRU-ơ3*&-ơLQLQGLYLGXDOVZLWKW\SHGLDEHWHV
(Mootha et al., 2003) as well as in offspring of type 2 diabetes parents (Patti et 
al., 2003). Together, in vivo and ex vivo data appear to suggest an important role 
of mitochondrial function related to type 2 diabetes. However, whether the 
abnormality in mitochondria relates to mitochondrial number and/or 
functionality and whether such abnormality is the cause or consequence of type 
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2 diabetes remains to be addressed. Furthermore, there is now emerging 
evidence to suggest that mitochondrial dysfunction is not required for the 
development of type 2 diabetes. 
 
 
1.5 Pathogenesis of Type 2 Diabetes 
1.5.1 Mechanism of insulin resistance 
The molecular mechanism of insulin resistance remains to be established. Many 
hypotheses have been proposed to explain insulin resistance including 
inflammation in adipocytes associated with increased adipocytokines 
(Hotamisligil, 2006, Shoelson et al., 2006), increased reactive oxygen species 
production (Evans et al., 2002) DQGWKH´OLSRFHQWULFµK\SRWKHVLV (Roden et al., 
1996, Shulman, 2000). Lipid infusion studies combined with repetitive muscle 
biopsies showed that the fatty acid-induced insulin resistance was associated 
with alterations in insulin signalling (Dresner et al., 1999). Elevated NEFA 
levels inhibited the increase in IRS-1-associated PI-3 kinase. Subsequent studies 
suggested that this might be a consequence of reduction in insulin-stimulated 
IRS-1 tyrosine phosphorylation, which was associated with activation of protein 
kinase C (Griffin et al., 1999, Morino et al., 2005). Although increased skeletal 
muscle and liver triglycerides correlate closely with insulin resistance, 
triglycerides are generally perceived to be metabolically inert and do not directly 
cause insulin resistance. Triglycerides are in a constant state of turnover, leading 
to the production of several lipid metabolites which include long-chain fatty 
acyl CoA, diacylglycerol and ceramides.  
It has been proposed that increased intracellular lipid in muscle and liver 
cells leads to an increase in these intracellular fatty acid metabolites which in 
turn lead to the activation of a serine/threonine phosphorylation cascade and 
subsequent decrease in insulin-stimulated IRS-1 tyrosine phosphorylation, PI-3 
kinase activity and downstream insulin signalling (Figure 1.3) (Shulman, 2000). 
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In the muscle, this results in decreased muscle glycogen synthesis due to 
reduced GLUT-4 translocation to the plasma membrane and reduced glucose 
uptake into muscle. In the liver, this results in decreased hepatic glycogen 
synthesis due to decreased activation of glycogen synthase, and increased 
hepatic gluconeogenesis. 
Diacylglycerol has been proposed to be the main candidate in mediating 
lipid-induced resistance compared to other fatty acid metabolites (Erion and 
Shulman, 2010). Yu and colleagues have been able to dissociate lipid-induced 
insulin resistance from any increases in intramuscular triglyceride or ceramide 
content, suggesting that these lipid metabolites are not the trigger in mediating 
fat-induced insulin resistance in muscle (Yu et al., 2002). Furthermore, Itani and 
co-workers observed that diacylglycerol accumulation in human muscle during 
lipid/heparin infusions was associated with increased protein kinase C activities 
(Itani et al., 2002). The use of transgenic and knockout mice, as well as 
antisense oligonucleotides to knock down specific pathways has allowed the 
validation of the diacylglycerol-mediated insulin hypothesis of insulin resistance 
through manipulation of key proteins in the pathway (Erion and Shulman, 
2010). 
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Figure 1.4 Proposed mechanism for fatty acid-induced insulin resistance in 
human skeletal muscle ² adapted from Shulman et al. (Shulman, 2000). An 
increase in delivery of fatty acids and/or a decrease in intracellular fatty acid 
metabolism lead to an increase in intracellular fatty acid metabolites such as 
fatty acyl CoA, diacylglycerol and ceramides. These metabolites activate a 
serine/threonine kinase cascade, presumably mediated by protein kinase C 
(PKC)-ƨ OHDGLQJ WR SKRVSKRU\ODWLRQ RI VHULQHWKUHRQLQH VLWHV DQG LQKLELWLQJ
phosphorylation of tyrosine sites on IRS. Consequently, the decreased ability of 
IRS to activate PI-3 kinase leads to impaired insulin signalling and decreased 
GLUT-4 translocation and glucose transport. 
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1.5.2 0HFKDQLVPRIƢ-cell dysfunction 
6HYHUDO LQKHULWHG DQG DFTXLUHG IDFWRUV KDYH EHHQ LGHQWLILHG WR DIIHFW Ƣ-cell 
function. Given that type 2 diabetes is very heterogeneous, genetic studies have 
so far yielded very diverse results. To date, only a few polymorphisms have 
been identified as risk factors with confidence. One of them is the Pro12Ala 
SRO\PRUSKLVPLQWKH33$5ƣZKLFKLVH[SUHVVHGLQLQVXOLQWDUJHWWLVVXHVDQGƢ-
cells. This polymorphism conveys susceptibility to adverse effects of NEFA on 
insulin release (Stumvoll and Haring, 2002). The second involves the gene 
encoding calpain-10, a cysteine protease that modulates insulin release as well as 
insulin effects on muscle and adipose tissue (Horikawa et al., 2000). The third is 
the E23K variant of the Kir6.2 gene (potassium inwardly-rectifying channel J11 
gene) which has been shown in a large association study to increase the risk of 
W\SH  GLDEHWHV E\  SUHVXPDEO\ WKURXJK LWV HIIHFW RQ Ƣ-FHOOV· SRWDVVLXP
channel and in turn on insulin secretion (Gloyn et al., 2003). Use of knockout 
mouse models has identified several elements of the insulin signalling cascade 
WKDW PLJKW EH SRWHQWLDO VLWHV ZKHUH JHQHWLF SRO\PRUSKLVPVPD\ DIIHFW Ƣ-cell 
function but to date none of these has been found to occur in individuals with 
type 2 diabetes (Saltiel and Kahn, 2001). 
Hyperglycaemia, both acute and chronic, has been shown to adversely 
DIIHFWƢ-cell function. Correction of hyperglycaemia with use of secretogogues, 
insulin sensitizers anGHYHQLQVXOLQLPSURYHVƢ-cell function in individuals with 
type 2 diabetes (Garvey et al., 1985, Yki-Jarvinen, 2004). Hyperglycaemia has 
been proposed to lead to large amounts of reactive oxygen species in Ƣ-cells, 
with subsequent damage to cellular components (Robertson et al., 2003). 
However, glucotoxicity is unlikely to be WKHSULPDU\FDXVDWLYHIDFWRUEHFDXVHƢ-
cell dysfunction does not completely reverse despite optimization of glycaemic 
control. Lipotoxicity associated with elevated levels of NEFA is commonly 
observed in the obese, the insulin-resistant and individuals with type 2 diabetes 
and has been linked to decreased insulin synthesis and increased metabolic 
VWUHVV LQƢ-cells (Standl, 2007, Poitout and Robertson, 2002). A number of in 
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vitro and animal studies have demonstrated that chronic exposure to elevated 
1()$OHYHOV LPSDLUVƢ-cell function (Poitout and Robertson, 2002). Evidence 
suggests that elevated NEFAs inhibit glucose-stimulated insulin secretion, 
LPSDLU LQVXOLQ JHQH H[SUHVVLRQ DQG SURPRWH Ƣ-cell apoptosis (Poitout and 
Robertson, 2002). One proposed mechanism involves the uncoupling protein-2 
(UCP-2), a mitochondrial carrier protein that uncouples substrate oxidation 
from ATP synthesis (Fleury and Sanchis, 1999). NEFA is said to increase UCP-
 DFWLYLW\ LQ Ƣ-cells, which leads to impaired ATP generation from glucose 
metabolism and consequently decreased glucose-stimulated insulin secretion 
(Chan et al., 1999, Medvedev et al., 2002). Another mechanism might involve 
DSRSWRVLVRIƢ-cells via fatty acid or triglyceride-induced ceramide synthesis or 
generation of nitric oxide (Robertson et al., 2004).  
$P\ORLG GHSRVLWLRQ LQ Ƣ-cells is a characteristic histopathology feature of 
type 2 diabetes, and has been observed in up to 90% of individuals with type 2 
diabetes at autopsy (Clark et al., 1990, Kahn et al., 1999). Human amyloid, 
composed of insoluble fibrils formed from a protein called amylin or islet 
DP\ORLG SRO\SHSWLGH KDV EHHQ UHSRUWHG WR EH F\WRWR[LF WR Ƣ-cells, possibly 
related to radical production (Butler et al., 2003b). However, it is unlikely to 
have a major role in the pathogenesis of type 2 diabetes as it is not present in all 
patients with type 2 diabetes and is actually found in up to 20% of islets in 
elderly individuals with normal glucose tolerance (Clark et al., 1988). 
 
1.5.3 Reversibility of type 2 diabetes  
Gastric bypass surgery has been known for 25 years to bring about major 
weight loss and improve glucose tolerance in morbidly obese individuals. In the 
original series by Pories et al., 86 of 88 obese people with diabetes reverted to 
normal glucose tolerance within 4 months, and this remained normal over 6 
years of follow-up (Pories et al., 1987). A large prospective, case control study, 
the Swedish Obese Subjects Study, suggests that weight loss arising from 
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bariatric surgery reduces the incidence of type 2 diabetes by up to 97% 
(Sjostrom et al., 1999, Sjostrom et al., 2004). In a recent meta-analysis by 
Buchwald and colleagues, resolution of diabetes was achieved in 99% after 
bilio-pancreatic diversion, 84% for gastric bypass and 48% for gastric banding 
(Buchwald et al., 2004). Bilio-pancreatic diversion consists of distal gastric 
resection with closure of duodenal stump, transaction of the small intestine, 
proximal anastomosis to stomach and anastomosis of the remaining ileum to 
the distal ileum. At the other end of the scale, gastric banding involves 
placement of an adjustable cuff around the gastro-oesophageal junction, and 
may be done via a laparoscope. Simple gastric bypass involves ileo-gastric 
anastomosis so that food bypasses the duodenum and upper jejunum. Initially, 
the resolution of type 2 diabetes has been attributed to the weight loss imparted 
by these operations;; however, there are observations that suggest other factors 
may play a role. Resolution of diabetes often occurred days following bariatric 
surgery, before any substantial weight loss (Guidone et al., 2006, Pories et al., 
1995). It has therefore been suggested that diabetes resolution or improvement 
after bariatric surgery may be related to some of the changes in the gut-related 
hormones (Bose et al., 2009). One proposed hypothesis regarding the 
mechanism of increased incretins following bariatric surgery is the rapid 
exposure of the distal gut to nutrients ² VR FDOOHG WKH ¶KLQGJXW· WKHRU\
0HDQZKLOHWKH¶IRUHJXW·WKHRU\SURSRVHVWKDWJOXFRVHKRPHRVWDVLVLVLPSURYHG
as a consequence of the exclusion of the foregut from nutrient exposure. 
However, both hypotheses overlook a crucial change that immediately follows 
all categories of bariatric surgery ² an acute, profound decrease in calorie intake.  
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1.6 Magnetic Resonance Techniques in Metabolism 
Magnetic resonance is a phenomenon which occurs when the nuclei of certain 
atoms are immersed in a static magnetic field and exposed to a second 
oscillating magnetic field. This phenomenon forms the basis of magnetic 
resonance spectroscopy and magnetic resonance imaging, both of which are 
non-invasive techniques suitable for metabolic research into both normal 
physiology and disease in humans. Specifically, MR spectroscopy allows for the 
continuous monitoring of tissue concentrations of metabolites and metabolic 
fluxes while MR imaging is well-suited for fat quantification due to its ability to 
provide sensitive mechanisms for differentiating fat from lean tissues based on 
relaxation time and chemical-shift properties.  
 
1.6.1 Basic principles 
Certain atomic nuclei possess magnetic properties known as magnetic moment 
RUVSLQ,QWKHHDUWK·VZHDNPDJQHWLFILHOGƬ7HVODVXFKQXFOHLDUHXVXDOO\
randomly aligned. However in the presence of a strong magnetic field, the 
nuclei will precess around their own axes with a characteristic frequency so as 
to align with or against the magnetic field. The frequency of the precession is 
directly proportional to the strength of the magnetic field and is known as the 
resonant frequency. By applying a transient radio signal at the resonant 
frequency of the nuclei, energy is absorbed by the nuclei causing them to move 
out of alignment, usually at 90 degrees to the direction of the magnetic flux. 
Once the signal has ceased, the nuclei will swing back into their original 
alignment and emit the energy they have absorbed. This energy is released in 
the form of an oscillating magnetic field which induces an electric current in a 
receiver coil. Under standard experimental conditions, resonant signals from 
nuclei incorporated into different chemical species are superimposed, 
generating a picture of oscillating amplitudes in an intensity vs. time display 
(known as free induction decay, FID).  Fourier transformation, a mathematical 
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transformation is used to convert the FID display into a display of signal 
intensities vs. frequencies, thereby enabling one to distinguish compounds with 
characteristic peak frequencies (Figure 1.4). 
 
 
 
 
 
Figure 1.5 Diagrammatic representation of the signal emitted by the excited 
nuclei LQ LWV´UDZµIRUP, known as free induction decay (FID) which displays 
the signal in the time domain (left). Before an FID can be usefully analysed, it 
must first be transformed to the frequency domain (right) by a mathematical 
operation known as Fourier transformation.   
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The intensity of each signal in the spectrum is proportional to the amount 
of the originating atomic nuclei from the tissue under study, while the 
radiofrequency range where the radio signal could appear depends on the 
atomic nuclei and the strength of the magnetic field. The exact position of the 
signal in its possible radiofrequency range depends mainly on the electronic 
environment of the molecule in which the nucleus is located and on the 
interaction with neighbouring nuclei, although in some instances other 
microenvironment conditions (i.e. pH, solvent, binding to ions, temperature) 
could affect this position as well. Each peak of the spectrum is characterised by 
its resonance frequency, height, width and area. The area under the peak may 
be calculated to give a relative measure of the concentration of the nuclei being 
studied. This result can be converted into molar terms by comparison with data 
obtained from a phantom containing a known amount of that compound. It 
can also be compared with the area under the peak of an intrinsic compound 
with a known concentration e.g. water peak in muscle. The ability to distinguish 
between different molecules containing the same nucleus relies upon what is 
NQRZQ DV ´FKHPLFDO VKLIWµ 7KLV LV D GLVSODFHPHQW RI WKH VSHFWUDO SHDN E\ D
unique amount which is measured in parts per million (ppm). The electrons 
surrounding each nucleus have a shielding effect and the nuclei of different 
molecules thereby experience an altered static magnetic field and in turn 
resonate at an altered frequency, i.e. chemical shift, which is typical for the 
respective molecule. In order to examine a defined small volume of tissue, a 
surface coil which receives the MR signal is placed over the region of interest to 
ensure homogenous tissue filling in that region. 
 
1.6.2 Magnetic resonance spectroscopy 
This is a technique for acquiring metabolic information from a volume of 
tissue. It relies on the inherent differences in resonance frequency or chemical 
shift that exist due to different chemical environments experienced by the 
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nuclei. It allows continuous, non-invasive monitoring of tissue concentrations 
of metabolites and metabolic fluxes in vivo. The most common nuclei exploited 
in MR spectroscopy studies applied to metabolic organs are 1H, 31P and 13C. 
The suitability of a nucleus for MR spectroscopy depends on its relative 
magnetic sensitivity, the tissue concentration range of the studied metabolites, 
and the chemical shift range. The 1H nucleus is the most sensitive of the 
resonant nuclei, its natural abundance is almost 100% of the available pool of 
hydrogen containing molecules, and almost all biological molecules contain 
hydrogen. 1H MR spectroscopy application in metabolic studies lies mainly in 
its evaluation of intra-organ lipid metabolism. The very large 1H signals of water 
and lipids in living samples, so useful for magnetic resonance imaging, obscure 
direct visualization of other signals from metabolites of much lower 
concentration in MR spectroscopy. 31P has 100% natural abundance, but its 
spectroscopic sensitivity is much lower than 1H. The molecules that are most 
commonly visualised by 31P MR spectroscopy are linked to skeletal muscle 
bioenergetics and the metabolism of carbohydrates. In contrast to 1H and 31P, 
13C has a natural abundance of 1.1% and therefore a relatively low sensitivity. 
Nevertheless, this nucleus can be used to study glycogen and fatty acid 
metabolism. When necessary, 13C-enriched isotopes can be used to enhance the 
13C signal strength by a factor of up to 100.  
 
1.6.2.1 31P MR spectroscopy 
31P MR spectroscopy is well suited for study of skeletal muscle bioenergetics. In 
muscle, the phosphorus atoms detected by MR spectroscopy reside 
predominantly in ATP, PCr and Pi. Other 31P-containing compounds present in 
much lower concentrations are ADP and AMP;; their concentrations are often 
below 1 mmol/l and therefore are too small to be visible on the spectra. These 
phosphorus-containing molecules (phosphagens) are of interest because of 
their central role in the energy flux of the cells. As previously mentioned, the 
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two different 31P MR spectroscopy techniques applied are the ATP saturation 
transfer experiment and the measurement of post-exercise PCr recovery. The 
ATP saturation transfer experiment yields the rate of unidirectional flux from Pi 
towards ATP through ATP synthase at rest. Using a specific 31P pulse sequence, 
the ATP signal is temporarily suppressed (saturated) and the subsequent 
changes of the steady state signal derived from Pi are monitored to calculate 
ATP synthesis rate. This process is illustrated by the spectra in Figure 1.5. The 
saturation transfer experiment can also be applied to study the creatine kinase 
(CK) reaction, in which Pi + creatine <-> PCr buffers the ATP <-> ADP + Pi 
reaction. Due to the relatively fast exchange of the reactants of the CK reaction, 
VDWXUDWLRQRIWKHƣ-ATP peak results in large differences in the magnetization of 
PCr.  
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Figure 1.6 Diagrammatic representation of a saturation transfer experiment 
between Pi and ATP from calf muscle. (A) Control spectrum with characteristic 
signals from Pi, PCr and the three phosphate molecules of ATP;; (B) spectrum 
obtained with WKH ƣ-phosphate spin of ATP selectively irradiated to make its 
signal invisible to MR (grey arrow);; (C) the difference spectrum showing a clear 
effect that part of the Pi signal has disappeared as well (black arrow), which is 
because this pool is in rapid H[FKDQJHZLWKWKHƣ-phosphate of ATP in the ATP 
synthase reaction. 
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1.6.2.2 13C MR spectroscopy 
The measurement of human skeletal muscle glycogen concentration using 13C 
MR spectroscopy has been validated against the more widely used method of 
muscle biopsy and direct biochemical assay for glycogen concentration (Taylor 
et al., 1992). There was a strong correlation between the two methods of 
measurement over a broad concentration range (r = 0.95;; p < 0.0001). 
Moreover, the 13C MR spectroscopy method was found to be more precise than 
the biopsy measurements;; the coefficient of variation being 4.3 ± 2.1% for MR 
spectroscopy compared with 9.3 ± 5.9% for the biopsy method despite the 
optimisation of the latter technique. Therefore, in vivo 13C MR spectroscopy is 
not only precise but also accurate as judged against biochemical assessment 
from biopsy samples. 
 
1.6.2.3 1H MR spectroscopy 
The use of 1H MR spectroscopy to detect and quantify the different cellular 
compartments for stored lipids has been well validated. In animal models, 
hepatic triglyceride content measured by this method has been shown to 
correlate very closely to that measured chemically by liver biopsy (r = 0.934;; p < 
0.0001) (Szczepaniak et al., 1999). When applied to human calf muscle, based 
on the observation of two distinct lipid resonances, it is possible to differentiate 
between fat stored within cytoplasm of muscle fibres i.e. IMCL and that stored 
in adipocytes between muscle fibres i.e. EMCL (Schick et al., 1993). The 
coefficient of variation of the technique in measuring the IMCL content was 
11.8% in non-obese subjects and 7.9% in obese subjects and of EMCL content 
was 22.6% and 52.5%, respectively. Hence, non-invasive in vivo 1H MR 
spectroscopy measurement of intramyocellular triglyceride is feasible and 
comparable in accuracy to other conventional methods such as electron 
microscopic morphometry and biochemical analysis from biopsy samples 
(Schick et al., 1993, Boesch et al., 1997).   
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1.6.3 Three-point Dixon magnetic resonance imaging 
The degree of fatty infiltration within an organ can be accurately estimated by 
either MR spectroscopy or chemical shift imaging. The difference between the 
precession frequencies of fat and water protons enables the use of chemical 
shift techniques to accurately detect and quantify fatty infiltration. In the 
original Dixon method, water and fat are separated using two image 
acquisitions (a two-point technique) (Dixon, 1984). Simple summation and 
subtraction of the two image sets yielded water-only and fat-only images that 
allowed direct image-based fat quantification. The main limitation of this 
method is that of magnetic field inhomogeneity (for example, homogeneity 
introduced from the presence of the patient within the MR scanner or at 
interfaces between air and soft tissue) which yields a phase error that leads to an 
incorrect solution for the water and fat images. The phase error can be 
corrected by using the information from a third data acquisition, thus termed 
the three-point Dixon method (Glover and Schneider, 1991). The chemical 
shift difference between water and fat resonances at 3 Tesla is 435 Hz, and 
therefore the proton spins of these two moieties are out of phase with each 
other at an echo time of 1000/(2*435) = 1.15 ms and all odd multiples of this 
echo time (3.45 ms, 5.75 ms): in short, the signals from fat and water moieties 
subtract. At even multiples of this echo time (2.3 ms, 4.6 ms, 6.9 ms) the water 
and fat proton signals add constructively. By acquiring three echoes (two out-
of-phase and one in-phase) at adjacent echo times, separate intensities of fat (F) 
and water (W) within the MR signal can be extracted while also making 
allowance for the magnetic field (B0) inhomogeneity. Additionally, the 
introduction of fast gradient-echo sequences with shorter echo times (TEs) and 
repetition times (TRs) with the three-point Dixon method has helped reduced 
acquisition time and also made breath-hold acquisitions possible. A 
comprehensive study of liver fat content in 110 subjects (including many with 
abnormally high liver fat content), compared various forms of multi-point 
Dixon method with proton MR spectroscopy in the liver and demonstrated 
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that the three-point Dixon technique with T2* correction was highly correlated 
with spectroscopy and had a slope very close to the line of identity (0.94) 
(Yokoo et al., 2009). However, in the pancreas, the correlation between 
methods of fat-water MR imaging and spectroscopic measurement has been 
observed to be weaker (Hu et al., 2009). The coefficient of variation in the 
repeatability of pancreatic proton MR spectroscopy itself varied widely from 4.5 
to 15.2% in comparison to liver proton MR spectroscopy (4.7%) (Tushuizen et 
al., 2007, Lingvay et al., 2009).  These discrepancies are most likely due to the 
varying degree of MR signal contamination from surrounding visceral fat 
presumably during respiratory motion. The three-point Dixon method has 
several advantages over MR spectroscopy in that it can be easily performed 
within a breath-hold, thus not requiring respiratory gating and in subsequent 
post-processing where manual segmentation of the organ allowed careful 
avoidance of blood vessels and non-tissue structures.  
 
1.6.4  Advantages and disadvantages 
MR methods are attractive for studies of human physiology and/or 
pathophysiology because they are non-invasive, non-radioactive and infinitely 
repeatable, thus allowing for longitudinal monitoring. Major metabolic organs 
such as liver, skeletal muscle, pancreas, adipose tissue and brain are suitable for 
either MR spectroscopy or imaging studies or even both. On the other hand, 
these techniques are limited by practical difficulties. MR methods in general are 
very susceptible to movement of the observed region. Subjects must lie still 
within the confined space of the magnet for long periods of time, for example, 
20 minutes for 13C spectrum acquisition. Movement during the acquisition of 
MR images and spectra can lead to smearing effects in phase direction of 
images and spectral line distortion, resulting in inaccurate quantification. In 
order to record enough signal for reliable calculation, signal to noise ratio must 
be optimal. For example, when 13C MR spectroscopy is performed on natural 
42 
 
abundance 13C metabolites at physiological concentrations, sensitivity is poor 
due to low signal to noise ratio. In order to derive quantitative information 
from MR spectroscopy, it is necessary to convert the obtained spectra into 
meaningful metabolic measurements. The quantitative evaluation of the spectra 
is performed using special software programmes which allow the incorporation 
of previous knowledge for improved spectral fitting. Although the AMARES 
method within java-based magnetic resonance user interface (jMRUI) is well 
validated for use in spectral analyses, two commonly encountered problems are 
the need to adjust for baseline correction to broad peaks and for overlapping 
spectral peaks. In addition subjects with metal implants must be excluded for 
safety reasons.  
 
 
1.7 Aims of the Studies 
The aims of this thesis are to address the concept of skeletal muscle 
mitochondrial dysfunction in relation to insulin resistance and type 2 diabetes, 
and to investigate the reversibility of the twin defHFWVRIƢ-cell dysfunction and 
insulin resistance in type 2 diabetes so as to unravel the basic pathogenetic 
mechanism of the disease. Non-invasive MR techniques play a crucial role in 
being the methodologies that were predominantly applied in the presented 
studies.  
The studies described in Chapter 3 and 4 relate to the study of in vivo 
skeletal muscle mitochondrial function in type 2 diabetes and healthy subjects. I 
postulated that the observations of impaired capacity of the mitochondria to 
produce ATP in muscle of type 2 diabetes may be a consequence of reduced 
insulin action. This in turn is reflected by reduced glucose transport and muscle 
glycogen synthesis. Inhibition of lipolysis is known to improve insulin 
sensitivity and evidence suggests that it does so by improving glucose 
metabolism, specifically by increasing muscle glycogen synthesis. Consequently, 
43 
 
this would be expected to also improve muscle ATP turnover rate. The study, 
described in Chapter 3, was therefore designed to test this hypothesis using 
acipimox, a nicotinic acid derivative that reduces lipid availability. In addition, 
by enhancing muscle glycogen synthesis through mass action of raising blood 
glucose level, I was able to examine the relationship between muscle glycogen 
synthesis rate and ATP synthesis rate.  
Chapter 4 deals with the sub-study that arose as a consequence of the 
initial observations of the study described in Chapter 3. Given the findings in 
the literature presented earlier, I expected to observe an acute effect of insulin 
on muscle ATP turnover rate in the healthy control subjects. When I did not 
observe this in the first three healthy control subjects (one male, two females;; 
age 46 ± 3 years;; and BMI 27 ± 1) in Chapter 3, I set up this sub-study to 
examine the relative time course of insulin action in stimulating muscle ATP 
turnover rates and glucose uptake into skeletal muscle in a group of young, lean 
normoglycaemic subjects. I purposefully selected this cohort so as to maximise 
any measurable effect. Measurements of muscle ATP turnover rate were 
performed continuously over 150 min period during a standard euglycaemic-
hyperinsulinaemic clamp. 
The third study, described in Chapter 5, was designed to test the 
hypothesis that acute negative energy balance alone can reverse type 2 diabetes 
E\ QRUPDOLVLQJ Ƣ-cell function and insulin sensitivity. Specifically, this work 
aimed to test whether the reduction of intracellular fatty acid concentrations in 
the pancreas and liver would result in the reversal of the twin defects of Ƣ-cell 
dysfunction and insulin resistance respectively.    
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2.1 Research Subjects 
2.1.1 Recruitment 
Subjects with an established diagnosis of type 2 diabetes, with or without 
metformin and/or sulphonylurea therapy were recruited. Subjects on other oral 
hypoglycaemic agents or insulin treatment were excluded. Subjects were also 
excluded if they had evidence of renal dysfunction (defined by serum creatinine 
> 150 mmol/l) or liver dysfunction (defined by serum alanine transaminase > 
2.5 fold above upper limit of reference range) or if they were on thiazide 
diuretics or steroids as these would have an effect on metabolism (Lithell, 1991, 
Pagano et al., 1983).  
The subjects were recruited from the Newcastle Diabetes Centre and 
General Practices within the North and South of Tyne Primary Care Trusts. 
Suitable individuals were identified from Newcastle Diabetes Centre databases, 
or by their General Practitioner. Once identified, a letter was sent giving a brief 
outline of the study and asking whether or not they would be interested in 
participating. Those who then responded positively were sent the information 
sheet detailing the purpose, nature and potential risks of the study.  
Healthy volunteers were identified and subsequently recruited by advertising 
for research participants in the Newcastle Hospitals, Newcastle University, and 
Newcastle City Council. The advertisement provided brief outline of the study 
and details of how to volunteer. Those who responded to the advertisement 
were then sent the information sheet giving further details of the study. Again 
subjects were excluded if they were taking any of the medications listed above. 
No subjects in the control group had a family history of diabetes. Normal 
glucose metabolism was confirmed by a standard 75g OGTT (Lucozade Energy;; 
GlaxoSmithKline Ltd., Middlesex, UK) following an overnight 12 hour fast. A 
total of 22 healthy volunteers were screened;; 17 had normal glucose tolerance 
test while four had impaired glucose tolerance and one had impaired fasting 
glycaemia according to WHO criteria. None of the control or the type 2 diabetic 
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subjects performed intense exercise, heavy physical work or physical training on 
a regular basis. 
Individuals who expressed an interest in participating in the studies were 
contacted by telephone. The study concerned was explained to them in detail, 
and any queries they had were answered. It was made clear to the subjects that 
agreeing to participate in the study was not binding, and that they were free to 
withdraw from the study at any time. On the day of the study, subjects were 
again informed of the procedure and the purpose, nature and potential risks of 
the study. Written, informed, voluntary consent was then obtained prior to their 
participation. All study protocols were reviewed and approved by the Newcastle 
upon Tyne and North Tyneside Local Research Ethics Committee 2.   
 
2.1.2 Anthropometric and body composition 
2.1.2.1 Body mass index 
Body weight was measured to the nearest 0.1 kg with subjects in light indoor 
clothing (shoes removed) on an upright pedestal digital scale (Seca Ltd., 
Birmingham, UK). Height was measured to the nearest 0.5 cm (shoes removed) 
using a stadiometer (Seca Ltd., Birmingham, UK). Body mass index was 
calculated from weight and height measurements (BMI = weight in kilograms 
divided by height in meters squared). 
 
2.1.2.2 Waist-hip ratio 
A non-sticking plastic tape measure was used for all measurements, which were 
taken with the subjects in DUHOD[HGSRVWXUH7KHVXEMHFW·V waist circumference 
was taken as the mid-point between the anterior superior iliac spine and the 
lower edge of their ribcage. Hip circumference was taken from the level of the 
VXEMHFW·VJUHDWHUWURFKDQWHU 
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2.1.2.3 Air displacement plethysmography 
Body composition was determined after an overnight fast by whole-body air 
displacement plethysmography using the BodPod Body Composition System 
(Life Measurement Inc., Concord, USA). This system is based on a two-
compartment model of body composition (fat mass and fat-free mass), and uses 
WKH LQYHUVH UHODWLRQVKLS EHWZHHQ SUHVVXUH DQG YROXPH %R\OH·V ODZ WR GHULYH
body volume (l) for each subject. Once body volume is determined, the 
principles of densitometry are used to determine body composition from body 
density. Percent body fat is then estimated using the Siri equation [% body fat = 
(495 divided by body density) ² 450] (Siri, 1961). Prior measurement of the 
volume of the chamber is calibrated with a known standard (49.550 l) and the 
weighing scales calibrated against a known weight (20 kg). Subjects were asked 
to wear minimal clothing (swimsuit and swim cap) as hair and clothing had 
negative volume effects that alter body volume measurements. Before entering 
WKH %RG3RG FKDPEHU VXEMHFW·V Eody weight was measured on the calibrated 
scale attached to the BodPod system. Whilst in the chamber, the subject was 
instructed to sit quietly in a relaxed manner with normal respirations. The 
VXEMHFW·V DJH KHLJKW DQG VH[ ZHUH HQWHUHG LQ WKH FRPSXWHU V\VWHP DQG WZR
estimates of body volume were then obtained using predicted lung volume to 
calculate percent body fat. The intra-device repeatability, indicated by within-
subject coefficient of variation (CV) for repeated measurements within a day 
was 0.9%.   
 
2.1.3 Physical activity level 
Physical activity was assessed over 3 days using the Body Monitoring System and 
SenseWear Armband (BodyMedia®, Pittsburgh, USA). The SenseWear 
Armband is a multi-sensor body monitor, worn on the back of the upper 
dominant arm, that allows calculation of energy expenditure and quantification 
of metabolic physical activity in free-living individuals (Fruin and Rankin, 2004, 
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Mignault et al., 2005). Validation of resting and activity related energy 
expenditure against doubly labelled water show high degrees of correlation and 
correspondence (Mignault et al., 2005). The SenseWear Armband employs four 
physiological sensors to continuously record an array of physiological data 
allowing overall measurement of energy expenditure. A two-axis accelerometer 
tracks the movement of the upper arm and provides information about body 
position. A heat-flux sensor measures the rate at which heat is being dissipated 
from the body. Surface skin temperature changes are also measured by sensitive 
thermistors. The device also measures galvanic skin response (the conductivity 
RIWKHZHDUHU·VVNLQGXHWRVZHDWDQGGLODWLRQRIWKHVZHDWJODQGVZKLFKYDULHV
due to physical and emotional stimuli. Data are analysed using the InnerView® 
Professional software which contains activity detection and lifestyle algorithms 
to apply appropriate formula to estimate energy expenditure from the sensor 
data. Parameters calculated and reported include total energy expenditure, active 
energy expenditure, resting energy expenditure, metabolic equivalent of task 
(MET), total number of steps, physical activity duration, sleep duration and time 
spent lying down.  
 
 
2.2 Magnetic Resonance Methods  
Magnetic resonance data were acquired using a 3 Tesla Philips Intera Achieva 
scanner (Philips, Best, The Netherlands) with an in-built body coil used for 
imaging.  
 
2.2.1 Magnetic resonance spectroscopy  
A 14-cm diameter surface coil was used for phosphorus spectroscopy and a 6-
cm diameter 13C coil with an integral quad 1H decoupling coil (PulseTeq, 
Wotton under Edge, UK) was used for 13C spectroscopy. Subjects remained 
supine inside the magnetic resonance spectrometer with each coil positioned 
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beneath the widest part of the left calf during each investigation. The coil 
position was marked on the leg with indelible ink. Scout images were acquired 
to ensure identical coil positioning on repeat scans. To prevent movement 
during each study, the coil was secured in place using fabric straps around the 
calf. Analysis of all spectra was performed with jMRUI (version 3.0) (Naressi et 
al., 2001) using the AMARES fitting algorithm (Vanhamme et al., 1999).  
 
2.2.1.1 31P MR spectroscopy 
Resting ATP turnover rate was measured using saturation transfer sequence 
between J-ATP and Pi (Lebon et al., 2001). For each measurement, the Pi 
concentration was estimated from a 1D-ISIS spectrum centered on the 
gastrocnemius and soleus muscles (TR = 25 s, 8 averages, duration 3.3 min). 
Broadband 1H decoupling was applied to data acquisition in all experiments. 
The J-ATP resonances were assumed to have concentration 8.2 mM in line with 
previous studies (Harris et al., 1974, Arnold et al., 1984): the resonance 
frequency was placed mid-way between the J-ATP and Pi resonances to ensure 
as even an excitation as possible at 3 Tesla. The pseudo-first order rate constant 
of the ATP synthase reaction was then estimated by a saturation transfer 
experiment as follows. The steady state-magnetization (Mz) of Pi was measured 
during selective irradiation of J-ATP and compared with the equilibrium Pi 
magnetization (M0) measured with the irradiation placed symmetrically down-
field from the Pi frequency (TR = 25 s, bandwidth = 3000 Hz, 2048 points, 16 
averages each, duration 13.3 min). The resonant frequency was set at the Pi 
frequency to allow symmetrical saturation pulses about that resonance. The 
fractional reduction of Pi magnetization upon saturation of J-ATP,  
(M0 - Mz)/M0, was used to calculate the pseudo-first order rate constant using 
the Forsen-Hoffman equation: k1 = [(M0 - Mz)/M0](1/T1*), where T1* is the 
spin-lattice relaxation time for the phosphorus nucleus of Pi when ATP is 
saturated (Forsen and Hoffman, 1963). T1* was measured using an inversion 
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recovery experiment (W1 - 180q - W2 - 90q - acquire, TR = 25 s, four averages), 
while saturation of J-ATP was performed during the delay times W1 and W2. Eight 
variable W2 time delays were used ranging from 635 to 9,035 ms. Therefore the 
time required for a complete saturation transfer measurement was 26.7 mins. 
Unidirectional turnover of ATP synthesis was then calculated by multiplying the 
constant k1 by the Pi concentration. The Pi concentration was measured from 
the spectrum acquired without irradiation. Prior knowledge was used to solve 
the dataset as follows: single Lorentzian peaks were modeled for Pi, 
phosphodiesters (PDE) and 3&U7KHơ- DQGƣ-ATP resonances were modeled 
as Lorentzian duplets of equal magnitude separated by 18Hz. Due to the 
bandwidth of the pulses used and tuning Pi WR EH RQ UHVRQDQFH WKH Ƣ-ATP 
resonance is only weakly detected and is not modeled. To fit the saturation 
transfer and inversion recovery experiments the zero and first order phasing and 
the Pi linewidth was determined from the control saturation scan. Phase values 
were then applied using the previous prior knowledge to fit the saturation, 
control and inversion recovery data. This provides sufficient stability to fit 
inversion recovery spectra with peaks of different T1* value using the AMARES 
algorithm. Sample spectra are given in Figures 2.1 and 2.2.  In preparatory work 
using implementation of the saturation transfer technique, three healthy subjects 
were studied three times on one day without repositioning of the radiofrequency 
coil, yielding an intra-day variability of 6.5% in ATP turnover rate, and were 
studied twice more on two further separate days to examine the effect of coil 
repositioning, yielding an inter-day reproducibility of 8.0% in ATP turnover rate 
(Trenell et al., 2008).  
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Figure 2.1 MR spectra from a study subject acquired using the saturation 
WUDQVIHUPHDVXUHPHQWVKRZLQJERWWRPWKHVDWXUDWLRQRIƣ-ATP at -2.38 ppm 
and (top) the control saturation at 2.38 ppm. The differences in the amplitudes 
of PCr and Pi show the saturation transfer effect. 
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Figure 2.2 (A) Inversion recovery data showing Pi, PDE and PCr during 
inversion recovery and saturation. 12 Hz line broadening has been applied 
though fitting is in time domain. (B) Inversion recovery curve for Pi plotted 
through the eight inversion recovery data points. In this case, T1* = 3.90 s. 
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2.2.1.2 13C MR spectroscopy 
The distance between the 13C/1H decoupling coil surface and the muscle was 
recorded from scout images. The 13C pulse power was calibrated to a nominal 
value of 80q in the tissue of interest by observing the power-dependent variation 
in signal from a fiducial marker located in the coil housing, containing a sample 
exhibiting a 13C signal with short T1 (213 mM [2-13C]-acetone and 25 mM GdCl3 
in water). Spectra showing the glycogen [1-13C] resonance were acquired using a 
non-localized 1H-decoupled 13C pulse-acquire sequence (TR = 200 ms, spectral 
width = 8 kHz, 3000 averages, WALTZ decoupling, nominal tip angle = 80q) 
over a 15-min acquisition time. Calibration of 13C spectra was performed by 
comparison of in vivo glycogen [1-13C] signal amplitudes with that of a standard 
glycogen solution [100 mM oyster glycogen (Sigma Aldrich Ltd., Gillingham, 
UK), 70 mM KCl and 0.05% sodium azide). Quantitation was performed by 
comparison of signal amplitude to those from a leg-shaped phantom acquired at 
a range of separations between coil and phantom, representative of the 
separation between coil and muscle due to skin and subcutaneous fat. The same 
coils, pulse sequences, and tip angles as employed for in vivo spectra were used 
for acquisition of these calibration data. The concentration of muscle glycogen, 
[Glyc]muscle, was calculated using the formula: 
 
                                  
phantom
phantom muscle
muscle
[Glyc]
 [Glyc]
S
S u
  
 
where Sphantom and Smuscle are the signal intensities arising from glycogen in the 
phantom and muscle, respectively, and [Glyc]phantom is the concentration of 
glycogen in the phantom (100 mmol/l). The coefficient of variation for muscle 
glycogen measurement using this method has been reported at 4.3% (Taylor et 
al., 1992). The increments in muscle glycogen concentration at x min and y min 
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RI WKH FODPS >ƅ*O\Fx@ DQG >ƅ*O\Fy] respectively, were calculated from the 
published equation (Jue et al., 1989):  
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where S0, Sx and Sy represent the signal intensity of glycogen at 0, x and y min, 
and [Glyc0] is the basal glycogen concentration in mmol/l. f0 corresponds to the 
natural abundance enrichment of 13C-glycogen at baseline (1.1%), and fx and fy 
correspond to the mean percentage 13C enrichment of plasma glucose at x and y 
min respectively. Each increment was then added to the previous concentration, 
and the slope calculated by linear regression to yield the rate of muscle glycogen 
synthesis (Shulman et al., 1990).  
 
2.2.1.3 1H MR spectroscopy 
Proton spectroscopy was acquired using a PRESS sequence localised to a 15 x 
15 x 20 mm voxel of tissue located in the soleus muscle with water suppression 
(TR = 3000 ms, bandwidth = 2000 Hz, 2048 points and 32 averages). Sixteen 
averages were collected without suppression for reference. Proton spectra were 
analysed for IMCL from the water suppressed spectra and water from the non-
water suppressed spectra. IMCL was then expressed relative to the water 
reference. 
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2.2.2 Three-point Dixon magnetic resonance imaging 
Three gradient echo scans where acquired with adjacent out-of-phase, in-phase 
and out-of-phase echoes. For human studies, the fat-water frequency difference 
at 3 Tesla is 435 Hz, and echo times of 3.45 ms, 4.60 ms and 5.75 ms were used 
to acquire adjacent out-of phase, in-phase and out-of phase images. A breath 
hold time of less than 17 seconds was used. The real and imaginary data (not 
magnitude corrected data) was then uploaded to a custom MATLAB 
(Mathworks, Cambridge, UK) script, following the algorithm outlined in Glover 
et al. (Glover and Schneider, 1991) to produce separate fat and water images 
(Figure 2.3). The fat content of the image (F) was then expressed as a 
SHUFHQWDJH RI WKH WRWDO VLJQDO LQ WKH RULJLQDO VLJQDO ): OHDGLQJ WR D ´IDW
SHUFHQWDJH LQ WKH YLVLEOH 05 VLJQDOµ RU ZKDW LV KHQFHIRUWK UHIHUUHG DV ´IDW
FRQWHQWµ 7KLV H[cludes components which are invisible to MR at these echo 
times (chiefly structural macromolecules). Region-of-interest (ROI) definition 
was performed with ImageJ 1.43 (Abramoff et al., 2004), a freely available 
software, using the polygon ROI tool. 
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Figure 2.3 Three-point Dixon technique of the liver and pancreas. Water (top 
panel), fat (middle panel) and combined water and fat images (bottom panel) of 
the liver and pancreas. 
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2.2.2.1 Hepatic and pancreatic fat  
7KHDQDWRPLFDOSRVLWLRQRIWKHVXEMHFW·VOLYHUDQGSDQFUHDVZDVILUVWDVFHUWDLQHG
by axial sections acquired by a single shot balanced turbo-field echo (bTFE or 
true-FISP) sequence (TR = 2.8 ms, TE = 1.4 ms, number of averages = 1, flip 
angle = 40°, matrix of 172 x 192, median field of view = 440 mm, range 400 ² 
480 mm to suit subject size with 70% phase field of view, turbo factor 101, 18 
slices, slice thickness 5 mm and scan duration of 12.1 s). A SENSE factor 
(parallel imaging) of two was used in the phase direction. After completion of 
the automated reconstruction of the three-point Dixon images, the images were 
then independently analysed. The signal intensity in the images was calculated 
with investigator-defined ROIs (Figure 2.4). A total of five ROIs for the liver 
and two ROIs for the pancreas were acquired and averaged, with care given to 
placement of the ROIs to avoid contamination from blood vessels, gallbladder 
and visceral fat. The smaller number of ROIs was acquired for the pancreas due 
to its small size and elongated shape. The analysis was carried out in a blinded 
fashion by a single trained investigator (Dr Kieren Hollingsworth). To assess the 
reproducibility of this process of image analysis, one-quarter of the images were 
independently analysed by another trained investigator (myself). There was close 
DJUHHPHQWEHWZHHQ WKH WZR LQYHVWLJDWRUV· DQDO\VHVRIKHSDWLF DQGSDQFUHDV IDW
content, with the inter-observer CV at 1.9% and 2.5% respectively. Validation 
of the three-point Dixon method of measuring hepatic and pancreatic fat 
content by this method has been established and the inter-scan repeatability 
coefficients were found to be 0.5% for the liver and 0.9% for the pancreas. 
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Figure 2.4 Polygonal ROI manually drawn at the same location in both water 
(left-side) and fat (right-side) images of the pancreas to avoid confounding 
anatomy such as large vessels and also to avoid the edges of the organ due to 
problems of partial averaging. A total of 2 contiguous slices of the pancreas 
were selected for drawing ROIs.  
 
 
2.2.2.2 Visceral and subcutaneous adipose tissue areas 
Visceral and subcutaneous fat measurements were performed by acquiring 
images at the L4/L5 junction using a three-point Dixon sequence (TR = 50 ms, 
TE = 3.45, 4.60 and 5.75 ms, number of averages = 1, flip angle = 30°, matrix 
of 160 x 109, median field of view = 440 mm, range 400 ² 480 mm to suit 
subject size with 70% phase field of view). The slice was acquired during a 
breath-hold of 16-18 seconds and with slice thickness of 10 mm (Donnelly et 
al., 2003, Shen et al., 2004). Fat and water signals were separated, and binary 
gating applied to produce a map of structures containing more than 50% fat, 
identified as subcutaneous and visceral fat. A watershed algorithm was used to 
divide the binary image into distinct areas and allowed easy separation of the 
subcutaneous and visceral fat. Total adipose tissue area was calculated using 
image analysis software ImageJ 1.43 (Abramoff et al., 2004). The subcutaneous 
adipose tissue (SAT) area was then segmented and measured. The visceral 
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adipose tissue (VAT) area was then calculated as total adipose tissue area minus 
SAT area. This is illustrated in Figure 2.5. The inter-observer CV for SAT and 
VAT measurements were 2.8% and 2.2% respectively.    
 
62 
 
 
 
Figure 2.5 Top panel: The three-point Dixon fat percentage map acquired at 
the L4/L5 junction. Middle panel: Segmentation of structures with more than 
50% fat (visceral and subcutaneous fat). Total area is calculated. Bottom panel: 
Application of thresholding algorithm divides segmented image into chunks and 
separates visceral and subcutaneous fat around muscle boundaries. Selection of 
subcutaneous fat allows measurement of this area and subtraction from the total 
yields visceral fat area.  
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2.3 Metabolic Studies 
2.3.1 Venous cannulation and blood sampling 
An 18 gauge cannula (Vasofix£;; B. Braun Medical Ltd., Sheffield, UK) was 
inserted into a large antecubital vein for administration of intravenous glucose 
and insulin. A second cannula was inserted into the contralateral wrist vein for 
the purpose of blood sampling. Both lines were flushed with 0.9% sodium 
chloride. The hand with the wrist vein cannulation was kept warm for sampling 
of arterialised blood by placing it in between two hot water bottles which were 
changed regularly at 30 minutes interval to ensure continuous vasodilatation. 
Pilot blood samples were collected into a heparinised syringe and put on ice for 
transport to the Biochemistry Department at Royal Victoria Infirmary where 
pH, pO2, O2 saturation and pCO2 were measured using the 800 Blood Gas 
System (Bayer Corporation, Norwood, MA, USA) to confirm complete 
arterialisation. After 10 minutes of placement of the hot water bottles, oxygen 
VDWXUDWLRQ RIZDVmaintained throughout (Figure 2.6). The intravenous 
line for the sampling of arterialised blood was flushed with 0.9% sodium 
chloride after each blood sample was taken to keep the line patent. In order to 
avoid dilution of blood samples, the initial 2 ml of blood withdrawn was 
discarded and a fresh syringe was used to collect the blood sample. Blood 
samples were spun down and separated before being frozen at ²40qC at the 
Newcastle Magnetic Resonance Centre before being transported in dry ice to 
the Diabetes Research Laboratory for assaying.   
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Figure 2.6 Measurement RIR[\JHQFRQWHQWRI¶DUWHULDOLVHG·YHQRXVEORRGWDNHQ
from a wrist vein of one subject as a function of time. The hand was placed 
between two hot water bottles at time zero. At 30 minutes, the hot water bottles 
were replaced with new ones. 
 
 
2.3.2 Hepatic glucose production  
2.3.2.1 6,6-dideuterated glucose 
The 6,6-dideuterated glucose was made up into 10% solutions using sterile 
technique. All subjects were given a priming dose of 6,6-dideuterated glucose 
intravenously adjusted according to fasting plasma glucose level to allow early 
establishment of steady-state isotope enrichment (Hother-Nielsen and Beck-
Nielsen, 1990, Ravikumar et al., 2008). This was followed by a continuous 
infusion for 270 min. The prime dose for a fasting plasma glucose level of 5 
mmol was 300 mg and the resulting equation for other fasting plasma glucose 
level was: 
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To achieve equilibrium of 6,6-dideuterated glucose, a continuous infusion of 
6,6-dideuterated glucose (0.04 mg/kg/min) was commenced after the bolus 
injection. The 6,6-dideuterated glucose was infused at a rate of 0.12 ml/kg/hr, 
at a concentration of 20 mg/ml. For each study, a 1 ml sample (labelled NINF) 
was taken from the prepared 6,6-dideuterated glucose infusate (2% strength) for 
later analysis. In order to prevent any fall in atom percent excess (APE) of 6,6-
dideuterated glucose during the insulin-glucose clamp, the 6,6-dideuterated 
glucose infusate was continued for the duration of the clamp. In addition, the 
variable glucose infusion used in order to maintain glycaemia during the clamp 
was enriched with 2% of 6,6-dideuterated glucose. For each enrichment, a 1 ml 
sample (labelled GINF) was taken for later analysis.  
Plasma samples for determination of 6,6-dideuterated glucose APE were 
taken as follows: 
Time Plasma glucose  Plasma 2H2 APE 
-160 Y Y 
-150 Y Y 
-90 Y Y 
-30 Y Y 
-20 Y Y 
-10 Y Y 
0 Y Y 
5 Y  
10 Y  
15 Y  
20 Y  
25 Y  
30 Y Y 
35 Y  
40 Y  
45 Y  
50 Y  
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55 Y  
60 Y Y 
65 Y  
70 Y  
75 Y  
80 Y  
85 Y  
90 Y Y 
95 Y  
100 Y Y 
105 Y  
110 Y Y 
115 Y  
120 Y Y 
 
Table 2.1 Blood sampling schedule for assessing hepatic glucose production. 
 
 
2.3.2.2 Gas chromatography-mass spectrometry analysis 
Frozen samples were allowed to thaw and approximaWHO\  ƬO SODVPD ZDV
WUDQVIHUUHG WR DQ(SSHQGRUI WXEH EHIRUH  ƬO DFHWRQLWULOHHWKDQRO  ZDV
added. Following a vortex mix, the sample was spun in a micro-centrifuge at 
13000 rpm for 5 min. The supernatant was then transferred to a 1 ml v-vial and 
eYDSRUDWHGWRGU\QHVVDW&XQGHUDJHQWOHVWUHDPRIGU\DLUƬOS\ULGLQH
DQGƬODFHWLFDQK\GULGHZHUHDGGHGWRGU\WKHUHVLGXH7KHYLDOZDVFDSSHG
and heated on a dry block heater at 90 °C for 20 min. The samples was then 
cooled and evaporated to dryness at 90 °C under a gentle stream of dry air.  The 
SHQWDDFHWDWHGHULYDWLYHRIJOXFRVHZDVWKHQGLVVROYHG LQƬODFHWRQLWULOH7KH
samples were then analysed using gas chromatography-mass spectrometry (GC-
MS) analysis.  
GC-MS analysis was carried ouWRQD7KHUPR¶9R\DJHU·VLQJOHTXDGUXSROH
PDVVVSHFWURPHWHULQWHUIDFHGWRD7KHUPR¶7UDFH·*&ZLWKDXWRPDWHGLQMHFWLRQ
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YLD D7KHUPR ¶$6· DXWRVDPSOHU 7KHUPR6FLHQWLILF:DOWKDP0$86$
Samples for the glucose analysis were analysed under EI-SIM conditions with 
separation of the pentaacetate derivatives carried out on a Zebron 30 m x 0.25 
PP[ƬP=%-5 ms capillary column (Phenomenex, Torrance, CA, USA). 
,QMHFWLRQVRIƬOZHUHPDGHLQWKHVSOLWPRGHZLWKDVSOLWDQGWKHLQMHFWLRQ
port was maintained at a constant 260 °C. The carrier gas was Helium at a 
constant flow of 1 ml/min. GC conditions were: 100 °C ramping to 275 °C at a 
rate of 20 °C/min with a terminal hold of 5 min;; MS: the mass detected were 
200 and 206 (6,6 di-deuterated glucose). The CV for the precision of plasma 2H2 
APE measurements was 4.1%. The APE of the 2H2 infusate was measured 
similarly and the CV was 3.4%. 
 
2.3.2.3 Calculation of hepatic glucose production 
Hepatic glucose production (HGP) can be estimated during steady-state 
conditions. HGP can be measured in the basal state and under conditions of 
hyperinsulinaemia ² giving an index of hepatic insulin action. HGP is estimated 
indirectly using the model proposed by Steele et al (Steele et al., 1965), which are 
based on a single-compartment model for glucose and non-steady-state 
conditions. This approach assumes that the liver is the only source of 
endogenous glucose production during steady-state glucose infusion, and thus 
that HGP represents the difference between the rates of glucose appearance in 
circulation (Ra) and its disappearance (Rd). Although gluconeogenesis does occur 
in the kidneys, it is at a low rate and accounts for a very small portion of HGP 
(Ekberg et al., 1999, Gerich et al., 2001). 
Basal rates of Ra or HGP were calculated during the last 30 min of the 150 
min basal period by dividing the tracer infusion rate times tracer enrichment by 
the tracer enrichment in plasma and subtracting the tracer infusion rate 
(Inzucchi et al., 1998). During the insulin-glucose clamp, calculations were made 
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over the last 30 min of the 120 min clamp and HGP was calculated by the 
following formula: 
 
Clamp HGP = GIRmean x [(enrichmentinf/enrichmentplasma) ² 1] 
 
where GIRmean is the mean glucose infusion rate during the last 30 min of the 
clamp, enrichmentinf is the APE of glucose in infusate, and enrichmentplasma is the 
APE of plasma glucose during the steady-state conditions of the clamp. 
 
2.3.3 Peripheral insulin sensitivity 
2.3.3.1 Preparation of [1-13C] glucose 
In order to increase sensitivity of measurement of muscle glycogen synthesis by 
13C MR spectroscopy, the variable glucose infusion used during the insulin-
glucose clamps was enriched with 20% of [1-13C] glucose. The [1-13C] glucose 
(Cambridge Isotope Laboratories, Andover, MA, USA) was made up into 20% 
solutions in either 10 ml or 50 ml vials by the Pharmacy Production Unit at the 
Pharmacy Department of the Royal Victoria Infirmary. 
 
2.3.3.2 Isoglycaemic-hyperinsulinaemic clamp 
Isoglycaemic hyperinsulinaemia was induced with the insulin-glucose clamp 
technique (DeFronzo et al., 1979). Isoglycaemia rather than euglycaemia was 
maintained in order to ensure that the true basal condition of each subject could 
be observed. Insulin (Actrapid;; Novo Nordisk, Bagsvaerd, Denmark) was 
administered as a prime-continuous infusion (40 mU/m2/min) for 150 mins. To 
inhibit endogenous insulin secretion, somatostatin (Somatostatin-UCB;; UCB 
Pharma, Netherlands) was infused at 0.06 µg/kg/min from 5 min before the 
start of the insulin infusion and continued for the duration of the clamp. Fasting 
isoglycaemia was maintained by a variable glucose infusion containing 20% [1-
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13C] glucose based on plasma glucose measurements performed at 5 min 
intervals in studies employing 13C MR spectroscopy. For studies using 6,6-
dideuterated glucose to determine hepatic glucose production, a 10% dextrose 
infusion labelled with 6,6, di-deuterated glucose (2% enriched) according to the 
hot glucose infusion (hot GINF) protocol was periodically adjusted to maintain 
isoglycaemia during clamps.  
The amount of insulin required for each clamp was individually calculated 
according to body surface area (BSA) at 40 mU/m2/min to achieve plasma 
insulin concentration ~400 pmol/l as follows: 
 
BSA (m²) = 0.007184 x Height 0.725 x Weight 0.425 
where the height is in centimetres and the weight is in kilograms (DuBois and 
DuBois, 1916).  
 
Units of insulin needed to add to 50 ml 0.9% sodium chloride 
=   BSA (m2) x 0.04 (U) x 60 (min) x syringe volume (50 ml)   
constant infusion rate (15 ml/h) 
 
Example, for an 80 kg man of 175 cm in height;; 
the amount of insulin required = (1.956 x 0.04 x 60 x 50) y 15 = 15.6 Units 
 
A 7-min priming insulin infusion was then started as follows: 
 4 x constant infusion rate from time 0 ² 4 min 
 2 x constant infusion rate from time 4 ² 7 min 
This was followed by a continuous infusion of: 
 1x constant infusion rate from time 7 ² end of clamp 
where constant infusion rate was set at 15 ml/hr. 
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The mean CV of plasma glucose level in the last 30 min of the clamps was 
2.0%, while the mean CV of glucose infusion rate in the last 30 min of the 
clamps was 4.5%. 
 
2.3.3.3 Hyperglycaemic-hyperinsulinaemic clamp 
The hyperglycaemic-hyperinsulinaemic clamps were carried out in the same way 
as the isoglycaemic-hyperinsulinaemic clamps except that blood glucose was 
clamped at 5 mmol/l above fasting concentration. The mean CVs of plasma 
glucose level and of glucose infusion rate in the last 30 min of the clamps were 
2.1% and 6.5% respectively. 
 
2.3.3.4 Calculation of whole-body glucose metabolism  
Whole-body insulin sensitivity was determined during the last 30 min of the 
hyperinsulinaemic glucose clamp as whole-body glucose disposal corrected for 
glucose space and urinary loss (DeFronzo et al., 1979). Whole-body glucose 
disposal was calculated from the glucose infusion rate (Rizza et al., 1981). 
Glucose metabolic clearance rates during steady-state conditions were calculated 
by dividing whole-body insulin sensitivity expressed as mg/kgffm/min (where 
ffm is fat free mass) by steady-state plasma glucose. To assess rate of oxidation 
of infused glucose, breath samples for 13CO2 measurements were obtained as 
described in the next sub-section. As this measure would be affected by 
differences in plasma 13C glucose enrichment, the index of whole-body glucose 
oxidation was calculated as the ratio of breath to plasma 13C APE ([breath 
APE/plasma APE] x 100). 
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2.3.3.5 Breath 13C analysis 
Breath samples for 13C enrichments were collected by asking subjects to exhale 
fully through a short straw into a glass tube (Labco Exetainer;; Labco Ltd., 
Buckinghamshire, UK). The tube was immediately stoppered. 13C enrichments 
of breath samples were determined by continuous flow isotope ratio mass 
spectrometry (ABCA System;; PDZ Europa Ltd., Crewe, UK). Breath samples 
were obtained just before the start of the insulin-glucose clamp (0 min), at 15 
min, 45 min, 90 min and at the end of the clamp (150 min). In one of the 
control subject (randomly selected), eight breath samples were obtained 
consecutively over a 5 min period at the end of the insulin-glucose clamp. Data 
from this collection was used to calculate the CV for the analysis of 13C 
enrichment of expired air and for the collection of the breath sample, which 
were 0.07% and 0.3% respectively. All results of 13C enrichment of expired air 
measurements are expressed as APE.  
 
2.3.4 Ƣ-cell sensitivity to glucose 
2.3.4.1 Stepped insulin secretion test with arginine  
To fully characterize first phase and maximal insulin secretory responses to 
consecutive steps of hyperglycaemia, a modified protocol from Toschi et al. 
(Toschi et al., 2002) was carried out. This consisted of two consecutive 30-min 
square-wave steps of hyperglycaemia (2.8 and 5.6 mmol/l above baseline) 
followed by an intravenous bolus of 5 g arginine. The priming dose of glucose 
for each step was calculated by multiplying the desired increment in plasma 
glucose concentration by the body glucose space (estimated to be 150 ml per kg 
of body weight). The 20% dextrose volume thus calculated was administered 
over 1 min. After the glucose bolus, plasma glucose concentrations were 
maintained at the desired plateau by means of a variable 20% glucose infusion 
according to the glucose clamp technique (DeFronzo et al., 1979). Blood 
samples for the determination of plasma glucose, plasma insulin and C-peptide 
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concentrations were obtained every 2 min for the first 6 min, at 10 min and 
every 5 min for the other 20 min of each step. After the arginine bolus, blood 
was sampled every 2 min for 10 min. 
 
2.3.4.2 Calculation of insulin secretion rate 
Insulin secretion rate was calculated using ISEC (Hovorka et al., 1996). ISEC is 
a computer program which implements a regularisation method of 
deconvolution (Twomey, 1965) constrained to non-negative values and uses a 
population model of C-peptide kinetics (Van Cauter et al., 1992). (DFKVXEMHFW·V
age, weight, height, gender and classification of diabetes status together with C-
peptide concentrations were supplied to ISEC as input and it produced the 
insulin secretion rate as output. A 1 min step-size was used and the coefficient 
of variation was individually and experimentally selected for each subject (range 
of CV = 5-9%). The computer programming and analysis were carried out by 
Dr Benjamin Aribisala. All insulin secretion values were expressed per square 
meter of body surface area.   
 
2.3.5 Metabolites and hormone assays 
Plasma glucose levels were measured by the glucose oxidase method (YSI 
glucose analyser;; Yellow Springs Inc., Ohio, USA) (CV for measurement 
[control (10 mmol/l)]: 2.8%). Plasma insulin and C-peptide levels were both 
measured using ELISA kits (DAKO;; Ely, Cambridgeshire, UK) (CV for 
measurement [insulin range 400 ² 500 pmol/l]: 5.5% and [C-peptide range 1.20 
² 2.00 nmol/l]: 7.1%). Plasma NEFA concentration was measured on a Roche 
Cobas centrifugal analyser using an enzymatic colorimetric Wako kit (Wako 
Chemicals, Neuss, Germany) (CV for measurement [range 1.02 ² ƬPROO@
3.2%). Plasma triglyceride levels were hydrolysed by lipase, and the released 
glycerol was measured on a Roche Cobas centrifugal analyser using a 
colorimetric assay (ABX Diagnostics, Montpellier, France) (CV for 
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measurement [range 1.07 ² 1.39 mmol/l]: 6.2%). Plasma 3-hydroxy-butyrate 
levels were measured on perchloric acid extracts using a Cobas biocentrifugal 
analyser (Roche Diagnostics, Welwyn Garden City, UK). HbA1c was measured 
by Biorad HPLC (TOSOH Corporation, Tokyo, Japan). The HbA1c assay was 
standardised upon that used in the diabetes complications and control trial 
central laboratory at the University of Minnesota, with an upper limit of normal 
of 6.1% (Gibb et al., 1997). 
The 13C enrichment in plasma glucose was determined by GC-MS of the 
pentaacetate derivatives of plasma glucose after deproteinization and 
deionization as described in sub-section 2.3.3.2. The glucose pentaacetate was 
analysed on a Thermo Finnigan Trace 2000 GC interfaced to a Voyager MS and 
AS2000 autosampler. Selective ion monitoring was used to determine tracer 
enrichments in the molecular mass ion fragment of glucose. The masses 
detected were 331 and 332 molecular weight (MW). The CV for the precision of 
13C enrichment in plasma glucose was 5.8% at an average enrichment of 14.4 
APE. 
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3.1 Introduction 
Skeletal muscle mitochondrial dysfunction has been hypothesised to contribute 
to the development of insulin resistance and type 2 diabetes. Muscle biopsy 
studies of type 2 diabetes subjects demonstrated smaller mitochondria and 
reduced activities of oxidative enzymes compared with glucose-tolerant subjects 
(He et al., 2001, Kelley et al., 2002). Using 31P MR spectroscopy to determine in 
vivo skeletal muscle mitochondrial function, Petersen and colleagues were the 
first to observed impairment in ATP turnover rates in skeletal muscle of 
insulin-resistant offspring of type 2 diabetic patients, both in the basal 
overnight-fasted condition and after stimulation by insulin (Petersen et al., 
2004, Petersen et al., 2005b). This was associated with an increase in 
intramyocellular lipid content. These findings led the authors to suggest that 
insulin resistance in these young offspring was due to dysregulation of 
intramyocellular fatty acid metabolism, which may be caused by an inherited 
defect in mitochondrial oxidative phosphorylation. A similar impairment in 
muscle ATP turnover rates have been observed in individuals with type 2 
diabetes (Szendroedi et al., 2007). Decreased expression of nuclear-encoded 
genes that regulate mitochondrial biogenesis such as PGC-1D has also been 
reported in non-diabetic individuals with impaired glucose tolerance and in 
healthy first-degree relatives to type 2 diabetes patients (Mootha et al., 2003, 
Patti et al., 2003). These studies provide further support that abnormalities in 
oxidative metabolism may contribute to the development of insulin resistance 
and hence type 2 diabetes (Chanseaume and Morio, 2009, Pagel-Langenickel et 
al., 2010).  
In humans, the causal relationship between dyslipidaemia and insulin 
resistance has been examined in detail over the past several decades (McGarry, 
1994, Boden, 1997). Elevated plasma NEFA levels are associated with many 
insulin-resistant states including type 2 diabetes and obesity (Reaven et al., 
1988). Mitochondrial dysfunction has been suggested to be a key factor linking 
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increased NEFA levels to insulin resistance. Indeed, elevation of plasma NEFA 
levels in young healthy individuals via the use of lipid infusion induces hepatic 
and peripheral insulin resistance by a similar mechanism to that described in 
subjects with type 2 diabetes, i.e. increased intracellular fatty acid metabolites 
and impaired insulin signaling (Roden et al., 1996, Dresner et al., 1999, Griffin 
et al., 1999, Itani et al., 2002, Belfort et al., 2005). Employing in vivo 
measurement of mitochondrial function, Brehm and colleagues showed that 
short-term elevation of circulating lipids via lipid infusion was associated with 
impaired insulin-stimulated ATP synthesis in skeletal muscle of insulin-sensitive 
individuals in parallel with induction of insulin resistance as seen in type 2 
diabetes (Brehm et al., 2006). Physiological elevation of NEFA levels in insulin-
sensitive individuals increased intramyocellular fatty acyl CoA levels and down-
regulated the expression of multiple genes encoding mitochondrial proteins 
including those involved in oxidative phosphorylation (Richardson et al., 2005), 
suggesting that elevated concentrations of fatty acid metabolites cause an 
acquired mitochondrial defect that leads to impaired substrate oxidation in 
skeletal muscle (Abdul-Ghani et al., 2008).  
However, a substantial number of recent studies both in humans and 
rodents directly challenge the view that a defect in mitochondrial function, 
whether inherited or acquired, is responsible for the development of insulin 
resistance. In obese humans, muscle biopsy studies have observed 
improvement in mitochondrial function, reflected by an increase in electron 
transport activity without changes in mitochondrial content, after programs of 
weight loss and physical exercise (Menshikova et al., 2005). Furthermore, 
improvement in insulin sensitivity through calorie restriction has been 
demonstrated in overweight and obese subjects in the absence of any 
measurable change in mitochondrial DNA content and NADH-oxidase activity 
(Toledo et al., 2008). Several studies of genetically modified mice have failed to 
demonstrate a clear effect of altering mitochondrial function on insulin action 
(Handschin et al., 2007, Calvo et al., 2008). In light of all the evidence 
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presented, the reduced capacity of the mitochondria to produce ATP in muscle 
of type 2 diabetes could be secondary to the metabolic state itself, and a feature 
of insulin resistance rather than its cause (Phielix and Mensink, 2008, 
Szendroedi and Roden, 2008).  
Increased lipid availability could have a deleterious effect on mitochondrial 
respiratory capacity via down-regulation of the expression of the genes involved 
in biogenesis of mitochondria (Richardson et al., 2005, Hoeks et al., 2006), fatty 
acid peroxidation (Schrauwen and Hesselink, 2004)DQGLQFRPSOHWHƢ-oxidation 
leading to intra-mitochondrial accumulation of acyl CoA (Koves et al., 2008). 
The suppression of lipolysis by acipimox or nicotinic acid has long been known 
to improve meal tolerance and insulin sensitivity (Fulcher et al., 1992, Vaag et 
al., 1991b, Johnson et al., 1992). Sustained suppression of NEFA is associated 
with a decrease in intra-muscular long-chain fatty acyl CoAs and it is believed 
that this enhances glucose metabolism via substrate competition (Bajaj et al., 
2005). The mechanism for this interaction is well described, involving control 
of cellular glucose uptake in muscle (Roden et al., 1996). Both glucose oxidation 
and non-oxidative metabolism are involved, and as one of the original 
descriptions reported increase in the active form of glycogen synthase it has 
been assumed that increased rates of glucose storage as glycogen underlie the 
phenomenon (Vaag et al., 1991b). However, there is no direct in vivo evidence 
that glycogen synthesis rate is enhanced by NEFA suppression. This 
mechanism is important in fully understanding the insulin resistance of type 2 
diabetes and evaluating potential interventions. 
Application of 13C MR spectroscopy has demonstrated that insulin-
stimulated muscle glycogen synthesis is the major metabolic pathway of glucose 
disposal under post-prandial conditions, and that a defect in muscle glycogen 
synthesis was responsible for the decrease in insulin sensitivity in type 2 
diabetes (Shulman et al., 1990). Further study showed that reduced muscle 
glucose transport is responsible for the decreased rate of insulin-stimulated 
glycogen synthesis in muscle of type 2 diabetes (Cline et al., 1999). Therefore, 
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the hypothesis that acute suppression of lipolysis by acipimox in type 2 diabetes 
would improve the rate of glucose metabolism specifically by increasing muscle 
glycogen synthesis and thus muscle mitochondrial ATP turnover rates was 
tested in this study. In addition, it was hypothesised that impairment in insulin-
stimulated ATP turnover rates in type 2 diabetes would reflect the lower rates 
of muscle glucose uptake and glycogen synthesis, rather than causing it. If this 
is true, muscle ATP turnover rates in type 2 diabetes could be increased if 
glycogen synthesis rates were normalized by the mass action effect of 
hyperglycaemia. To test this second hypothesis, MR spectroscopy was used to 
quantify muscle ATP turnover rates and glycogen synthesis rates during 
isoglycaemic- and hyperglycaemic-hyperinsulinaemia in type 2 diabetic and non-
diabetic control subjects. 
 
 
3.2 Study Design 
3.2.1 Subjects 
Ten subjects with well-controlled type 2 diabetes (3 female, 7 male) and eight 
physical activity-, age- and BMI-matched normal glucose tolerant subjects (2 
female, 6 male) were studied (Table 3.1). All subjects were recruited by means 
of advertisement and underwent a complete medical history, clinical 
examination and lab tests to exclude hepatic and renal diseases. Patients with 
diabetes on insulin treatment or any oral hypoglycaemic medications apart from 
metformin were excluded. The individuals in the control group had neither a 
family history of diabetes nor were taking any medication known to affect 
glucose tolerance or insulin sensitivity. All subjects with diabetes and no control 
subjects were taking statins. Normal glucose metabolism was confirmed by a 
standard 75g OGTT. None of the subjects performed moderate or intense 
exercise on a regular basis. The research was carried out in accordance with the 
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Declaration of Helsinki (2000) and the study protocol was approved by the 
Newcastle upon Tyne Ethics Committee No. 2.   
 
 
Table 3.1 Clinical characteristic of study subjects 
 T2D 
(7M, 3F) 
Control 
(6M, 2F) 
p value 
Age (years) 57 ± 5 53 ± 7 0.3 
BMI (kg/m2) 28.7 ± 3.8 28.1 ± 3.1 0.8 
Fat mass  (kg) 26.1 ± 6.5 26.4 ± 4.8 0.9 
Fat free mass (kg) 54.7 ± 11.9 58.5 ± 10.1 0.5 
Fasting glucose (mmol/l) 7.7 ± 1.1 5.1 ± 0.3 0.001 
Fasting insulin (pmol/l) 93 ± 44 49 ± 18 0.026 
HbA1c (%) 
HbA1c (mmol/mol) 
6.5 ± 0.5 
48 ± 5 
5.4 ± 0.2 
36 ± 3 
0.001 
0.001 
Fasting triglyceride (mmol/l) 1.6 ± 0.7 1.4 ± 0.6 0.5 
Fasting total cholesterol (mmol/l) 
Fasting LDL-cholesterol (mmol/l) 
Fasting HDL-cholesterol (mmol/l) 
Average daily energy 
expenditure (cal) 
4.0 ± 0.9 
2.1 ± 0.8 
1.2 ± 0.2 
 
2455 ± 561 
5.6 ± 1.1 
3.7 ± 0.9 
1.4 ± 0.4 
 
2248 ± 215 
0.003 
0.001 
0.3 
 
0.4 
Average daily steps taken  6160 ± 1090 5701 ± 815 0.4 
Values are mean r SD. T2D, type 2 diabetes 
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3.2.2 Experimental protocol 
All subjects refrained from any physical exertion during the 3 days preceding 
the studies and fasted overnight for 12 hours before the experiments. 
Metformin was withdrawn 3 days before each experiment. For all experiments, 
subjects travelled to the Newcastle Magnetic Resonance Centre by taxi and 
were transported within the centre by wheelchair. At 0830 hours (-270 min), 
one cannula was inserted into an antecubital vein for administration of glucose 
and insulin. A second cannula was inserted into the contralateral wrist vein for 
blood sampling. Hand warming device was used to ensure arterialisation of 
venous blood (Copeland et al., 1992). 
 
3.2.2.1 Isoglycaemic-hyperinsulinaemic clamp tests 
Basal blood samples were taken and muscle spectroscopy to measure ATP 
turnover rate, glycogen and IMCL were performed (-260 to -180 min). Subjects 
were then given either acipimox 250mg or identical placebo tablets in a double 
blind fashion. Further 31P and 13C MR spectroscopy were acquired (-60 to -10 
min) before the start of the isoglycaemic-hyperglycaemic clamp (DeFronzo et 
al., 1979). Isoglycaemia was maintained in order to ensure that the true basal 
condition of each participant could be observed. Insulin (Actrapid;; Novo 
Nordisk, Bagsvaerd, Denmark) was administered as a primed-continuous 
infusion (40 mU/m2 body surface area/min) from 0 to 150 mins. To inhibit 
SDQFUHDWLF KRUPRQH VHFUHWLRQ VRPDWRVWDWLQ ZDV LQIXVHG DW  ƬJNJPLQ
(Somatosation-UCB;; UCB Pharma, Netherlands) from 5 min before the start of 
the insulin infusion and continued for the duration of the clamp. In order to 
increase sensitivity of measurement of the glycogen synthesis rate by 13C MR 
spectroscopy, the variable glucose infusion contained 20% [1-13C]-glucose 
(Cambridge Isotope Laboratories, Andover, MA). A further dose of acipimox 
250mg or placebo was given before the start of the clamp. Two further sets of 
31P and 13C MR spectroscopy measurements were acquired during the clamp. 
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The protocol is illustrated diagrammatically in Figure 3.1. Control subjects were 
studied with the administration of placebo tablets only. To permit the frequent 
MR measurements, subjects were studied lying in the scanner for the entire 
duration of each study (~6 hours). Subjects lay in a supine position and had 
their arm with the wrist vein cannula outstretched in a 90q angle to allow for 
frequent blood sampling.  
 
 
 
 
Figure 3.1 Schematic representation of experimental protocol where  denotes 
either doses of acipimox (250 mg) or identical placebo tablets were 
administered. 
 
 
3.2.2.2 Hyperglycaemic-hyperinsulinaemic clamp tests 
A hyperglycaemic-hyperinsulinaemic clamp was performed in all subjects on a 
separate day to examine the combined effect of insulin and glucose. The 
experimental protocol was the same as that for the isoglycaemic-
hyperinsulinaemic clamp except that plasma glucose was clamped at a stable 
level 5 mmol/l above fasting concentrations. The protocol is illustrated 
diagrammatically in Figure 3.2. Studies for each subject were carried out not 
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more than 4-8 weeks apart, during which their body weight and lifestyle 
remained unchanged during the period of the study. 
 
 
 
 
Figure 3.2 Schematic representation of the hyperglycaemic-hyperinsulinaemic 
clamp test. 
 
 
3.2.3 Statistical analysis 
Data are presented as mean ± SD, unless otherwise stated. Statistical analyses 
were performed using SPSS 15.0 software (SPSS Inc., Chicago, IL, USA). Prior 
to any comparisons, the data was tested for normality using Shapiro-Wilk test. 
Statistical comparisons between diabetic and control groups were performed 
XVLQJ 6WXGHQW·V t test while within group differences were determined using 
paired t test where appropriate. Changes of sequential data within experiments 
were evaluated by repeated measures analysis of variance (ANOVA) with post 
hoc Tukey correction where appropriate. Non-parametric tests were used to 
determine differences for non-normally distributed data. Correlations were 
examined using Spearman rank test. Statistical significance was accepted at p < 
0.05. 
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3.3 Results 
3.3.1 Plasma glucose, insulin and NEFA 
The experimental conditions necessary to test the hypothesis were achieved. 
During the 3 hour basal period, plasma glucose concentration remained steady 
in the control subjects (5.1 ± 0.3 to 5.0 ± 0.3 mmol/l) and gradually fell as 
expected in the diabetic subjects (7.7 ± 1.1 to 6.5 ± 1.0 mmol/l;; p = 0.002). As 
per protocol, plasma glucose concentration was clamped at 5.0 ± 0.3 mmol/l in 
control group, 6.6 r 0.8 mmol/l in diabetes/placebo group and 6.4 ± 0.6 
mmol/l in diabetes/acipimox group respectively (p < 0.001 diabetes vs. control;; 
Figure 3.3A). Average clamp plasma insulin concentration for all three 
experimental conditions was stable at 573 ± 61 pmol/l (Figure 3.3B). Plasma 
NEFA concentrations rapidly suppressed below 0.2 mmol/l in the 
diabetes/acipimox study (p = 0.005) and were stable;; plasma NEFA 
concentrations were similar in diabetes/placebo and control groups until 
commencement of insulin infusion (Figure 3.3C). Plasma enrichment of 13C-
glucose increased steadily upon the [1-13C] glucose infusion in all clamps (Table 
3.2). 
 
 
Table 3.2 Plasma enrichment of 13C-glucose (APE) during the studies 
Time (min) 0 15 45 90 150 
Isoglycaemic clamp: 
  Control 
  Diabetes/P 
  Diabetes/A 
0 
0 
0 
3.8 ± 1.1 
3.0 ± 1.4 
3.8 ± 1.3 
7.5 ± 2.1 
6.3 ± 1.6 
8.0 ± 1.4 
12.3 ± 1.9 
9.7 ± 1.9 
11.3 ± 1.9 
15.2 ± 2.0 
12.2 ± 1.8 
14.2 ± 2.0 
Hyperglycaemic clamp: 
  Control 
  Diabetes 
0 
0 
7.5 ± 2.0 
4.8 ± 1.4 
11.2 ± 2.5 
9.7 ± 1.6 
13.3 ± 2.1 
13.1 ± 2.3 
15.0 ± 1.8 
15.4 ± 2.4 
Values are mean ± SD. A, acipimox;; P, placebo 
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Figure 3.3 Time course of (A) plasma glucose, (B) insulin and (C) NEFA 
concentrations during the isoglycaemic-hyperinsulinaemic clamps in control 
ɿGLDEHWHVSODFHERƅDQGGLDEHWHVDFLSLPR[ɻVWXGLHV9DOXHVDUHPHDQ
± SD. *p < 0.05 diabetes vs. control. 
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3.3.2 IMCL content 
The ratio of IMCL to water was not different between the diabetes subjects and 
controls (0.022 ± 0.012 vs. 0.018 ± 0.009, p = 0.452). 
 
3.3.3 Glucose disposal rates and muscle glycogen  
During the clamp, glucose disposal rate was lower in the diabetes/placebo 
group compared with the control group (4.8 ± 2.0 vs. 6.6 ± 1.4 mg/kgffm/min, 
p = 0.04;; Figure 3.4A). Prior suppression of plasma NEFA by acipimox 
brought about a 23% increase of glucose disposal rate in the type 2 diabetic 
group (6.2 ± 2.6 vs. 4.8 ± 2.0 mg/kgffm/min, acipimox vs. placebo respectively, 
p = 0.005;; Figure 3.4A) so that it approached that of the control group (6.6 ± 
1.4 mg/kgffm/min;; p = 0.72). Fasting muscle glycogen concentration was similar 
in all three groups (diabetes/placebo: 67.5 ± 14.3 mmol/l, diabetes/acipimox: 
69.0 ± 6.8 mmol/l and control: 71.1 ± 7.3 mmol/l) and remained unchanged 
during the basal period. The increment in muscle glycogen concentration after 
70 min of insulin stimulation was small and not significantly different between 
the three groups. By the end of the clamp, insulin-stimulated muscle glycogen 
concentration increased by 3.8 ± 2.1 mmol/l in the control group and 1.9 ± 3.3 
mmol/l in the diabetes/placebo group (p < 0.05;; Figure 3.4B). Prior 
administration of acipimox did not change the increment in muscle glycogen 
(2.0 ± 2.3 mmol/l;; Figure 3.4B). The mean rate of muscle glycogen synthesis 
from 70 to 150 min was 40 ± 19 Ƭmol/l/min in the control subjects, 19 ± 27 
ƬPROOPLQ LQ the diabetes/placebo and 22 ± 24 ƬPROOPLQ LQ WKH
diabetes/acipimox groups (p < 0.05 for control vs. both diabetes groups). 
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3.3.4 Breath 13C enrichments 
13C APE in expired breath increased during the clamp in all groups (control 
0.23 ± 0.10 and 0.44 ± 0.15;; diabetes/placebo 0.14 ± 0.04 and 0.31 ± 0.08;; 
diabetes/acipimox 0.22 ± 0.05 and 0.44 ± 0.10 at 90 and 150 min respectively). 
In order to compare rates of glucose oxidation corrected for plasma glucose 
enrichment the ratio of breath to plasma 13C APE was examined. At the end of 
the clamp period this index of glucose oxidation was 2.53 ± 0.53 vs. 3.16 ± 
0.67 for diabetes/placebo and diabetes/acipimox respectively (p < 0.005) and 
2.87 ± 0.69 for controls (Figure 3.4C). 
 
3.3.5 Muscle ATP turnover rate 
Muscle ATP turnover rates are shown in Table 3.3 and Figure 3.5. Baseline 
ATP turnover rate in the diabetes/placebo group (8.6 ± 2.6 Ƭmol/g/min of 
muscle) was similar to that of the control subjects (8.6 ± 2.0 ƬPROJPLQRI
muscle). Muscle ATP turnover rate in the control group did not change during 
the basal period or during the insulin infusion (end of clamp: 8.6 ± 3.6 
Ƭmol/g/min of muscle). Although not statistically significant, there was a 
suggestion of a declining trend in ATP turnover rate during insulin infusion in 
the diabetes/placebo group HQGRIFODPSƬmol/g/min of muscle, p 
= 0.09).  This suggestion of a decline was not seen in the diabetes/acipimox 
group such that by the end of the clamp, ATP turnover rate was significantly 
higher than in the diabetes/placebo group (8.4 ± 2.1 vs. 7.1 ± 1.6 Ƭmol/g/min 
of muscle;; p = 0.02).  
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Figure 3.4 (A) Glucose infusion rates during the final 30 minutes in the 
isoglycaemic-hyperinsulinaemic clamps: control, diabetic with placebo and 
diabetic with acipimox. (B) Incremental changes in muscle glycogen 
concentration in the three studies. (C) Ratio of breath 13CO2 to plasma 13C-
glucose APE at the end of the each study. Values are mean ± SD. *p < 0.05;; **p 
< 0.005. 
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Table 3.3 Muscle ATP turnover rates (ƬPROg/min) during the studies 
Time -180 to -150 
min  
-60 to -30 
min 
15 to 45  
min 
90 to 120  
min 
Isoglycaemic clamp: 
  Control 
  Diabetes/P 
  Diabetes/A 
8.6 ± 2.0 
8.6 ± 2.6 
9.0 ± 2.1 
8.3 ± 2.6 
7.4 ± 1.6 
8.4 ± 1.8  
9.3 ± 3.1 
7.7 ± 2.1 
9.8 ± 3.0 
8.6 ± 3.6 
7.1 ± 1.6 
8.4 ± 2.1 
Hyperglycaemic clamp: 
  Control 
  Diabetes 
8.1 ± 2.4 
8.7 ± 2.2 
- 
- 
8.9 ± 2.0 
8.1 ± 1.9 
10.0 ± 2.6* 
8.6 ± 2.3 
Values are mean ± SD. A, acipimox;; P, placebo 
*p < 0.05 vs. baseline. 
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Figure 3.5 Muscle ATP turnover rate in control (open bar), diabetic with 
placebo (hatched bar) and diabetic with acipimox (filled bar) during basal 
period and after 120 min of isoglycaemic hyperinsulinaemia. Values are mean ± 
SD. *p < 0.05. 
 
 
3.3.6 Whole-body metabolism during hyperglycaemic- 
hyperinsulinaemic clamps 
The steady state plasma glucose concentrations necessary to test the second 
hypothesis were achieved. During the basal period, plasma glucose 
concentration decreased steadily in the diabetic group (7.7 ± 1.1 to 6.5 ± 1.0 
mmol/l, p = 0.002) and remained steady in the control group (5.1 ± 0.3 to 5.0 
± 0.3 mmol/l, p = 0.186). After observation of the basal state (-240 min to 0 
min), the clamp period was characterized by stable plasma glucose and plasma 
insulin concentrations (Figure 3.6). During this protocol, plasma glucose 
concentration was clamped at 10.6 ± 0.5 and 13.0 ± 1.1 mmol/l for control and 
diabetic subjects respectively (p < 0.01). Plasma enrichment of 13C-glucose 
increased steadily upon the [1-13C] glucose infusion during the studies (Table 
3.2).  
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Figure 3.6 Time course of (A) plasma glucose and (B) plasma insulin 
concentrations during the two experimental conditions: isoglycaemia in control 
ɿDQG LQGLDEHWLF ʀ VXEMHFWVK\SHUJO\FDHPLD LQFRQWURO ¨DQG LQGLDEHWLF
ɻVXEMHFWV9DOXHVDUHPHDQ6'*p < 0.01 control vs. diabetes. 
 
 
Data comparing glucose disposal rate, muscle glycogen synthesis and 
muscle ATP turnover rate during isoglycaemic hyperinsulinaemia and 
hyperglycaemic hyperinsulinaemia in the control and diabetes subjects is shown 
in Figure 3.7. Glucose disposal rate in the diabetes group increased 1.6-fold 
compared with the isoglycaemic clamp (7.7 ± 2.8 vs. 4.8 ± 2.0 mg/kgffm/min;; p 
= 0.005). Hence, the glucose disposal rate became similar to that of the control 
subjects at isoglycaemic hyperinsulinaemia (7.7 ± 2.8 vs. 6.6 ± 1.4 
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mg/kgffm/min;; p = 0.573). During hyperglycaemic clamps in the control group, 
glucose disposal rate also increased 1.6-fold compared with isoglycaemic clamps 
(10.5 ± 3.1 vs. 6.6 ± 1.4 mg/kgffm/min;; p = 0.01). 
Fasting muscle glycogen concentrations were similar on the isoglycaemic 
and hyperglycaemic clamp days (67.5 ± 14.3 and 67.0 ± 12.0 mmol/l 
respectively for diabetic subjects;; and 71.1 ± 7.3 and 72.3 ± 17.6 mmol/l 
respectively for control subjects). The mean rate of muscle glycogen synthesis 
from 70 to 150 min was lower in the diabetic group compared to controls 
during isoglycaemia (19 ± 27 vs. 40 ±  Ƭmol/l/min;; p = 0.012). This 
subnormal rate in the diabetic subjects at isoglycaemia was increased 2.2-fold by 
hyperglycaemia (19 ± 27 to 41 ± 38 ƬPROl/min (p = 0.013), making the 
glycogen synthesis rate almost identical to that of the controls at isoglycaemia 
(40 ± Ƭmol/l/min;; p = 0.460). In control subjects, the mean rate of muscle 
glycogen synthesis between 70 and 150 min was increased 2.5-fold by 
hyperglycaemia compared with isoglycaemia (100 ± 67 vs. 40 ± 19 
Ƭmol/l/min;; p = 0.028). The absolute increment in glycogen concentration in 
the diabetic subjects during hyperglycaemia was similar to that seen during 
isoglycaemic clamp conditions in the control group (3.8 ± 4.2 vs. 3.8 ± 2.1 
mmol/l, p = 0.515). In the control subjects during hyperglycaemia, the 
increment in glycogen concentration was three-fold higher compared to during 
isoglycaemia (11.1 ± 7.6 vs. 3.8 ± 2.1 mmol/l, p = 0.012).  
Muscle ATP turnover rates are shown in Table 3.3 and Figure 3.7. In 
diabetic subjects, during isoglycaemia, muscle ATP turnover tended to decline 
(8.6 ± 2.6 to 7.1 ± 1.6 Ƭmol/g/min;; p = 0.09), whereas hyperglycaemia 
prevented this decline in insulin-stimulated muscle ATP turnover rates (7.1 ± 
1.6 and 8.6 ± 2.3 Ƭmol/g/min for isoglycaemia and hyperglycaemia 
respectively;; p = 0.04). In control subjects, during the hyperglycaemic-
hyperinsulinaemic clamps, insulin increased muscle ATP turnover rate by 23% 
   YV    Ƭmol/g/min;; p = 0.025). Overall, muscle ATP 
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turnover rates correlated positively with muscle glycogen synthesis rates (rs = 
0.46, p = 0.005;; Figure 3.8). 
13C APE in expired breath increased steadily during the hyperglycaemic-
hyperinsulinaemic clamps in both the diabetic and control groups (diabetes: 
0.28 ± 0.08 and 0.50 ± 0.10;; control: 0.44 ± 0.20 and 0.72 ± 0.22 at 90 and 150 
min respectively). Whole-body glucose oxidation index was higher during the 
hyperglycaemic clamps compared to the isoglycaemic clamps in both diabetic 
(3.32 ± 0.67 vs. 2.53 ± 0.53, p = 0.001) and control subjects (5.06 ± 2.39 vs. 
2.87 ± 0.69, p = 0.008).    
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Figure 3.7 (A) Glucose disposal rate during the final 30 mins of the clamps, (B) 
muscle glycogen synthesis rate between 70-150 min and (C) muscle ATP 
turnover rate between 90-120 min in the isoglycaemic- and hyperglycaemic-
hyperinsulinaemic clamps. Values are mean ± SD. *p < 0.05 and **p < 0.01. 
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Figure 3.8 Positive correlation between muscle glycogen synthesis rate 
between 70-150 min and muscle ATP turnover rate in control (ɿDQGGLDEHWLF
ʀVXEMHFWV(rs = 0.46, p = 0.005).  
 
 
3.4 Discussion 
In the first part of this study, results showed that prior suppression of lipolysis 
effectively normalizes glucose infusion rate during hyperinsulinaemia in type 2 
diabetes, but has no effect upon the rate of muscle glycogen synthesis. In 
contrast, the subnormal rate of whole-body glucose oxidation in type 2 diabetes 
was increased. The muscle ATP turnover rate was found to be normal in type 2 
diabetes but could be modulated to a degree by suppression of lipolysis.  
In type 2 diabetes, insulin-stimulated whole-body glucose uptake was 
observed to be associated with a 2-fold lower incorporation of 13C glucose into 
glycogen. Acipimox brought about a 23% increase in glucose infusion rate 
during hyperinsulinaemia, similar to that reported by others (Vaag et al., 1991b, 
Bajaj et al., 2005). Previously observed increases in glucose disposal rates during 
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acipimox administration have been attributed to change in rate of glycogen 
synthesis (Vaag et al., 1991b, Lindegaard et al., 2007). Clearly this was not the 
case over the 6 hours of NEFA suppression in the present study, a period 
which has been shown to be sufficient for the effect upon glucose metabolism 
to be maximal (Roden et al., 1996). The concept that the synthesis rate of 
glycogen would be increased under such circumstances derives from the 
observation of an increase in the active form of muscle glycogen synthase, even 
though no change in muscle glycogen concentrations could be detected (Vaag 
et al., 1991b). Subsequently it has been demonstrated that a change in the 
activation state of glycogen synthase by suppression of lipolysis occurs in the 
absence of change in the proximal steps of insulin activation of glycogen 
synthase (GSK-ƢDQG$NW7KU(Lindegaard et al., 2007), and its relevance 
to substrate flux must be questioned.  
Glucose infusion rate is a useful independent measure of overall glucose 
disposal, but does not take into account possible incomplete suppression of 
hepatic glucose production during the clamp. An estimate of endogenous 
glucose production can be obtained from the measured isotopic enrichments of 
infusate and plasma together with glucose infusion rate (Ravikumar et al., 2008). 
However, as this is affected by recycling of the 13C, it will be a modest 
underestimation. Hepatic glucose production was 0.01 ± 0.79, 1.13 ± 0.56 and 
0.39 ± 0.75 mg/kgffm/min in control, diabetes/placebo and diabetes/acipimox 
groups.  By adding this value to the glucose infusion rate, total glucose disposal 
rates can be estimated to be 6.61 ± 0.79, 5.93 ± 1.97 and 6.59 ± 2.30 
mg/kgffm/min respectively. Hence, acipimox brought about an 11% increase in 
total glucose disposal. Isoglycaemic-hyperinsulinaemic clamps were used in this 
study in order to observe the physiological mechanisms operating at ambient 
plasma glucose concentrations in the diabetic and control subjects, and in 
respect of the primary comparison between acipimox and placebo studies in the 
diabetic subjects clamp glucose levels were similar.  
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Whole-body glucose oxidation rate was increased approximately 25% by 
acipimox administration. This could not be quantified using indirect calorimetry 
in the present study as subjects remained in the 3 Tesla magnet throughout the 
test periods. However, the extent of acipimox-induced change in glucose 
oxidation has previously been shown to be approximately one third of the 
simultaneous change in rate of whole-body glucose uptake (Vaag et al., 1991b). 
It is likely that processes additional to glucose oxidation and muscle glycogen 
synthesis could explain the change in whole-body glucose uptake. Glycolysis 
with lactate release (Cori cycle activity) could account for some of the change. 
Approximately 15% of a glucose load is taken up by skeletal muscle then 
released as lactate in normal health (Kelley et al., 1988) and accounts for 
approximately 45% of systemic lactate appearance (Consoli et al., 1992). In type 
2 diabetes, the proportion of glucose taken up by muscle then released as 
lactate is 2 to 3-fold higher than normal during hyperinsulinaemia (Mitrakou et 
al., 1990, Capaldo et al., 1990). This flux could be affected if early steps in 
glucose metabolism were rate limiting so that the increased transport of glucose 
into the muscle cell by low fatty acid availability caused increased export from 
muscle as lactate, and an 18% increase in plasma lactate has been observed to 
accompany acipimox-induced suppression of lipolysis during a clamp (Vaag et 
al., 1991a). Further work is required to examine specifically the acute changes in 
glycolysis and glucose oxidation in response to change in NEFA supply.  
Although the change in plasma NEFA is a useful general indicator of rate 
of lipolysis, suppression of lipolysis would be expected to exert greatest effect 
upon muscle metabolism by preventing breakdown of intramyocellular 
triglyceride and decreasing intracellular availability of fatty acid and 
diacylglycerols. Evidence is accumulating for diacylglycerols to be major 
modulators of substrate level control of metabolism (Chibalin et al., 2008, 
Erion and Shulman, 2010). In the present study the overweight control subjects 
were not restudied with acipimox, and although it would appear likely that 
similar effect would be produced, this awaits experimental verification. As all 
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subjects with type 2 diabetes were taking statin therapy, reflecting current 
clinical practice, the possible effect of this on glucose metabolism must be 
considered. Statins do not affect glucose tolerance nor modulate 72 hour 
glucose profiles, but may bring about a very small beneficial effect on insulin 
sensitivity as shown in a randomized crossover study designed for this purpose 
(Huptas et al., 2006).  No impact of statins would be expected on the primary 
comparison of acipimox or placebo exposure within the diabetic group.  
In the second part of this study, the design was successful in using the mass 
action effect of acute hyperglycaemia to increase the rate of glycogen synthesis 
in muscle of type 2 diabetes subjects to that of the non-diabetic control group 
studied at isoglycaemic hyperinsulinaemia. Hyperglycaemia increased muscle 
glycogen synthesis rate by 2.2-fold in the diabetic subjects and by 2.5-fold in the 
control subjects with a simultaneous increase in muscle ATP turnover rates 
(1.2-fold for both). Muscle ATP turnover rates were found to be positively 
correlated with muscle glycogen synthesis rates. Hyperglycaemic clamp studies 
have previously demonstrated that acute hyperglycaemia, by the mass-action 
effect of glucose, can stimulate oxidative and non-oxidative glucose disposal 
(Yki-Jarvinen et al., 1987, Yki-Jarvinen, 1990). Vaag and colleagues showed that 
fasting and insulin-stimulated glucose oxidation, glucose storage and muscle 
glycogen synthase activation were all fully normalized during hyperglycemia in 
type 2 diabetic patients (Vaag et al., 1992). Rate of insulin-stimulated glucose 
disposal in type 2 diabetic subjects was shown to be 57% greater during 
hyperglycaemia compared with euglycaemia, and the major part (89%) of the 
increase in glucose metabolism during hyperglycaemia was due to an increase in 
non-oxidative glucose metabolism (Franssila-Kallunki et al., 1992).  
Overall in this study, insulin had no effect upon muscle ATP turnover rates 
in neither diabetic nor exercise-, weight- and age-matched non diabetic subjects. 
This is in contrast with previous work which observed that acute elevation of 
insulin to post-prandial levels would increase muscle ATP turnover rate in 
healthy normoglycaemic controls but not in the diabetic subjects (Petersen et 
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al., 2004, Szendroedi et al., 2007, Petersen et al., 2005b). Hence, the present 
study was designed with this expectation. When it became clear that there was 
no stimulation of ATP turnover rates in the matched control subjects of the 
present study, a separate investigation of time course of stimulation of muscle 
ATP turnover rates was conducted. This study is presented in Chapter 4. There 
is also the considerable variation amongst ATP turnover rates at different 
glycogen synthesis rates observed during isoglycaemia and hyperglycaemia to 
consider (Figure 3.8). The reason for this is unclear, as is the proportion of 
ATP utilization related to glycogen synthesis per se. Bajpeyi and co-workers also 
reported a broad range of maximal ATP synthesis rate, determined from the 
rate of phosphocreatine recovery, within type 2 diabetes subjects whereby 52% 
had maximum ATP synthesis rates that were within the range observed in 
healthy sedentary controls and 24% had overlapped with the active control 
group (Bajpeyi et al., 2011).  
In vivo skeletal muscle ATP turnover rate has typically been observed over 
considerably longer periods of time to achieve a summed single measurement 
(Petersen et al., 2004, Brehm et al., 2006, Szendroedi et al., 2007). These studies 
used measurements of ATP turnover rate averaged over 120-350 min of insulin 
stimulation, and made the assumption that an insulin-stimulated increase in 
ATP turnover rate was responsible for the changes in glucose metabolism. The 
time period over which ATP turnover rate is measured is crucial. Brehm and 
colleagues did not observe any change in muscle ATP turnover rate during 3 
hours of elevated NEFA levels despite observing a marked reduction in whole-
body glucose disposal (Brehm et al., 2010). The authors only observed a 
decrease in insulin-stimulated ATP turnover rate when NEFA levels were 
elevated for more than 4 hours (Brehm et al., 2006). In the present study the 
time resolution of the technique allowed acquisition of data over 30 minutes 
time periods. This revealed a gradual fall in muscle ATP turnover rate in the 
type 2 diabetic subjects during the isoglycaemia study. Although the reasons for 
this cannot be determined from the present study, it is postulated that the 
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downward trend occurred as a consequence of prolonged fasting (~15 hours) 
and a decrease in plasma glucose concentration during the basal period of the 
study protocol (7.7 ± 1.1 to 6.5 ± 1.0 mmol/l), and that increased mobilization 
of fatty acid from intramyocellular lipid as acipimox administration prevented 
the fall in ATP turnover rate and would have inhibited intracellular lipolysis. 
This phenomenon requires further study. During hyperglycaemic-
hyperinsulinaemic clamp conditions, this fall in muscle ATP turnover in the 
diabetic subjects was prevented. The suppression of plasma NEFA in the 
diabetic subjects during the 5.5 hour protocol did modestly affect the rate of 
muscle ATP turnover, and the converse finding of elevation of plasma NEFA 
and suppression of muscle ATP turnover rate has been reported (Brehm et al., 
2006). However, other recent work has demonstrated decreased glucose 
disposal during short-term elevation of plasma NEFA without change in 
muscle ATP turnover rate in healthy subjects (Brehm et al., 2010). The time 
course of change in fatty acid supply also requires further study. Taken 
together, these results further emphasizes the dependence of ATP turnover rate 
upon intracellular substrate supply and that ATP turnover rates are not limited 
by the fact of the type 2 diabetes but respond to metabolic conditions.   
The present results together with other recent studies suggest that changes 
in metabolic state rather than diabetes per se can affect measured ATP turnover 
rates in muscle. Other recent studies support this interpretation. A high fat diet 
decreases ATP turnover rate in muscle in rodents (Laurent et al., 2007). Raising 
NEFA levels in young healthy individuals for more than 6 h decreases insulin-
stimulated muscle ATP production (Brehm et al., 2006). Despite early reports 
of studies showing an association between mitochondrial dysfunction and 
insulin resistance in type 2 diabetic patients, there are increasing reports of a 
lack of association between the two. Recent ex vivo studies found no effect of 
short term elevation of NEFA levels on mitochondrial function in healthy 
individuals despite reduction in whole-body glucose metabolism (Chavez et al., 
2010, Brands et al., 2011). Improvement in insulin sensitivity through either 
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calorie restriction (Toledo et al., 2008) or pharmacological agents such as 
thiazolidinedione (Schrauwen-Hinderling et al., 2008) in both insulin-resistant 
states and type 2 diabetic patients have been observed without any 
accompanying changes in mitochondrial function in muscle. Using post-
exercise PCr re-synthesis rate as an alternative method to assess mitochondrial 
function, rosiglitazone and pioglitazone were found to have opposite effects on 
mitochondrial function although both improve insulin sensitivity (Rabol et al., 
2010). Using the same technique, no defect was detectable in either early or late 
stage type 2 diabetes compared with exercise-matched normoglycaemic 
controls (De Feyter et al., 2008). This is in contrast to other studies which have 
reported reduced phosphocreatine recovery in type 2 diabetes subjects 
compared with matched controls (Schrauwen-Hinderling et al., 2007, Phielix et 
al., 2008, Meex et al., 2010). First-degree relatives of type 2 diabetes patients 
also showed ex vivo decreased mitochondrial capacity, and it has been suggested 
that gradual changes in mitochondrial function may occur (Phielix et al., 2008). 
The importance of matching for physical activity must be noted, as the greatest 
deficits in ATP turnover rates have been reported in a study which explicitly 
compared extremes of insulin sensitivity with no matching for habitual physical 
activity (Petersen et al., 2004). It should also be noted that different exercise 
protocols used in the phosphocreatine recovery method may account for the 
differences reported (De Feyter et al., 2008). Furthermore, the observation by 
Schrauwen-Hinderling and colleagues that muscle ATP turnover rates are 
inversely proportional to fasting blood glucose is critical in that abnormal ATP 
turnover cannot be an early feature explaining the onset of type 2 diabetes 
(Schrauwen-Hinderling et al., 2007, Phielix et al., 2008).  
Ex vivo studies of mitochondria have also shown discordance between 
mitochondrial function and insulin sensitivity in offspring of mothers with type 
2 diabetes (Irving et al., 2011). In earlier observations by Kelley et al., obese and 
type 2 diabetic subjects were found to have less mitochondria in their muscles 
than age-matched insulin-sensitive individuals (Kelley et al., 2002). The 
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subsarcolemmal fraction of mitochondria content has also been found to be 
lower in type 2 diabetes (Ritov et al., 2005). In addition, mitochondrial surface 
area was positively correlated with insulin-stimulated glucose disposal (Kelley et 
al., 2002). On the other hand, intramyofibrillar mitochondrial content has been 
observed not to differ between type 2 diabetes and weight-matched control 
subjects even though it was lower compared to lean insulin-sensitive controls 
(Chomentowski et al., 2011). Although the present data relate to observations 
during established type 2 diabetes, overall the concept of mitochondrial 
dysfunction as a primary abnormality in type 2 diabetes is not well supported.  
The present data demonstrate that lowering fatty acid availability increased 
whole-body glucose uptake without increasing the rate of glucose storage as 
glycogen but with increase in whole-body glucose oxidation rates. A change in 
fasting ATP turnover rate in muscle was observed after suppression of lipolysis 
in type 2 diabetes, but this change was associated with no effect on muscle 
glycogen synthesis. The study also demonstrated that normalizing the rate of 
glycogen synthesis by hyperglycaemia is associated with increase in muscle ATP 
turnover rate in type 2 diabetes. Therefore, ATP turnover rates reflect 
prevailing substrate availability and defects in mitochondrial function are 
unlikely to underlie and initiate the metabolic abnormalities of type 2 diabetes.  
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4.1 Introduction    
ATP is the universal energy currency in cells for supporting the energy 
demands of various cellular activities and functions. Healthy skeletal muscle is 
abundant with mitochondria and relies heavily on oxidative phosphorylation for 
regenerating ATP from carbohydrate- and fat-based fuels. In resting skeletal 
muscle, mitochondrial oxidative phosphorylation provides up to 90% of cellular 
ATP, with the balance coming from substrate-level phosphorylation such as 
glycolysis. Insulin plays a key role in regulating fuel metabolism. Its main 
metabolic action can be summarised as anabolic affecting not only glucose but 
also lipid and protein metabolism. In insulin-responsive tissues such as skeletal 
muscle, insulin stimulates the uptake, utilization and storage of glucose and the 
inhibition of lipid oxidation. Insulin maintains glucose homeostasis throughout 
the fed and fasted states by regulating these processes. 
Mitochondrial dysfunction in skeletal muscle has been reported in skeletal 
muscle in type 2 diabetes (Kelley et al., 2002), insulin-resistant offspring of type 
2 diabetes patients (Petersen et al., 2004), obesity (Ritov et al., 2005) and in age-
related insulin resistance (Petersen et al., 2003, Short et al., 2005), and it has 
been proposed that there is a causative link between the impairment of 
oxidative capacity and pathogenesis of insulin resistance and type 2 diabetes in 
humans (Morino et al., 2005). Several research laboratories have applied 31P MR 
spectroscopy magnetization saturation transfer methods to calculate 
unidirectional ATP synthesis rate (Lebon et al., 2001, Brehm et al., 2006, 
Trenell et al., 2008). Using this methodology, some have reported that insulin 
increases ATP turnover rate in muscle of normal subjects but not in insulin 
resistant subjects (Petersen et al., 2005b, Szendroedi et al., 2007). This has led 
to a widespread acceptance that a defect in ATP generation could be a direct 
cause of insulin resistance (Petersen et al., 2004, Szendroedi et al., 2007, Pagel-
Langenickel et al., 2010, Ritov et al., 2010, Schrauwen et al., 2010).  
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However, all previous studies measured ATP turnover rate in muscle after 
an insulin infusion of 2-8 hours duration, whereas insulin is a rapid-acting 
regulator of metabolism which brings about major metabolic changes within 
minutes. The time course of stimulation of ATP turnover rate during the rapid 
RQVHW RI LQVXOLQ·V DFWLRQ RQ PHWDEROLF SURFHVVHV KDV QRW EHHQ SUHYLRXVO\
examined. Therefore, having observed a lack of insulin stimulation on ATP 
turnover rates in the matched control subjects of the previous study, a separate 
investigation to determine the time course of insulin stimulation on muscle 
ATP turnover rate was designed and conducted. In this study, the 31P MR 
spectroscopy saturation transfer method was applied continuously during the 
first 150 min of insulin stimulation in young, lean and normoglycaemic 
individuals to examine whether the time course of ATP stimulation is 
FRQVLVWHQWZLWKDSULPDU\UROHLQLQVXOLQ·VPHWDEROLFHIIHFWV 
 
 
4.2 Study Design 
4.2.1 Subjects 
Seven healthy volunteers (3 male, 4 female) without family history of diabetes 
were studied. None were glucose intolerant or taking any medication known to 
affect glucose tolerance or insulin sensitivity (for example steroids, beta-
blockers or diuretics). Anthropometric and metabolic characteristics of the 
subjects are summarised in Table 4.1. All participants refrained from any 
physical exercise during the 3 days preceding the studies and fasted overnight 
for 12 hours before the experiments. The study protocol was approved by the 
Newcastle upon Tyne Research Ethics Committee 2, and informed consent was 
obtained from all subjects.  
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Table 4.1 Clinical characteristics of study subjects.  
Male: female 3:4 
Age (years) 28 r 5 
Weight (kg) 66.6 r 17.4 
BMI (kg/m2) 22.9 r 4.4 
Fat mass  (kg) 14.9 r 3.6 
Fat free mass (kg) 51.7 r 14.2 
Estimated body fat (%) 22.6 r 2.8 
Fasting plasma glucose (mmol/l) 5.1 r 0.3 
Fasting plasma insulin (pmol/l) 49 r 22 
HbA1c (%) 
HbA1c (mmol/mol) 
5.3 r 0.6 
34 ± 6 
Values are mean r SD. 
 
 
4.2.2 Experimental protocol 
For all experiments, participants travelled to the magnetic resonance facility by 
taxi and were transported within the centre by wheelchair. At 0800 (-90 min), 
one cannula was inserted into a large antecubital vein for administration of 
intravenous glucose and insulin. A second cannula was inserted into the 
contralateral wrist vein for the purpose of blood sampling. Use of a hand 
warming device ensured arterialisation of venous blood. Conditions of fasting 
glycaemia and standardised hyperinsulinaemia were achieved for 150 min using 
the euglycaemic-hyperinsulinaemic clamp technique (DeFronzo et al., 1979).   
Skeletal muscle ATP turnover rate was measured in the left calf muscle 
using the saturation transfer experiment applied to the exchange between Pi and 
ATP. Two consecutive baseline measurements were acquired from 0830 to 
0930 (-60 to -30 min and -30 to 0 min respectively, relative to the start of 
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infusion). During the 150 min of the hyperinsulinaemic glucose clamp, four 
measurements were performed (15-45 min, 50-80 min, 85-115 min, and 120-
150 min). Unidirectional rates of ATP synthesis from Pi are the product of the 
pseudo-first order rate constant of ATP synthesis, k1, and the concentration of 
intracellular Pi. Owing to the fact that it takes 27 minutes to acquire data to 
measure k1, and that Pi concentration can increase across this time, it was 
decided to take the average of two measurements of Pi concentration before 
and after the saturation transfer measurement of k1 in every case for 
calculations of ATP turnover rate. All seven subjects were studied twice on 
identical study days and the fourteen sets of ATP turnover rate measurements 
obtained were averaged. Blood samples were drawn at timed intervals for 
measurement of hormones and metabolite concentrations. The experimental 
protocol is shown in Figure 4.1. 
 
 
 
 
 
Figure 4.1 Schematic representation of the experimental protocol. 
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4.2.3 Statistical analysis 
Statistical analyses were performed using SPSS 15.0 software (SPSS Inc., 
Chicago, USA). Data are presented as mean ± SD in the text and in the figures, 
unless otherwise stated. Prior to any comparisons, the data was tested for 
normality using Shapiro-Wilk test. Non-parametric Wilcoxon test was used to 
determine within group differences. Statistical significance was accepted at p < 
0.05.  
 
 
4.3 Results 
4.3.1 Plasma glucose and insulin  
Mean plasma glucose concentration during baseline measurement was 5.1 ± 0.3 
mmol/l and was maintained at this concentration during the euglycaemic-
hyperinsulinaemic period (5.2 ± 0.2 vs. 5.1 ± 0.2 mmol/l). Fasting plasma 
insulin concentration was 49 ± 22 pmol/l, and this increased approximately 10 
fold within 15 min of the clamp. Plasma insulin concentration remained 
constant for the duration of the clamp (456 ± 71 pmol/l, p < 0.001 vs. 
baseline).  
 
4.3.2 Glucose disposal rates 
A rapid increase in whole body glucose disposal rate was observed via a rise of 
glucose infusion rate from 0 to 2.90 ± 0.42 mg/kgffm/min during the first 10 
min and further to 6.17 ± 2.14 mg/kgffm/min between 15-45 min (Figure 4.2). 
There was a subsequent slower increase to 8.31± 2.52 mg/kgffm/min during the 
120-150 min period.  
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4.3.3 Resting muscle ATP turnover rate 
Resting muscle ATP turnover rates are shown in Figure 4.2. Mean baseline 
ATP turnover rate was 9.0 ± 1.3 Pmol/g/min of muscle. During the first 45 
min of the clamp, there was no increase in ATP turnover rate to match the 
acute onset of the metabolic action of insulin as reflected by the steep increase 
in glucose utilisation. Between 50 and 80 minutes after the insulin infusion was 
commenced, ATP turnover rate increased by 8% and remained steady until the 
end of the clamp (9.7 ± 2.1 Pmol/g/min of muscle, p = 0.03 vs. mean 
baseline). 
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Figure 4.2 Simultaneous time course change in muscle ATP turnover rate. 
(represented by histogram bars) and glucose infusion rate (solid line) during the 
euglycaemic-hyperinsulinaemic clamp. Values are mean ± SD. *p < 0.05 vs. 
mean baseline.  
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     Components of the muscle ATP turnover rate measurement are presented 
in Table 4.2. The average of the two Pi concentration acquired at baseline was 
3.62 ± 0.26 mmol/l. Pi concentration did not change during the early period of 
insulin infusion (15-45 min period: 3.58 ± 0.32 mmol/l, p = 0.463). Thereafter, 
Pi concentration increased to 3.98 ± 0.34 mmol/l between 50 and 80 min (p < 
0.05 vs. baseline). This corresponded to a 14% increase compared to baseline. 
Pi concentration remained steady thereafter. There was no significant change in 
k1 for ATP turnover rate between baseline and insulin-stimulated conditions. 
This was reflected by there being no significant change in either the T1* of Pi 
(the longitudinal relaxation time during J-ATP saturation) or the fraction of Pi 
signal during saturation compared to control saturation (Mz/M0) under insulin 
stimulation. As k1 was unchanged, all change in ATP turnover rate was derived 
from change in Pi concentration. 
  
 
Table 4.2 Components of the ATP turnover rate measurement at baseline and during insulin stimulation 
 Baseline During isoglycaemic hyperinsulinaemic clamp 
15-45 min 50-80 min 85-115 min 120-150 min 
k1 (min-1) 
Pi (mmol/l) 
T1* (s) 
Mz/M0 (-) 
4.09 ± 0.67 
3.62 ± 0.26 
4.00 ± 0.38 
0.73 ± 0.03 
3.89 ± 0.77 
3.58 ± 0.32 
4.30 ± 0.43 
0.72 ± 0.04 
3.91 ± 1.01 
3.98 ± 0.34* 
4.10 ± 0.54 
0.73 ± 0.05 
4.01 ± 0.96 
3.99 ± 0.50* 
4.25 ± 0.54 
0.72 ± 0.05 
4.08 ± 1.09 
3.90 ± 0.41* 
4.08 ± 0.47 
0.73 ± 0.05 
Values are mean r SD.  *p < 0.05 vs. baseline. 
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4.4 Discussion 
To my knowledge, this is the first study to investigate the acute effect of insulin 
on muscle ATP turnover rate, and to track the time course of ATP turnover 
rate during physiological hyperinsulinaemia. Insulin is responsible for increasing 
whole-body glucose disposal mainly by stimulating glycogen synthesis in the 
transition from fasted to fed state (Bonadonna et al., 1993). Carbon-13 MR 
spectroscopy studies have shown physiological hyperinsulinaemia to increase 
muscle glycogen concentration in as little as 15 min in healthy individuals 
(Shulman et al., 1990, Roden et al., 1996), which is reflected in the rapid 
increase in glucose disposal rate observed in this experiment.  
The glucose infusion rate data shown in Figure 3.2 illustrate that the 
highest rate of change in glucose disposal occurs in the first 30-60 min of 
euglycaemic hyperinsulinaemia. The ATP turnover rate was unchanged during 
the first 20-50 min of the clamp, with an 8% increase after 50 min. There are 
notable differences with other reported measurements of ATP turnover rate 
during physiological hyperinsulinaemia. The single most important difference 
lies in the timing of the measurements. The original report of mitochondrial 
dysfunction associated with diabetes measured ATP turnover rate averaged 
over 30-150 min of euglycaemic hyperinsulinaemia (Petersen et al., 2005b) 
while subsequent studies compared the later effects (120-350 min) of insulin 
stimulation of ATP turnover rate (Szendroedi et al., 2007, Brehm et al., 2006). 
The long scan duration of previous studies limited the time resolution and 
prevented examination of time course. However, in order to determine the 
relationship between parameters it is important to measure ATP turnover rate 
during the onset of insulin action, as early as 15 min of insulin stimulation 
(Shulman et al., 1990) 2WKHU SURFHVVHV VHSDUDWH IURP LQVXOLQ·V HIIHFW RQ
PXVFOHJO\FRJHQV\QWKHVLVVXFKDVLQVXOLQ·VHIIHFWRQPLWRFKRQGULDOIXVLRQDQG
proliferation (Molina et al., 2009, Yang et al., 2009) and mitochondrial protein 
synthesis (Stump et al., 2003), may affect ATP turnover rate on a timescale of 
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4-8 hours of insulin stimulation. These processes are temporally dissociated 
from and not relevant to the early metabolic effects of insulin. They are likely to 
affect data on ATP turnover rates in longer studies of prolonged 
hyperinsulinaemia.  
In the present study insulin stimulation for 150 minutes brought about an 
8% increase in ATP turnover rate, less than that the 11-90% previously 
observed in normal control subjects (Petersen et al., 2004, Szendroedi et al., 
2007). The report of a 90% increase in ATP turnover rate in insulin-sensitive 
subjects with insulin stimulation (Petersen et al., 2004) related to extreme 
phenotypes of insulin sensitivity. Additionally, the insulin resistant offspring 
were reported to have a low basal resting ATP turnover rate. This has not been 
confirmed in subsequent studies comparing subjects with and without type 2 
diabetes when subjects have been matched for habitual physical activity 
(Szendroedi et al., 2007, Trenell et al., 2008). During a  240 minute period of 
hyperinsulinaemia, Szendroedi and colleagues reported a 10.5% increase in 
ATP turnover rates in the diabetic subjects, 11% in the age matched controls, 
and a 26% increase in ATP turnover rate in the young controls (Szendroedi et 
al., 2007). It has been widely postulated within the MR and diabetes 
communities that defects in mitochondrial function may underlie the reduced 
glucose disposal rate during hyperinsulinaemia in type 2 diabetes (Szendroedi et 
al., 2007, Pagel-Langenickel et al., 2010, Ritov et al., 2010, Schrauwen et al., 
2010). Although the data suggest a relationship between insulin sensitivity and 
ATP turnover rate, this does not indicate cause and effect. Hence, the 
extrapolation of hypothesis from the original observations (Petersen et al., 
2004) to the pathophysiology of type 2 diabetes itself has not been well 
justified.  
In addition to the shorter period of insulin stimulation in the present study 
as explanation for a lesser increase of ATP turnover rate with insulin, other 
factors such as surface coil placement, coil diameter and acquisition sequences 
could affect the results in comparing between studies. The relative composition 
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of the radiofrequency FRLO·V VHQVLWLYH YROXPH RI JDVWURFQHPLXV DQG VROHXV
muscles requires consideration as soleus muscle, which has predominantly Type 
I muscle fibres, has been shown to have higher resting ATP turnover rate than 
gastrocnemius (Befroy et al., 2008).  A larger coil was used in this study 
compared to Szendroedi et al. (Szendroedi et al., 2007) (14 cm diameter 
compared to 10 cm) and thus it would be expected that a higher percentage of 
contribution of signal from the soleus muscle.  
ATP turnover rate is calculated from both the intramyocellular Pi 
concentration and the measured rate constant k1.  To ensure that the estimates 
of ATP turnover rate were as accurate as possible during the rapidly changing Pi 
concentration in the first hour after insulin stimulation, the average of the Pi 
concentrations before and after the 27-minute saturation transfer measurement 
was used. Insulin-stimulated Pi concentration was observed to increase by 14% 
until the end of the euglycaemic hyperinsulinaemic clamp, in agreement with 
previous studies (Roden et al., 1999, Szendroedi et al., 2007). The concentration 
of Pi in the muscle tissue may be an important mechanism by which insulin 
regulates ATP synthesis (Bose et al., 2003):  there was no change in measured 
reaction rate, k1 across the two hour duration of this clamp, or in any of the 
parameters measured to calculate k1. Such changes were observed only in the 
early work in this field on young insulin sensitive volunteers (Petersen et al., 
2004, Petersen et al., 2005b).  
Measurements of ATP turnover rate by the 31P saturation transfer method 
report flux of ATP through Pi incorporation into ATP. They are thus 
comprised of ATP generated by glyceraldehyde-3-phosphate dehydrogenase 
and 3-phosphoglycerate kinase reactions as well as by ATP synthase. This could 
result in a mismatch between oxygen consumption and ATP synthesis, as 
demonstrated in studies performed in aerobic yeast suspensions Saccharomyces 
cerevisiae (Brindle and Krikler, 1985) and perfused rat myocardium (Ugurbil et 
al., 1987). However, arterio-venous balance studies across the leg have shown 
that there is no net export of lactate from human muscle following 
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insulinisation in either type 2 diabetic subjects or leaner normal controls such as 
used in the present study (Dela et al., 1995). This net measurement does not 
exclude the possibility of a change in redundant cycling of 3-carbon 
compounds through the glycolytic exchange flux, but the extent to which this 
cycling contributes to the observed rate of overall ATP turnover still remains to 
be determined (Laurent, 2008).  
A hallmark of muscle physiology is the ability to support a high energy 
demand for muscle function by phosphocreatine buffering of ATP, and by 
aerobic and anaerobic respiration. Thus postulation that muscle glycogen 
synthesis may be limited by ATP production, especially in resting muscle where 
ATP capacity is high, seems at odds with muscle function. In support of this, 
more recent reconsideration of the data supporting mitochondrial dysfunction 
as pathogenic for type 2 diabetes has concluded that the cause-and-effect 
relationship between mitochondrial dysfunction and insulin resistance is not 
supported by all data (Trenell et al., 2008, De Feyter et al., 2008, Turner and 
Heilbronn, 2008).  
For the first time, the early time course of skeletal muscle ATP turnover in 
response to insulin has been quantified in young, healthy controls.  There was 
no increase in ATP turnover rate during the first hour of exposure to a high 
physiological concentration of insulin, the timescale within which glycogen 
synthesis is initiated.  ATP turnover rate was observed to increase only after 1 
hour, indicating that glycogen synthesis is not limited by ATP availability in 
healthy controls. This provides further support that mitochondria have no 
direct role in the origins of defective insulin sensitivity in type 2 diabetes. 
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EFFECT OF CHANGES IN INTRA-
ORGAN FAT CONTENT ON GLUCOSE 
HOMEOSTASIS IN TYPE 2 DIABETES 
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5.1 Introduction    
The pathogenesis of type 2 diabetes is complex but it is clear that both defects 
LQ Ƣ-cell function and insulin sensitivity are necessary prerequisites. Type 2 
diabetes has long been regarded as a chronic progressive condition, capable of 
amelioration but not cure. The striking findings of the United Kingdom 
Prospective Diabetes Study (UKPDS) affirmed the clinically recognised 
progressive nature of the disease (1998). A steady rise in plasma glucose 
occurred irrespective of the degree of control or type of treatment. In fact, only 
25% of the subjects in the intensive arm of the study achieved target HbA1c of 
less than 7% with monotherapy alone after 9 years (Turner et al., 1999). The 
8.3'6DOVRGHPRQVWUDWHGWKDWƢ-cell function, assessed using the homeostasis 
model assessment (HOMA), declined linearly with time without a change in 
insulin sensitivity, and after 10 years over 50% of individuals required insulin 
therapy (1995). Similar observations were made in the Belfast diet intervention 
study in which progressive deterioration in glycaemic control was associated 
ZLWK D SURJUHVVLYH GHWHULRUDWLRQ LQ Ƣ-cell function (Levy et al., 1998). The 
underlying changes in Ƣ-cell function have been well described (Weyer et al., 
1999a, Kahn, 2003)DQGƢ-cell mass decreases steadily during the course of type 
2 diabetes (Butler et al., 2003a, Hanley et al., 2010) whereas insulin resistance in 
muscle and liver can be modified at least to some extent (Williams et al., 2003). 
Overall, type 2 diabetes is inexorably progressive, with a high likelihood of 
insulin therapy being eventually required to maintain good glycaemic control.  
However, it has been recently VKRZQWKDWERWKGHIHFWVRIƢ-cell and insulin 
resistance can be reversed in type 2 diabetes subjects after weight loss surgery 
(Camastra et al., 2007). Mean fasting plasma glucose fell from 7.7 to 5.1 mmol/l 
and HbA1c from 8.2 to 4.1 % following biliopancreatic diversion in a group of 
severely obese type 2 diabetes patients. Insulin sensitivity, as measured by 
glucose infusion rate during euglycaemic-hyperinsulinaemic clamp, doubled 
when assessed at 24 months (glucose disposal rate rose from 26.4 to 55.2 
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ƬPRONJffm/min). Most stULNLQJZDVWKHUHWXUQRIƢ-cell sensitivity to the level 
of non-diabetic post-surgery control group (from 44 to 76 pmol/min/m2 per 
mmol/l, compared to 65 pmol/min/m2 per mmol/l in the non-diabetic 
controls). 
The normalisation of plasma glucose concentration occurred within days of 
surgery, long before major weight loss has occurred, and it has become widely 
assumed that the protective effects of gastrointestinal surgery are mediated by 
altered secretion of incretin hormones (Rubino et al., 2006, Kashyap et al., 
2010). Improved control of blood glucose in type 2 diabetes by moderate 
energy restriction has been demonstrated by others (Petersen et al., 2005a). 
Petersen and colleagues observed a marked fall in fasting plasma glucose after 
an 8% decrease in body weight achieved over 7 weeks (Petersen et al., 2005a). 
The authors reported improved insulin sensitivity and normalisation of insulin 
suppression of hepatic glucose production which were associated with a fall of 
81% in hepatic fat content. It is established that hepatic fat is mobilised within 
days of onset of hypocaloric feeding (Hollingsworth et al., 2006). This early and 
significant decrease in hepatic fat occurred at the same time as normalisation of 
hepatic insulin sensitivity and fall in fasting blood glucose, thus reflecting the 
tight relationship between hepatic response to insulin and hepatic fat content. 
Direct observations on the pancreas in type 2 diabetes have shown that the 
triglyceride content is twice as great as in normal individuals and is negatively 
FRUUHODWHGWRƢ-cell function (Tushuizen et al., 2007). In animal models of type 2 
GLDEHWHV HFWRSLF SDQFUHDWLF WULJO\FHULGH KDV EHHQ VKRZQ WR DIIHFW Ƣ-cell 
dysfunction through the process of lipoapoptosis (Lee et al., 1994, 
Shimabukuro et al., 1998).   
It is therefore hypothesised that the profound effect of a sudden negative 
energy balance could explain the post-bariatric surgery effect (Taylor, 2008) and 
that the decrease in the intracellular fatty acid concentrations in the liver would 
lead to a lower export of lipoprotein triacylglycerol to the pancreas, with 
reduced chronic inhibitory effects of excess fatty acid exposure on the Ƣ-cells. 
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7KLVSURYLGHVDXQLI\LQJDHWLRORJ\IRUWKHWZLQGHIHFWVRIƢ-cell dysfunction and 
insulin resistance that characterises type 2 diabetes. In order to test this 
hypothesis, weight loss was induced by an 8 week hypocaloric diet protocol in a 
group of patients with type 2 diabetes of less than 4 years duration. Changes in 
insulin secretory capacity, hepatic and peripheral insulin sensitivity to glucose 
were studied after 1, 4 and 8 weeks to define the sequence of 
pathophysiological events involved in resolution of type 2 diabetes. 
Additionally, the simultaneous changes in triglyceride content of the pancreas 
and liver were quantified to examine the mechanistic basis of the observed 
outcomes.  
 
 
5.2 Study Design  
5.2.1 Subjects  
Individuals with type 2 diabetes who fulfilled the following inclusion criteria 
were recruited: 1) age between 35 and 65 years, 2) a diagnosis of diabetes not 
more than 4 years in duration, 3) HbA1c between 6.5 and 9.0% (48-75 
mmol/mol), 4) on treatment with diet alone or metformin alone or metformin 
plus sulphonylurea, and 5) BMI of 25-45 kg/m2 with stable body weight for the 
preceding 3 months. Subjects were excluded if they: 1) had evidence of renal 
dysfunction (defined by serum creatinine > 150 mmol/l) or liver dysfunction 
(defined by serum alanine transaminase > 2.5 fold above upper limit of the 
reference range), 2) had contraindications to MRI, and 3) were on treatment 
with thiazolididinediones, insulin, steroids or beta blockers. At the time of study 
enrolment, three VXEMHFWV·GLabetes were controlled with diet, nine others were 
taking metformin alone, while one subject was treated with sulphonylurea alone 
and the remaining two subjects were taking metformin and sulphonylureas to 
control their diabetes. Subjects discontinued sulphonylureas two months before 
the baseline study. Metformin was discontinued one week before the baseline 
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study. Statin therapy was continued. Dietary adherence was assessed using 
capillary ketone levels (Xceed Optium;; Abbott Diabetes Care, Maidenhead, 
UK) to assist ongoing monitoring and counselling and not for the purpose of 
testing study outcome. Capillary ketone levels were measured following an 
overnight 12 hour fast at baseline, week 1, 4 and 8 of the dietary intervention. 
An increase in capillary ketone level occurs after the first week of a very-low-
calorie diet (VLCD) subsequent to increased fat catabolism (Henry et al., 1986). 
Therefore, a doubling of capillary ketone level was considered to indicate net 
lipolysis and dietary adherence. Weight loss of > 2.8% of initial body weight 
after one week of the diet plus total weight loss of > 8% at the end of the diet 
were considered to have achieved the necessary weight loss to be included in 
the study analysis. Three subjects failed to comply with the diet (two during the 
first week and one during weeks 4-8), and one left the study for an unrelated 
medical reason. Hence, eleven subjects completed the study (nine male and two 
female, age 49.5 ± 8.4 years). Their baseline metabolic and anthropometric data 
are summarised in Table 5.1 and 5.2 respectively. 
A group of nine subjects with normal glucose tolerance matched for 
sex, age and BMI were also studied (seven male and two female, age 49.7 ± 7.5 
years). These subjects had neither a family history of diabetes nor were taking 
any medication known to affect glucose tolerance or insulin sensitivity. Normal 
glucose metabolism was confirmed by a standard oral 75g glucose tolerance 
test. Their baseline metabolic and anthropometric data are summarised in Table 
5.1  and 5.2 respectively. All subjects were recruited by means of advertisement 
and underwent a complete medical history, clinical examination, and lab tests to 
exclude hepatic and renal diseases. It was made clear to the subjects that 
agreeing to participate in the study is not binding, and that they were free to 
withdraw from the study at any time. The study protocol was approved by the 
Newcastle upon Tyne and North Tyneside Local Research Ethics Committee 
No. 2, and informed consent was obtained from all subjects. 
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5.2.2 Experimental protocol 
A full dietary assessment was carried out at the screening visit and subjects were 
asked to continue with their habitual pattern of eating until the start of the 
study. A combined assessment of Ƣ-cell function, insulin sensitivity, liver and 
pancreas fat content and body fat composition was carried out on 4 occasions 
in subjects with type 2 diabetes: immediately prior to the hypocaloric period 
(day -1), and after 1, 4 and 8 weeks of the VLCD. A group of matched non-
diabetic controls were studied on one occasion only, without dietary 
intervention.  
Each combined assessment was carried out over 2 days. On the morning of 
the first day, after an overnight 12 hour fast, a cannula was inserted into an 
antecubital vein for infusions and a second cannula was inserted into the 
contralateral wrist vein for blood sampling. Assessments of hepatic glucose 
production and insulin sensitivity were then carried out using isoglycaemic-
hyperinsulinaemic clamp with stable isotope dilution technique (Figure 5.1). 
Isoglycaemia rather than euglycaemia was used to ensure that the true fasting 
condition of each subject could be observed at each study time point. 
Following the insulin clamp, subjects rested for 60 mins before undergoing a 
stepped insulin secretion test with arginine to assess Ƣ-cell sensitivity to glucose 
(Figure 5.2). 
 
 
 
124 
 
 
 
Figure 5.1 Isoglycaemic-hyperinsulinaemic clamp study with stable isotope 
dilution technique.  
 
 
 
 
 
Figure 5.2 Stepped insulin secretion test with arginine. 
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The following morning, subjects attended the Newcastle Magnetic 
Resonance Centre following an overnight fast for tests to determine pancreas 
and liver triglyceride content and total body fat. Pancreas and liver triglyceride 
content were measured using the 3-point Dixon method on a 3 Tesla Achieva 
scanner (Phillips, Best, The Netherlands). Body composition was measured 
using air displacement plethysmography (BOD POD Express;; Life 
Measurement, Concord, CA, USA). Waist and hip circumferences were 
measured using a non-sticking plastic tape measure with the subjects in a 
relaxed standing posture. All measurements were taken at baseline and 
throughout the study period by a single investigator (myself).  
 
5.2.3 Weight loss diet 
After completion of the baseline measurements, subjects with type 2 diabetes 
started a weight-loss regimen for 8 weeks. They were prescribed a very-low-
calorie diet which consisted of a liquid diet formula (Optifast;; Nestlé Nutrition, 
Croydon, UK) with 46.4% carbohydrate, 32.5% protein and 20.1% fat plus the 
recommended daily intake of vitamins, minerals and trace elements (2.1 MJ 
[600 kcal]/day). This was supplemented with 240g of non-starchy vegetables 
such that total energy intake was about 2.5 MJ (690 kcal)/day. Subjects were 
provided with suggestions of suitable vegetable recipes at the start of the 
programme to enhance compliance by varying daily eating (Appendix A). They 
were also encouraged to drink at least 2 L water and other calorie-free 
beverages each day, and asked to maintain their habitual level of physical 
activity. On-going support and encouragement during the dieting period was 
provided by means of regular telephone contact. At the end of the 8-week 
dietary intervention, subjects returned to normal eating but were provided with 
information about portion size and healthy eating 
(http://www.bhf.org.uk/publications/publications-search-
results.aspx?m=simple&q=weight). 
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5.2.4 Statistical analysis 
Statistical analyses were performed using SPSS 17.0 software (SPSS Inc., 
Chicago, IL, USA). Data are presented as mean ± SD. Prior to any comparison, 
the data was tested for normality using Shapiro-Wilk test. Statistical 
comparisons between diabetes and control groups were performed using 
6WXGHQW·V t test, while within group differences were determined using paired t 
test. Changes of sequential data within experiments were evaluated by repeated 
measures one-way analysis of variance (ANOVA) with post hoc Bonferroni 
testing where appropriate. Non-normally distributed data was analysed using 
non-parametric tests. Correlations were examined using Spearman rank test. 
Statistical significance was accepted at p < 0.05. 
 
 
5.3 Results 
5.3.1 Plasma glucose, insulin and C-peptide 
After 1 week of dietary intervention, fasting plasma glucose decreased from 9.2 
± 1.4 to 5.9 ± 1.2 mmol/l (p = 0.003;; Figure 5.3A) and was not significantly 
different from that of the non-diabetic control group (5.3 ± 0.3 mmol/l;; p = 
0.18). It remained stable for the rest of the study (5.7 ± 1.6 mmol/l at weeks 4 
and 8;; p = 0.52 compared with control). HbA1c decreased from 7.4 ± 0.9% (57 
± 10 mmol/mol) and at 8 weeks was not significantly different from non-
diabetic control values (6.0 ± 0.7 vs. 5.7 ± 0.3% [42 ± 8 vs. 39 ± 3 mmol/mol];; 
p = 0.27). Fasting plasma insulin fell from 151 ± 104 to 73 ± 34 pmol/l after 1 
week (p = 0.03) and to 57 ± 36 pmol/l by 8 weeks (p = 0.03 vs. baseline;; p = 
0.04 vs. control). Fasting plasma C-peptide decreased similarly (Table 5.1). 
During the isoglycaemic clamp, plasma glucose was clamped at 4.6 ± 0.3 
mmol/l in the control group compared with 7.0 ± 1.1 mmol/l in the diabetes 
group at baseline (p < 0.001). At week 1, the achieved clamped plasma glucose 
level was 4.8 ± 0.6 mmol/l (p < 0.001 vs. baseline) in the diabetes individuals 
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and this was similar at weeks 4 and 8 (4.8 ± 1.1 and 4.8 ± 1.3 mmol/l 
respectively, p < 0.001 vs baseline). 
 
5.3.2 Hepatic insulin sensitivity and hepatic triglyceride content 
Basal hepatic glucose production decreased significantly during the first week of 
energy restriction (2.40 ± 0.92 to 1.59 ± 0.23 mg/kgffm/min;; p = 0.05), 
remained decreased compared with baseline for the rest of the study, and at 8 
weeks was not significantly different from that of the control group (1.77 ± 
0.37 vs. 2.11 ± 0.65 mg/kgffm/min respectively;; p = 0.60;; Figure 5.3B). Hepatic 
insulin sensitivity, assessed by the suppression of hepatic glucose production by 
insulin infusion, was 43 ± 14% in the diabetic group compared with 68 ± 16% 
in the control group (p = 0.001) at baseline. During the first week of energy 
restriction, there was a marked improvement in hepatic insulin responsiveness, 
with insulin suppression of hepatic glucose production increasing to 74 ± 17% 
(p = 0.003 vs. baseline).  
Hepatic triglyceride content decreased by 30 ± 17% during week 1 of 
intervention (p < 0.001), becoming similar to control values (p = 0.75). It 
continued to decline throughout the intervention period to reach the normal 
range for non-obese individuals (Szczepaniak et al., 2005) (2.9 ± 0.8%;; p = 
0.003;; Figure 5.3C), i.e. a total reduction of 70 ± 18%. At baseline, hepatic 
triglyceride content was 8.5 ± 5.6% in the control group compared with 12.8 ± 
7.9% in the diabetic group (p = 0.14). Hepatic triglyceride at baseline correlated 
with BMI in the controls (rs = 0.71;; p < 0.05) but not in the diabetic group (rs = 
²0.50;; p = 0.12). 
  
Table 5.1 Metabolic response to 8 weeks of dietary intervention in subjects with type 2 diabetes in comparison with controls 
Fasting concentration Controls Baseline Week 1 Week 4 Week 8 
HbA1c (%) 
HbA1c (mmol/mol) 
Plasma glucose (mmol/l) 
Plasma insulin (pmol/l) 
Plasma C-peptide (nmol/l) 
Triglycerides (mmol/l) 
NEFA (mmol/l) 
Cholesterol (mmol/l) 
LDL-cholesterol (mmol/l) 
HDL-cholesterol (mmol/l) 
ALT (U/l) 
Gamma GT (U/l) 
Capillary ketone (mmol/l) 
3-%2+ƬPROO 
5.7 ± 0.3 
39 ± 3 
5.3 ± 0.3 
115 ± 81 
1.06 ± 0.36 
1.8 ± 0.4 
0.57 ± 0.22 
5.1 ± 0.8 
3.2 ± 0.8 
1.1 ± 0.2 
33 ± 8 
39 ± 15 
0.09 ± 0.06 
3.5 ± 5.7 
7.4 ± 0.9 
57 ± 10 
9.2 ± 1.4 
151 ± 104 
1.21 ± 0.67 
2.4 ± 1.7 
0.69 ± 0.20 
4.0 ± 0.8 
1.7 ± 0.6 
1.1 ± 0.3 
46 ± 24 
62 ± 38 
0.08 ± 0.04 
3.6 ± 2.4 
7.1 ± 0.9* 
55 ± 10 
5.9 ± 1.2** 
73 ± 34* 
1.14 ± 0.53 
1.2 ± 0.4* 
0.93 ± 0.16* 
3.3 ± 0.8 
1.8 ± 0.9 
1.0 ± 0.2 
61 ± 34* 
49 ± 28 
1.18 ± 0.92** 
121.7 ± 87.4** 
6.5 ± 0.8** 
47 ± 9** 
5.7 ± 1.8** 
71 ± 37* 
1.19 ± 0.63 
1.0 ± 0.2* 
0.81 ± 0.26 
2.8 ± 0.6 
1.0 ± 0.6* 
1.1 ± 0.3 
44 ± 10 
25 ± 12 
1.17 ± 1.13** 
122.1 ± 110.0** 
6.0 ± 0.7** 
42 ± 8** 
5.7 ± 1.6** 
57 ± 36* 
0.86 ± 0.36 
1.3 ± 0.8* 
0.72 ± 0.20 
3.2 ± 0.8 
1.3 ± 0.7 
1.1 ± 0.2 
33 ± 11 
26 ± 17** 
1.00 ± 1.57** 
102.1 ± 154.3** 
Values are mean ± SD. 3-BOH, 3-hydroxy-EXW\UDWH$/7DODQLQHWUDQVDPLQDVHJDPPD*7ƣ-glutamyltransferase 
p < 0.05 vs. controls, p < 0.005 vs. controls, *p < 0.05 vs. type 2 diabetes baseline, **p < 0.005 vs. type 2 diabetes baseline. 
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Figure 5.3 Effect of 8 weeks of dietary intervention on (A) plasma glucose, (B) 
HGP and (C) hepatic triglyceride (TG) content in diabetic subjects (black 
triangles). White circles indicate the mean for the weight-matched non-diabetic 
control group. Values are mean ± SD. 
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5.3.3 Ƣ-cell sensitivity to glucose and pancreas triglyceride content 
Fasting insulin secretion rate decreased from 0.10 ± 0.03 to 0.06 ± 0.03 
nmol/min/m2 during the first week (p < 0.05) and remained constant 
thereafter. The planned step increases in plasma glucose concentration of +2.8 
and +5.6 mmol/l were achieved during the insulin secretion test (Figure 5.4A). 
Peak insulin secretion rate at 6 min was minimal at baseline in the diabetes 
individuals (0.19 ± 0.08 vs. control 0.62 ± 0.45 nmol/min/m2;; p < 0.001;; 
Figure 5.4B-C). The first-phase insulin response steadily increased and was 
significantly different from baseline by 8 weeks (0.29 ± 0.18, 0.34 ± 0.19 and 
0.46 ± 0.23 nmol/min/m2 at 1, 4 and 8 weeks;; p = 0.20, p = 0.09, p = 0.006, 
respectively). The insulin secretion rate in the individuals with type 2 diabetes at 
8 weeks was not significantly different from the controls (0.46 ± 0.23 vs. 0.62 ± 
0.45 nmol/min/m2;; p = 0.42). There was an increase in arginine-induced insulin 
response after 1 week (from 0.73 ± 0.35 to 0.95 ± 0.62 nmol/min/m2;; p < 
0.006), and by 8 weeks it was completely normalised (1.37 ± 0.90 vs. 1.15 ± 
0.55;; p = 0.77 vs. control;; p < 0.03 vs. baseline;; Figure 5.4B-F). It was 38% 
lower in the participants with type 2 diabetes at baseline compared with the 
controls (0.73 ± 0.35 vs 1.15 ± 0.55 nmol/min/m2;; p = 0.04). 
Pancreatic triglyceride content in the diabetic group was 8.0 ± 5.2% and 
fell steadily to 6.2 ± 3.7% after 8 weeks (p = 0.03;; Figure 5.5). In control 
individuals, pancreatic triglyceride content was 6.0 ± 4.0% (p = 0.17 compared 
with participants with type 2 diabetes at baseline). There was no correlation 
with BMI in either the control or the diabetic group (rs = 0.31, p = 0.36;; rs = 
0.01, p = 0.98, respectively).  
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Figure 5.4 Insulin secretion test data in controls and in diabetic subjects at 
each time point. (A) Plasma glucose levels achieved in each group. Insulin 
secretion rate (ISR) obtained in the (B) non-diabetic group, (C) the diabetic 
group at baseline, (D) the diabetic group at 1 week of the diet, (E) the diabetic 
group at 4 weeks and (F) the diabetic group at 8 weeks. Values are mean ± SD. 
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Figure 5.5 (A) Change in the first-phase insulin response, and (B) change in 
pancreas TG content during the 8 week dietary intervention in the diabetic 
individuals (black triangles). White circles indicate the mean for the weight-
matched non-diabetic control group. Values are mean ± SD.  
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5.3.4 Peripheral insulin sensitivity 
There was no significant change in peripheral insulin sensitivity expressed as 
glucose disposal rates during the entire study. Insulin-stimulated glucose 
disposal was 3.83 ± 0.76 and 4.36 ± 1.20 mg/kgffm/min at baseline and 8 weeks 
respectively (p = 0.21). Change in glucose metabolic clearance rate was 
examined to correct for the difference in clamp glucose levels between study 
days. Fasting plasma glucose decreased between baseline and week 1. There was 
no significant effect of the dietary intervention on glucose metabolic clearance 
rate at either 1 or 4 weeks (3.14 ± 1.01 vs. 4.23 ± 1.13 and 4.21 ± 1.20 
ml/kgffm/min, respectively), but improvement was demonstrable by week 8 
(5.21 ± 1.64 ml/kgffm/min;; p = 0.003 for baseline vs. 8 weeks respectively;; 
control group 5.23 ± 1.32 ml/kgffm/min;; p = 0.98). 
 
5.3.5 Weight, body composition and fat distribution  
Average weight loss during the 8 weeks of dietary intervention was 15.3 ± 4.0 
kg, equivalent to 15 ± 4% of initial body weight (Table 5.2). Weight loss was 
greatest during the first week (3.9 ± 0.5 kg, 61% of which was fat loss), 
between weeks 1 and 4 was 5.7 ± 1.9 kg (86% as fat), and during the final 4 
weeks was 5.7 ± 2.3 kg (94% as fat). Both waist and hip circumference 
decreased to the same extent and waist-hip ratio remained unchanged during 
the 8 weeks (Table 5.2). Changes in visceral adipose tissue (VAT) and 
subcutaneous adipose tissue (SAT) areas over the study period are shown in 
Table 5.2. VAT and SAT areas decreased by 43 ± 11 and 27 ± 13% 
respectively. By the end of the study period, both VAT and SAT areas in the 
type 2 diabetes subjects were lower compared to the control subjects (121 ± 38 
vs. 196 ± 52 cm2 and 277 ± 109 vs. 390 ± 95 cm2;; p = 0.001 and p = 0.025 
respectively).
  
Table 5.2 Anthropometric data before and during the 8 weeks of dietary intervention in comparison with control individuals 
Variable Controls Baseline Week 1 Week 4 Week 8 
Weight (kg) 
BMI (kg/m2) 
Fat mass (kg) 
Fat free mass (kg) 
Waist circumference (cm) 
Hip circumference (cm) 
Waist hip ratio 
VAT area (cm2) 
SAT area (cm2) 
101.5 ± 10.2 
33.4 ± 2.7 
36.2 ± 8.0 
64.7 ± 11.2 
105.0 ± 4.4 
109.8 ± 7.3 
0.96 ± 0.07 
196 ± 52 
390 ± 95 
103.7 ± 15.0 
33.6 ± 4.1 
39.0 ± 11.6 
64.7 ± 9.9 
107.4 ± 7.4 
109.5 ± 9.5 
0.98 ± 0.07 
214 ± 42 
370 ± 104 
99.7 ± 14.8** 
32.3 ± 4.1** 
36.6. ± 11.9** 
63.2 ± 10.4 
104.4 ± 7.4** 
108.3 ± 8.9* 
0.97 ± 0.05 
185 ± 48* 
361 ± 107 
94.1 ± 14.4** 
30.5 ± 4.1** 
31.7 ± 12.2** 
62.4 ± 9.8** 
99.7 ± 8.1** 
105.0 ± 8.6* 
0.95 ± 0.05 
149 ± 33* 
327 ± 112* 
88.4 ± 14.1** 
28.7 ± 4.2** 
26.3 ± 13.4** 
62.1 ± 10.0** 
94.2 ± 8.1** 
99.5 ± 8.7** 
0.95 ± 0.04 
121 ± 38* 
277 ± 109* 
Values are mean ± SD. SAT, subcutaneous adipose tissue;; VAT, visceral adipose tissue 
p < 0.05 vs. controls, p < 0.005 vs. controls, *p < 0.05 vs. type 2 diabetes baseline, **p < 0.005 vs. type 2 diabetes baseline. 
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5.3.6 Plasma lipids and other metabolites 
Plasma triglyceride levels halved during the first week of dietary energy 
restriction (2.4 ± 1.7 to 1.2 ± 0.4 mmol/l;; p < 0.02) and remained constant 
thereafter (Table 5.1). Both total cholesterol and LDL-cholesterol decreased, 
while HDL-cholesterol remained unchanged during the study period (Table 
5.1). Fasting plasma NEFA levels were modestly but not significantly higher in 
the diabetic participants compared with the matched controls at baseline (0.69 
± 0.20 vs 0.57 ± 0.22 mmol/l;; p = 0.24). During the study period, fasting 
NEFA in the participants with diabetes increased significantly at week 1 (0.93 ± 
0.16 mmol/l;; p = 0.03 vs baseline). With continued hypoenergetic intake, 
plasma NEFA declined steadily towards baseline values (0.81 ± 0.26 and 0.72 ± 
0.20 mmol/l at week 4 and 8, respectively).  
Plasma alanine transaminase level tended to be higher in the type 2 diabetes 
subjects compared with control subjects (46 ± 24 vs. 33 ± 8 U/l;; p = 0.13) and 
rose significantly after 1 week of dietary intervention (61 ± 34 U/l;; p = 0.006) 
and decreased thereafter (44 ± 10 and 33 ± 11 U/l at week 4 and 8 respectively;; 
p = 0.04 for week 8 vs. baseline). 3ODVPDƣ-glutamyl-transferase level tended to 
be higher in the type 2 diabetes subjects when compared with control subjects 
(62 ± 38 vs. 39 ± 15;; p = 0.09) and decreased gradually over the 8 weeks, 
although did not reach statistical significance (Table 5.1).  
After first week of the VLCD, capillary ketone levels increased by 15-fold 
and remained increased at that level throughout the 8 weeks of dieting (Table 
5.1). Fasting plasma 3-hydroxybutyrate increased ~30-fold after 1 week of 
calorie restriction (3.6 ± 2.4 vs. 121.7 ± 87ƬPROOp < 0.001) and remained 
at that level throughout the dietary intervention (122.1 ± 110.0 and 102.1 ± 
154.3 ƬPROO DWZHHNV DQG UHVSHFWLYHO\ p < 0.001 vs. baseline for both). 
There was strong positive correlation between capillary ketone and plasma 3-
hydroxy-butyrate levels (rs = 0.65, p < 0.0001). Both capillary ketone and 
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plasma 3-hydroxy-butyrate levels were positively correlated with the net 
percentage weight loss (rs = 0.37, p = 0.03;; rs = 0.39, p = 0.03, respectively). 
 
5.3.7 Post-intervention observation 
At follow-up 12 weeks after completion of the dietary intervention, mean 
weight gain was 3.1 ± 3.3 kg. Hepatic triglyceride remained low and unchanged 
(2.9 ± 0.8 vs. 3.0 ± 1.0%;; p = 0.80), and pancreatic triglyceride decreased 
further to a small extent (6.2 ± 3.7 vs. 5.7 ± 3.6%;; p = 0.005). HbA1c was 
unchanged (6.0 ± 0.7 vs. 6.2 ± 0.3%;; p = 0.10;; 42 ± 8 vs. 44 ± 4 mmol/mol), 
and fasting plasma glucose increased modestly (5.7 ± 1.6 vs. 6.1 ± 0.5 mmol/l;; 
p < 0.01), with a mean 2 h OGTT plasma glucose of 10.3 ± 3.2 mmol/l. Three 
participants had recurrence of diabetes as judged by a 2 h post-load plasma 
glucose of greater than 11.1 mmol/l. Fasting plasma insulin concentrations 
were unchanged (57 ± 36 vs. 65 ± 46 pmol/l), and fasting plasma NEFA 
decreased further (0.72 ± 0.20 vs. 0.54 ± 0.17 mmol/l;; p < 0.02). One 
individual was unavailable for retesting, having had surgery for a non-malignant 
ovarian cyst. 
 
 
5.4 Discussion 
This study demonstrates that the twin defHFWV RI Ƣ-cell failure and insulin 
resistance that underlie type 2 diabetes can be reversed by acute negative energy 
balance alone. A hierarchy of response was observed, with a very early change 
in hepatic insulin sensitivity and a slower change in Ƣ-cell function. In the first 7 
days of the reduced energy intake, fasting plasma glucose and hepatic insulin 
sensitivity fell to normal, and hepatocellular lipid decreased by 30%. Over the 8 
weeks of dLHWDU\ HQHUJ\ UHVWULFWLRQ Ƣ-cell function increased towards normal 
and pancreatic fat decreased. Following the intervention, participants gained 3.1 
± 3.3 kg body weight over 12 weeks, but their HbA1c remained steady while the 
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triglyceride content of both pancreas and liver did not increase. The data are 
consistent with the hypothesis that the abnormalities of insulin secretion and 
insulin resistance that underlie type 2 diabetes have a single, common aetiology, 
i.e. excess lipid accumulation in the liver and pancreas (Taylor, 2008). This 
provides a unified hypothesis to explain a common disease that previously 
appeared to require separate disease processes affecting the pancreas and 
insulin-sensitive tissues.  
Absence of rapid insulin secretion in response to a rise in plasma glucose is 
the hallmark of type 2 diabetes (Weyer et al., 1999a, Pfeifer et al., 1981), and the 
decline in Ƣ-cell function determines the progression towards a need for insulin 
therapy (1995). However, conventional therapy, even with sulfonylurea, fails to 
produce more than a small increase in the first-phase insulin response. As a 
consequence, the rapidity and extent of return of Ƣ-cell function in response to 
dietary energy restriction in the present study is striking. Insulin secretion in 
non-diabetic individuals can be blunted by constant hyperglycaemia (Ferner et 
al., 1986) DQG WKH UHPRYDO RI ´JOXFRWR[LFLW\µ FRXOG EH D SDUWLDO H[SODQDWLRQ
Observation from this study supports the accumulating information on the 
inhibitory effect of fatty acids on insulin secretion in vitro and in vivo (Igoillo-
Esteve et al., 2010, Cnop, 2008, Noushmehr et al., 2005) and is the first direct 
evLGHQFH LQ KXPDQV WKDW WKH Ƣ-cell defect of type 2 diabetes is reversible by 
sustained negative energy balance. Prolonged elevation of plasma fatty acids in 
humans decreases insulin secretion (Carpentier et al., 2003, Kashyap et al., 
2003), and it has previously been shown that there is an association between 
pancreatic fat content and type 2 diabetes (Tushuizen et al., 2007, Saisho et al., 
2008, Saisho et al., 2007). Prior to the onset of spontaneous diabetes in rodents, 
both total pancreatic fat and islet triglyceride content increase sharply (Lee et 
al., 1994, Lee et al., 2010). In vitro, chronic saturated fatty acid exposure of Ƣ-
cells inhibits the acute insulin response to glucose, and removal of fatty acids 
allows recovery of this response (Morgan et al., 2008). 
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The present data provide clear evidence that decreasing total pancreatic fat 
is associated with a return of Ƣ-cell function. However, it is probable that the 
QHJDWLYH HIIHFW RQ Ƣ-cell function is exerted by toxic intermediaries such as 
diacylglycerol and ceramides, which change rapidly in response to acute 
metabolic changes (Erion and Shulman, 2010), rather than by stored 
triacylglycerol per se, which acts as an index of fatty acid intermediary 
concentration. There was no correlation between indices of insulin secretion 
and pancreatic fat, which suggests that there are individual thresholds of 
tolerance for such toxic intermediaries rather than a simple dose²response 
relationship within the pancreas. 
Fasting plasma glucose concentration is determined by the rate of hepatic 
glucose production, and hepatic insulin sensitivity is inversely proportional to 
intrahepatic lipid content (Ravikumar et al., 2008, Perseghin et al., 2006, 
Gastaldelli et al., 2007, D'Adamo et al., 2010). Moderate weight loss has 
previously been shown to be associated with a fall in intrahepatic fat content 
(Petersen et al., 2005a, Tiikkainen et al., 2003). Petersen and colleagues have 
previously reported improved liver insulin sensitivity and no significant change 
in muscle insulin sensitivity measured by euglycaemic-hyperinsulinaemic clamps 
after 8 weeks of moderate energy restriction in type 2 diabetes (Petersen et al., 
2005a). A very low energy intake has been observed to lower liver fat content in 
healthy obese individuals within days (Kirk et al., 2009). The present study 
demonstrates for the first time the early time course with which both hepatic 
fat stores and hepatic glucose production fall in response to dietary restriction 
in type 2 diabetes. Change in peripheral insulin sensitivity played no part in the 
early return of normoglycaemia. It is possible that the sharp rise in plasma 
NEFA observed after 1 week of the hypocaloric diet could have prevented a 
change in peripheral insulin sensitivity even though this did not prevent the 
rapid improvement of hepatic insulin sensitivity. 
It has been hypothesised that establishing the pathophysiological changes 
that accompany the reversal of type 2 diabetes will illuminate the sequence of 
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changes determining the onset of the disease (Taylor, 2008). The twin-cycle 
hypothesis was informed by observations following bariatric surgery (Taylor, 
2008), especially with the demonstration of fasting plasma glucose 
concentrations falling within days after biliopancreatic diversion (Guidone et al., 
2006). As these changes occur before substantial weight loss, it has become 
widely accepted that bariatric surgery exerts such rapid effects by changes in 
incretin hormones. However, the extent of change in incretins is modest, not 
always present in type 2 diabetes, and absent after gastric banding (Morinigo et 
al., 2006, Rodieux et al., 2008, Knop, 2009, Rubino et al., 2004). Little attention 
has been paid to the potential role of a sudden negative energy balance on 
glucose metabolism after bariatric surgery, although a recent small study 
suggested that the improvement in insulin resistance in the first week after 
surgery can be attributed to negative energy balance alone (Isbell et al., 2010). 
Increased glucagon-like peptide-1 secretion following bariatric surgery 
compared with a hypocaloric diet has been reported, but the oral glucose load 
used in the presence of a gastroenterostomy is likely to explain the early rapid 
rise in both plasma glucose and the incretin, occasionally with the symptoms of 
early dumping (Laferrere et al., 2008). 
The limitations of this study must be considered. First, the sample size was 
necessarily small to allow the application of gold standard methods for 
metabolic investigation and examination by magnetic resonance techniques. 
However, the participants were drawn from the population with type 2 
diabetes, and their clinical and anthropometric characteristics were typical for 
the condition. Second, pancreatic fat measurements included intra-organ 
adipocyte fat content because current methodology precludes the assessment of 
the more mechanistically important islet intracellular fatty acid content. Animal 
data suggest that the two variables are linked (Lee et al., 2010). Although 
pancreatic fat content was 30% higher in the diabetic group, the study was 
powered to demonstrate responses to the dietary intervention rather than to 
test differences from weight matched non-diabetic individuals. No correlation 
140 
 
was observed between pancreatic fat and BMI within the restricted range of 
BMI examined in this study. 
Third, the participants were selected to have had a relatively short duration 
of type 2 diabetes (up to 4 years), and further studies must establish the extent 
of reversibility with longer duration type 2 diabetes. In addition, further studies 
are required to determine the long-term outcome in respect of glucose 
regulation as the observations made after 12 weeks of return to a normal diet 
were necessarily limited. Fourth, the raised liver fat levels despite metabolic 
normality in some controls can be considered in the light of the recent 
description of the patatin-like phospholipase 3 (PNPLA3) gene (He et al., 
2010). The G allele of this gene determines high liver fat levels, but in a form 
that is not associated with metabolic abnormality. This provides a clear genetic 
basis for the observed individual variation in susceptibility to insulin resistance 
despite raised liver fat content, and offers a partial explanation of the 
overlapping hepatic fat levels in type 2 diabetic and control groups. It is likely 
that other genetic factors yet to be defined underlie the differing individual 
levels of susceptibility to pancreatic fat accumulation in terms of inhibition of 
glucose-dependent insulin secretion. Finally, the full impact of sudden negative 
energy balance on the incretin system could not be explored because oral 
glucose or meal testing was not performed. 
This study demonstrates for the first time the time course of a return of 
normal Ƣ-cell function and hepatic glucose output by restricting dietary energy 
intake in individuals with type 2 diabetes over a short time course. The changes 
occurred in association with decreases in pancreatic and liver triglyceride 
concentrations. This new insight allows an understanding of the causality of 
type 2 diabetes in individuals as well as in populations. It carries major 
implications for information to be given to newly diagnosed patients, who 
should know that they have a potentially reversible condition and not one that 
is inevitably progressive.  
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Chapter 6 
 
 
 
GENERAL DISCUSSION 
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Type 2 diabetes affects a very large number of people worldwide, yet, the 
precise causes of the disease have been elusive. Since the earliest predictor of 
the development of type 2 diabetes is insulin resistance in skeletal muscle, this 
tissue has been extensively studied. The role of oxidative capacity, which in 
essence is determined by the density and intrinsic properties of the 
mitochondria, has recently gained much attention. Data from in vivo MR 
spectroscopy measurements (Petersen et al., 2004, Szendroedi et al., 2007, 
Schrauwen-Hinderling et al., 2007), ex vivo studies of mitochondrial function 
(Mogensen et al., 2007, Phielix et al., 2008) as well as expression analysis of 
genes involved in oxidative metabolism (Mootha et al., 2003, Patti et al., 2003) 
all suggest that skeletal muscle mitochondrial dysfunction might play a role in 
insulin resistance and type 2 diabetes. The mechanism that has been proposed 
to mediate the insulin resistance is a decrease in capacity to oxidise fat, resulting 
in the accumulation of intracellular fatty acid metabolites (Lowell and Shulman, 
2005).  
On the other hand, several recent studies in both humans and rodents 
directly challenge the concept that mitochondrial dysfunction/deficiency causes 
muscle insulin resistance (Nair et al., 2008, De Feyter et al., 2008, Wredenberg 
et al., 2006, Toledo et al., 2007). In support of the latter, work from this thesis 
revealed no evidence of a mitochondrial defect in type 2 diabetes, as 
determined by measuring the rate of unidirectional flux through ATP synthase. 
Skeletal muscle ATP turnover rate was found to be normal in type 2 diabetes 
and could be modulated to a degree by suppression of lipolysis with acipimox. 
Muscle ATP turnover rates in type 2 diabetes reflect muscle glucose uptake and 
glycogen synthesis. In addition, data obtained from the cohort of young, lean 
and insulin-sensitive individuals suggest that there is not a relevant role for a 
subtle mitochondrial problem. These data are in keeping with findings of 
Trenell et al. (Trenell et al., 2008). Here, the authors found that both resting 
and maximum ATP turnover were similar between patients with well-controlled 
type 2 diabetes and controls matched for age, weight and physical activity. 
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Furthermore, the issue of whether a decrease in mitochondrial function as 
observed in insulin-resistant individuals would limit the ability of skeletal 
muscle to oxidise fatty acids and lead to lipid accumulation as proposed must 
be carefully considered. The rate of oxygen utilisation in muscle under normal 
resting conditions is usually low. However when energy demands are high such 
as during maximal exercise, skeletal muscle has enormous capacity to increase 
substrate oxidation over basal levels (Bangsbo, 2000). Considering there is such 
¶VSDUH· FDSDFLW\ WR LQFUHDVH VXEVWUDWH R[LGDWLRQ LQ PXVFOH LW LV WKHUHIRUH
questionable whether mitochondrial deficiencies observed in insulin-resistant 
individuals would have any impact on the rate of fatty acid oxidation under 
normal, free-living conditions in which energy requirements would otherwise 
be low. 
,QVXOLQ UHVLVWDQFH DQGƢ-cell dysfunction are the two primary defects that 
are recognised to determine the pathogenesis of type 2 diabetes. The accepted 
YLHZ KDV EHHQ WKDW Ƣ-cell dysfunction progresses inevitably, whereas insulin 
resistance in muscle and liver can be modified at least to some extent. Recent 
observations on resolution of type 2 diabetes after bariatric surgery raise the 
possibility that these underlying pathophysiological abnormalities can be 
reversed. Work from this thesis supports the notion and specifically shows that 
this is independent of the surgery itself. Within 7 days of hypocaloric diet, 
normal hepatic insulin sensitivity is regained as liver fat content falls to level 
similar of that of the age- and weight-matched non-diabetic control subjects. 
These changes resulted in normalisation of fasting plasma glucose. Insulin 
secretory capacity, which was tested by a stepped glucose infusion with 
subsequent arginine bolus, showed a steady increase over the 8 weeks of 
hypocaloric diet to become indistinguishable from that of the control subjects. 
Pancreas fat content decreased steadily during the 8 weeks to level similar to the 
control group. This occurred over a time course exactly matching that of the 
increase in insulin secretory capacity. Change in peripheral insulin sensitivity 
played no part in the early return of normoglycaemia. Although a cause and 
144 
 
effect relationship between raised intra-organ fat levels and metabolic effect has 
not yet been proven, the time course of the data is highly suggestive of a causal 
link. 
Together with other evidence of normalisation of insulin secretion post-
bariatric surgery (Camastra et al., 2007), work from this thesis supports the 
SURSRVHG¶WZLQF\FOH·K\SRWKHVLVRIWKHDHWLRORJ\RIW\SHGLDEHWHV)LJXUH
(Taylor, 2008). Chronic calorie excess in the circumstance of pre-existing 
muscle insulin resistance will lead to increased plasma insulin, which in turn 
accelerates fatty acid synthesis from glucose in the liver (Sidossis and Wolfe, 
1996). The increase in liver fat will lead to resistance of insulin-suppression of 
hepatic glucose production and a modest increase in fasting plasma glucose 
level. Consequently, basal insulin secretion rates will rise to maintain 
euglycaemia. The resulting compensatory hyperinsulinaemia will further 
increase the conversion of excess calories into liver fat, leading to further rise in 
fasting plasma glucose due to hepatic insulin resistance. This vicious cycle of 
liver metabolism interacts with a second cycle involving pancreatic function. 
Fatty liver leads to increased export of very low-density lipoprotein (VLDL) 
triglyceride which will increase delivery of lipids to all tissues including the 
islets. Excess fatty acid derived from circulating and locally deposited 
triglyceride will suppress glucose-mediated insulin secretion, and at a certain 
level of fatty acid exposure, clinical diabetes will develop. 
145 
 
 
 
Figure 6.1 The twin cycles of type 2 diabetes ² reproduced with permission 
from Taylor et al. (Taylor, 2008). Liver cycle: Fat will accumulate in the liver 
during chronic intake of more calories than are expended. As this process is 
promoted by insulin, individuals with a degree of insulin resistance (determined 
by familial trait or lifestyle factors) will accumulate liver fat more readily than 
others. As the liver fat increases, the process of glucose production by the liver 
becomes less sensitive to suppression by insulin, resulting in the rise of plasma 
glucose and basal insulin secretion rate. Pancreas cycle: The increased liver fat will 
cause increased hepatic VLDL triglyceride secretion. All tissues will be exposed 
to more triglyceride than required, with pancreatic islets particularly susceptible 
to local triglyceride accumulation. The post-meal response to glucose becomes 
blunted, and this is exacerbated by the modestly raised plasma glucose. The 
pancreas cycle causes impaired glucose regulation, and eventually the fatty acid 
and glucose inhibitory effects on the islet reach a threshold, leading to a 
relatively sudden onset of clinical diabetes. 
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Despite the strong association between obesity and type 2 diabetes, some 
obese individuals never develop type 2 diabetes and conversely some type 2 
diabetic individuals are relatively lean. It is clear from this observation that 
individual susceptibility factors must therefore determine the onset of the 
condition. Given that diabetes cannot occur without a loss of acute insulin 
response to food, it would be expected that this critical step could relate either 
to the accumulation of fat in the pancreas, susceptibility to the adverse effect of 
excess fat in the pancreas, or to both of these factors. Tushuizen and colleagues 
observed that people with type 2 diabetes tended to have higher levels of 
pancreas fat than weight-matched controls (Tushuizen et al., 2007). However, 
they reported a wide scatter of pancreatic fat levels amongst the people with 
type 2 diabetes (range 13.4 ² 43.6%) and there was a clear overlap between the 
diabetic and non-diabetic subjects (range 7.0 ² 20.2%). This trend was also 
observed in my study despite using a more precise method of measuring 
pancreatic triglyceride content (diabetics: range 4.1 ² 22.2% and non-diabetics: 
2.9 ² :K\VKRXOGLWEHWKDWRQHSHUVRQKDVQRUPDOƢ-cell function with 
a pancreas fat level of 10% whilst another has type 2 diabetes with a level of 
5%? There must be varying degrees of liposusceptibility of the metabolic 
organs determining at which level of fat excess the adverse effects develop. 
7KHUHIRUHZKHQDQLQGLYLGXDODFTXLUHVH[FHVVIDWVWRUHVWKHQƢ-cell failure may 
or may not develop depending upon his/her individual degree of 
liposusceptibility. Such susceptibility may be genetically determined as seen in 
individuals with polymorphism in PNPLA3-(I148M) which confers high levels 
of liver fat without features of metabolic syndrome including obesity, 
hypertriglyceridaemia and insulin resistance (Speliotes et al., 2010, Sookoian and 
Pirola, 2011). This genetic variation allows build up of metabolically inert 
triglyceride, most likely without the excess of fatty acid intermediaries such as 
diacylglycerol which would normally be in equilibrium with the excess 
triglyceride deposit (Samuel et al., 2010). 
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Data from this thesis firmly support earlier observations that individuals 
with type 2 diabetes can return to normal metabolism by acute restriction of 
dietary energy intake and losing weight, at least in the early years after diagnosis. 
However, the extent of weight loss required is much greater than that 
conventionally advised. Dixon and colleagues showed in their randomised study 
that loss of 20% body weight allowed long-term remission in 73% of a bariatric 
surgery group, with weight change itself being the principal determinant of 
glucose control (Dixon et al., 2008). In my study, individuals with type 2 
diabetes achieved a loss of 15% body weight over an eight-week period. The 
role of physical activity must also be considered. Increased levels of daily 
activity results in improved insulin sensitivity at the levels of skeletal muscle 
(Perseghin et al., 1996) and decreased liver fat (Perseghin et al., 2007). Although 
physical activity was not specifically examined in the work of this thesis, 
exercise intervention alone rarely achieves the amount of weight loss required 
to reverse diabetes. The initial major loss of body weight demands substantial 
reduction in calorie intake to achieve a target weight, followed by a continued 
modest calorie restriction in association with increased daily physical activity to 
maintain the newly acquired lower body weight. Further recommendation on 
details on how to reverse type 2 diabetes in clinical practice must however await 
further studies. As for now, it will be helpful for all individuals newly diagnosed 
with type 2 diabetes to know that they have developed a metabolic syndrome 
which is reversible.  
Future work is also required to confirm a cause and effect relationship 
between raised intra-organ fat levels and metabolic effect in humans, especially 
that of islet triacylglyecrol concentration and insulin secretion. As yet, only 
animal data demonstrate that blocking ectopic deposition of lipids by the daily 
administration of troglitazone to prediabetic fa/fa ZDF rats completely 
prevents diabetes from developing by reducing lipogenesis and lipoapoptosis in 
thH Ƣ-cells (Higa et al., 1999). Furthermore, there is the need to examine the 
potential for reversibility of type 2 diabetes with increased duration of disease 
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process, as the patients that were studied here had diabetes diagnosed up to 4 
years previously. It also remains to be proven whether long-term outcome in 
respect of glucose regulation can be maintained as well as achieving the 
anticipated impact of diabetes remission on macrovascular outcomes.  
The work presented in this thesis demonstrates lack of a primary role for 
mitochondrial abnormalities in the aetiology of type 2 diabetes. However, 
FRPSOHWHUHYHUVDOE\GLHWDU\PHDQVKDVEHHQGHPRQVWUDWHGRIDEQRUPDOƢ-cell 
insulin secretion and hepatic insulin sensitivity, in close temporal association 
with fall in pancreas and liver fat content. These observations allow a new 
understanding of type 2 diabetes and permit simple explanation of the observed 
pattern of onset of type 2 diabetes both in individuals and in populations. 
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Very Low Calorie Diet: Meal Plans and Ideas 
 
 
Meal plan example: 
Breakfast:   Optifast milkshake 
Lunch:   Optifast soup or milkshake with salad 
Evening meal: Optifast soup or milkshake with one of the following 
(salad, roasted vegetables or homemade soup) 
Snacks/supper: Vegetable snacks 
 
Type of vegetables allowed (at least 240g per day): 
Cabbage  Tomatoes  Cauliflower   
Broccoli  Celery   Cucumber   
Onions   Bean Sprouts  Carrots   
Lettuce   Leeks   Mushrooms 
Peppers   Artichoke  Radish  
Water chestnuts Brussel sprouts Mung bean sprouts 
 
Boil, grill, dry fry, stir fry or wrap in tin foil and roast in the oven. 
 
Herbs and spices: 
You will need to use some flavouring to prevent your dishes tasting so bland. 
Try to find some you like e.g. 
Basil   Lemon juice  Parsley  Oregano 
Vinegar  Tumeric  Tarragon Chilli powder 
Cinnamon  Rosemary  Cumin  Curry powder 
Vanilla essence  Thyme   Sage  Dried chillies 
Rum essence  Coriander  Ginger  Black pepper  
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Meal ideas: 
x   Salads 
x   Stir fry 
x   Soups 
x   Tomato based sauces 
 
Some recipe ideas: SOUPS 
Just a small bowl of soup (200 ml) can fill you up for a long time, also good to 
freeze or leave in the fridge for a couple of days. 
 
French Onion Soup:    Vegetable Soup: 
1 kg onions, chopped    2 onions, chopped 
2 tbsp thyme     1 tsp mustard seeds 
1 litre beef stock    1 tsp cumin seeds  
      2 leeks, sliced 
       3 carrots, sliced 
Mushroom Soup:    2-3 tsp curry powder 
1 onion, chopped    1-2 litre vegetable stock 
1 garlic clove, crushed    
fresh thyme      
400g mushrooms 
850ml vegetable stock    Pea and watercress Soup: 
       1 onion, chopped 
       1 clove of garlic, crushed 
Tomato Soup:     500ml vegetable stock 
3 x 400g tins of chopped tomatoes  300g fresh peas 
850ml vegetable stock    100g watercress 
1 clove garlic, crushed    
basil leaves, chopped     
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Carrot Soup:      Carrot and Coriander Soup: 
600g carrots, grated    1 onion, chopped   
2 tsp cumin seeds     1 tsp ground coriander 
pinch of chilli flakes    450g carrots, chopped  
1 litre vegetable stock    1-2 litre vegetable stock 
       pinch of chilli flakes  
      pinch of cumin seeds   
 
Other recipe ideas: SALADS 
7U\GLIIHUHQWOHWWXFHVVXFKDVURFNHWDQGFULVS\OHDIGRQ·WMXVWVWLFNWRWKH
iceberg lettuce.  Try different types of fat free, low calorie dressings to add 
some different flavours.  Using herbs and vinegars can help with flavour too. 
 
Simple Salad: 
80g of mixed lettuce/salad leaves (around 1 cereal bowl full) 
1 medium tomato, sliced 
3 mushrooms, sliced 
2-3 sticks celery, chopped 
3 sliced rings of green pepper 
1 tablespoon fat free dressing 
 
Red pepper and chilli soup: 
6 red peppers, halved, cored and deseeded  
2 red chillies, halved, cored and deseeded  
1 bulb garlic, halved  
6 tomatoes, halved 
450ml vegetable stock  
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Tomato sauce: 
1 onion, chopped  
2 garlic cloves, crushed  
1 red pepper  
400g tinned chopped tomatoes  
1 tbsp basil  
1 tbsp parsley  
1 tbsp chives  
1 green pepper 
 
Salsa sauce: 
4 fresh plum tomatoes, finely chopped  
1 bunch rocket, finely chopped  
1 bunch flat leafed parsley, finely chopped 
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